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ABSTRACT
The acute administration of AsIII or AsV to rats 
produced in liver a decrease in the heme saturation of
tryptophan pyrrolase (TP) accompanied by dose-related 
increases in aminolevulinate synthetase (ALAS) and heme 
oxygenase (HO) activities and corresponding decreases in P- 
450 concentration. The relationship between heme synthesis 
and degradation was changed as a result of As treatment. 
The magnitude of these effects was related to the oxidation 
state of As, AsIII being more potent than AsV. These results 
support the contention that the heme saturation of TP is
sensitive to treatments that modify liver heme concentration. 
However, it remains to be stablished which parameter, heme 
saturation of TP or ALA synthetase activity reflect more 
accurately changes in the "free heme" pool size. The increase 
in heme oxygenase produced by As in liver appears to be 
mediated by a mechanism largely or entirely independent of
heme. There were indications that the inhibition of P-450-
dependent monooxygenases reflects a selective effect of As on 
certain P-450 isoforms. Although only the higher doses of As 
were able to affect testicular heme metabolism, the general 
effect was similar to that observed in liver. AsV affected 
renal ALAS, HO and P-450 at doses which were ineffective in 
liver and testis.
The main effects of continuous exposure to AsIII were 
: 1) an initial decrease in the degree of heme saturation of
TP which remained constant during the period of treatment and 
2) an initial increase in ALA synthetase which after 10 days 
of exposure was reduced to a 30'/. increase. No significant 
effects on heme oxygenase or P-450 concentration were 
observed. These observations were interpreted as indicative 
that a new balance between heme synthesis and degradation had 
been reached and that an adaptive response to the toxic 
effects of AsIII was taking place.
Se produced effects on TP, ALAS and HO similar to
those produced by As, but it was more potent than either
AsIII or AsV. Se appears to be unusual in that it increases 
HO without reducing P-450 concentration. Se also appears to
be the first element reported to increase epoxide
hydrolase (EH) activity, as yet there is no evidence to 
explain how or why Se induces EH. It appears that Se has a 
dual effect on As-induced hepatoxicity. On the one hand it
has additive effects in reducing the heme saturation of TP, 
and on the other it seems to protect against the decrease in 
P-450 levels produced by AsIII.
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CHAPTER ONE 
INTRODUCTION
1 . INTRODUCTION.
1 . 1 Arsenic.
1.1.1 Historical aspects.
Although arsenic has acquired since ancient times an
unparalleled reputation as a poison , one of its earliest
reported uses was in the field of therapeutics. Several 
arsenic compounds have been used as therapeutic agents and 
tonics for many centuries. Subsequently, the toxic 
properties of arsenic compunds came to be fully appreciated 
and some were put to extensive use by professional poisoners 
of the middle ages.
The medicinal use of different arsenic compounds has
been an important source of knowledge about their toxicity.
Nearly two centuries ago, Fowler’s solution containing M  
arsenic trioxide, was used in the treatment of chronic 
myelocytic leukemia, psoriasis and bronchial asthma. Arsenate 
solutions (Parson’s liquor) were prescribed for chronic skin 
diseases, parasitosis and anemia (Martindale, 1977). Organic 
arsenicals were used in the treatment of syphilis and other 
arsenicals, while atoxyl, carbarsone, glycobiarsol,
melarsoprol and tryparsamide are still in use as 
antiparasitic drugs (Martindale, 1977). However, most drugs 
containing arsenic have now been replaced by more effective
and less toxic compounds in most countries. Although a number 
of incidents of mass human poisoning have occurred following 
accidental exposure to arsenic (see Section 1.14), its 
current toxicological importance is due to environmental and 
occupational exposure.
1.1.2 Sources and ocurrence of arsenic in the environment.
Chemically, arsenic is a period IV metalloid and 
belongs to the Vb group of the periodic system which also 
includes nitrogen and phosphorus. Arsenic atomic number is 33 
and the atomic weight 74.9. Its valence states are -3, 0, +3
and +5. Arsenic trioxide is only slightly soluble in water 
while sodium arsenite and sodium arsenate are highly soluble. 
Interchanges in valence state may occur in water solutions, 
depending on the pH of the solution as well as the presence 
of other substances that can be reduced or oxidized (Fowler 
et al., 1979).
Arsenic ranks twentieth among the elements in 
abundance in the earth’s crust. The abundance of arsenic in 
the continental crust of the earth is generally given as 1.5 
- 2.0 mg/kg. Arsenic is present in all types of soils, the 
geological history of a particular soil determines its 
arsenic content. The natural content in virgin soils varies 
from 0.1 to 40 mg/kg. The average is about 5 - 6 ,  but it 
varies considerably among geographical regions. For example,
4in the Region Lagunera, in Mexico, values between 3 and 9 
mg/kg were found at the soil surface and more than 20 mg/kg 
deep down (Gonzalez, 1977). In addition to their natural 
arsenic composition, soils and sediments may also become 
substantially contaminated by arsenic from man-made sources.
Arsenic occurs widely in natural waters as both 
inorganic and organic compounds (Braman and Foreback, 1973). 
The main organic arsenic species, methylarsonic acid and 
dimethylarsinic acid, are generally present in smaller 
amounts than the inorganic forms, arsenite and arsenate. In 
the U.S. the EPA has stipulated a maximum allowable 
concentration of total arsenic in drinking water of 50 ug/1.
Much higher values have been reported from some areas of the 
world: in Antofagasta, Chile, the average As level in a river 
water supply of drinking water was 0.8 mg/1 (Borgono et al. , 
1977). In Region Lagunera, Mexico, there are several towns 
which have concentrations ranging from 0.24 to 1.0 mg/1 in 
the drinking water obtained from wells (Cebrian et al., 
1983). However, there is little information on the chemical 
form of arsenic in water; it appears that in anaerobic 
reservoirs most of it is in trivalent inorganic form, whereas 
in well-aereated water 90/ is in pentavalent inorganic form 
(Clement and Faust, 1973). In well water samples from an area 
in Alaska, Harrington et al. (1 978 ) reported that 397. of the 
arsenic present was trivalent, the rest being pentavalent, 
while Jauge and Cebrian (unpublished data) found that in well 
water from Region Lagunera, 707 of arsenic was present in its
pentavalent form.
The total industrial production of arsenic in the 
world is estimated to be around 60;000 tonnes; the major 
producing countries are Mexico, Sweden, France and Russia 
(Stokinger, 1981). The use pattern of arsenic trioxide in the 
period 1975 - 1978 has been reported as follows: manufacture
of agricultural chemicals (pesticides), 827.; glass and 
glassware, 87; industrial chemicals, copper and lead alloys, 
and pharmaceuticals, 107 (W.H.O., 1981). In agriculture,
compounds such as lead arsenate, copper acetoarsenite, sodium 
arsenite, calcium arsenate and organic arsenic compounds are 
used as pesticides. Methylarsonic acid and dimethylarsinic 
acid are used as selective herbicides. Chromated copper 
arsenate, sodium arsenate and zinc arsenate are used as wood 
preservatives. Some phenylarsenic compounds such as arsenilic 
acid are used as feed additives for poultry and swine. The 
war gas lewisite was used in World War I and was highly 
effective in producing casualties; less toxic arsenic 
compounds are available for use as riot-control agents 
(N.A.S., 19 7 7). The semiconductor industry is the youngest
market for pure arsenic and its compounds and is rapidly 
growing in importance (Willardson, 1983).
1.1.3 Metabolism of arsenic.
Gastrointestinal absorption. The absorption of
inorganic arsenic from the gastrointestinal tract is
dependent mainly on the solubility of the arsenic compounds. 
It can occur following the ingestion of food, water, 
beverages, or drugs containing arsenic, or as a result of 
inhalation and subsequent mucociliary clearance. Except for
arsenobetain and related compounds, most arsenicals in 
solution are readily bioavailable. In humans (Tam et al., 
1979) and most experimental animals (Vahter and Norin, 1980), 
more than 907 of trivalent or pentavalent inorganic arsenic 
given as a solution is absorbed from the gastrointestinal 
tract. Tsutsumi and Nozaki (1975) found that about 307 of
either AsIII or AsV injected into a ligated loop of rabbit
intestine was absorbed into the blood over one hour. The 
mechanism of intestinal absorption of inorganic and organic 
arsenicals was studied by Hwang and Schanker (1973), their 
results indicated that in isolated loops of rat small 
intestine the process was simple diffusion. When undissolved 
arsenic compounds are ingested the absorption is dependent on 
particle size. Another factor influencing absorption is the 
composition of the diet, for example, the absorption of 
arsenic trioxide in rabbit intestine ligated in the ileocecal
portion was inhibited by casein (Nozaki et al., 1975).
7Distribution in blood. The absorbed arsenic is
transported by the blood to different organs in the body. In
humans, dogs, mice and rabbits, the clearence of inorganic 
AsIII from the blood is fairly well characterized, following 
a two or possibly three phase exponential curve (Charbonneau 
et al., 1979; Vahter and Norin, 1980; Bertolero et al., 
1981). The major part (>907.) is cleared very rapidly, the 
half-life being 1 to 2 hours. The rest is cleared at a much 
lower rate, the half-lives of the second and third phase have 
been estimated to be about 30 and 200 hours respectively. In 
contrast to these other species, in the rat the half-time of 
trivalent or pentavalent inorganic arsenic in the blood is of 
the order of 60 to 90 days (Ducoff et al., 1948; Klaassen, 
1974). This long half-life in rat’s blood is probably 
attributable to tight binding to hemoglobin of the 
erythrocyte, release only occurring on breakdown of the red 
blood cells (N.A.S., 1977). The distribution of arsenic in
plasma and red cells seems to be dependent on the valence
form of the absorbed arsenic. Vahter and Norin (1980) 
examined the blood distribution in mice 0.5 to 24 hours after 
a single oral administration of labelled AsV or AsIII in 
doses of 0.4 and 4 mg/kg. At the high dose level, the ratio 
between the arsenic concentrations in the erythrocytes and 
plasma was about 2 to 3 after exposure to AsIII, but close to 
unity after AsV administration.
Tissue distribution. Experiments by Vahter and Norin 
(1980) on rabbits and mice have shown that a single dose of
inorganic arsenic (AsV or AsIII) reaches all studied organs, 
but produces elevated concentrations in liver, kidney, lung 
and intestinal mucosa. There was no difference in whole-body 
retention that could be related to the valence state of the 
administered arsenic. Some differences were seen at the organ 
level, these were most marked in liver and bile, where the 
concentrations of labelled As were up to 10 times higher in 
the AsIII treated animals than in those treated with AsV. At 
the higher dose level, the differences were more pronounced, 
all tissues studied except kidney and bones showing 
significantly higher levels in the AsIII treated mice. An 
even more pronounced difference between AsIII and AsV in 
tissue distribution was seen in mice after intravenous 
administration (Lindgren et al., 1982). In contrast, using 
considerably lower doses, Sabbioni et al. (1979) did not find 
any major differences in tissue distribution in mice after 
i.p. injection of AsV or AsIII. As concentration decreased 
rapidly in most organs, 2 to 3 days after injection of AsIII 
to mice, the highest concentrations were detected in skin, 
gastrointestinal tract, epididymis and stomach wall. AsV 
administration produced highest concentrations in skeleton, 
stomach wall, epididymis, skin and kidney. Four days after 
administration of AsIII or AsV, the small amount of labelled 
arsenic remaining in the body was localized primarily in the 
skin, epididymis, testis, thyroid and lens (Lindgren et al.,
1 982 ) . There are only a few reports available on accumulation 
of arsenic in tissues after prolonged exposure. Oral
administration of labelled AsV or AsIII 3 times a week for 12 
weeks to mice led to a 60-fold increase in As concentration 
in hair, an 8-fold increase in skin, but in liver, kidney, 
lung and intestinal mucose the increase was only 2 to 3- 
fold. The accumulation was significantly higher after AsIII 
than AsV exposure (Vahter, 1983). Other studies indicate a 
more complex accumulation pattern. In mice and rabbits 
continuously exposed to As via drinking water or inhalation, 
the tissue levels increased for about two weeks, but then 
decreased in spite of the continued exposure (Bencko and 
Symon, 1969). The mechanism for these observations is not
known, but presumably these effects partly explain the
adaptation or tolerance which has been reported to the 
toxicity of arsenic.
Elimination. The elimination of As in rats is very 
slow because of its accumulation in erythrocytes . In animals 
other than the rat, As is excreted from the body at a much 
higher rate, mainly via the kidneys. Normally 40 to 70'/ of a 
single dose is excreted within 48 hours. In mice, exposure to 
AsV produces higher elimination rates than AsIII, since it 
does not bind to tissues to the same extent as the trivalent 
form. Orally administered As is excreted at a higher rate 
than As administered by the parenteral route, probably 
because more complete methylation occurs via the oral route
leading to an increased elimination rate (Vahter, 1981).
As a result of an almost complete absorption in the
gastrointestinal tract 090'/.) rather little arsenic is 
eliminated via the feces in experimental animals. Klaasen 
(1974) has shown that As is excreted into the bile and that 
this occurs against a large bile/plasma concentration ratio 
in rats, suggesting excretion by an active transport
mechanism. Marked species differences in the biliary 
excretion were observed, in rats the level was 40 times that 
in rabbits and 800 times that in dogs.
Studies in rats on the elimination of As via the lungs 
have indicated that, in contrast to selenium, little is
eliminated by this route (Dutkiewicz, 1977).
Biotransformation. It has been shown that
dimethylarsinic acid (DMA) is the major urinary metabolite 
following administration of either trivalent or pentavalent 
inorganic arsenic to rats, hamsters, rabbits and dogs.
Methylarsonic acid (MMA) only accounts for a few percent of 
the urinary As (Charbonneau et al., 1979; Tam et al., 1979; 
Bertolero et al., 1981). The methylation process is dependent 
on the valence form of As, the dose level, the route of 
administration as well as the animal species. In the mice 
given a low dose of labelled arsenic, the methylation of 
AsIII and AsV was equally efficient, and about 80/ of the 
dose was excreted as DMA in the 48 hour urine. As the dose 
increased, the excretion of DMA was reduced, possibly 
reflecting the saturation of the methylation enzymes. The
decrease in methylation was more pronounced after AsV
administration (Vahter, 1981). The excretion of DMA in rat
urine was considerable less than in mice and rabbits. In
rats the 48-hour excretion of DMA following exposure to AsIII
or AsV, corresponded to only about 41 of the given dose
(Vahter, 1981). It seems likely that both inorganic arsenic
and DMA are retained in the rat erythrocytes. Recently, it
has been reported that more than 807. of the total As in the
blood of rats one hour after the administration of labelled
AsV was in the form of DMA (Rowland and Davies, 1982),
indicating that the methylation of inorganic As in the rat is
not significantly lower than in other animals. The site of
methylation in the body is not yet known, the finding that
orally administered As is methylated to greater extent than
that given parenterally, suggests that besides occurring in
liver, the reduction and methylation by the gastrointestinal
microflora plays an important role (Rowland and Davies,
1981). The mechanisms for the methylation of inorganic As in
mammals have not been elucidated. It has been suggested that
in bacteria, AsV has to be reduced to AsIII before
methylation can take place, and that the methylation occurs
by non-enzymically mediated nucleophilic or free radical
attack by metalloid salts of lower oxidation state on S-
adenosylmethionine or methyl-B (Wood et al., 1 9 78 ). Studies
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by Vahter and Envall (1983) have shown that in rabbits 
exposed to AsV, arsenite appeared in the urine before DMA, 
which may support the proposal that AsV has to be reduced to 
AsIII before methylation can take place. Furthermore, it has
recently been shown that periodate-oxidized adenosine, a
known inhibitor of methyl transferases, significantly 
decreased the methylation of As in mice, suggesting that
AsIII may be a substrate for an enzymically mediated, as well 
as chemically mediated methylation (Marafante and Vahter,
1983). Which of the methyl transferases is involved remains 
to be established.
Another important aspect of the in vivo metabolism of
inorganic As is the means by which change in the oxidation
state of the non-methylated As is brought about. Since AsIII 
is the more toxic form, reduction of AsV to AsIII is of
toxicological interest. Reduction of AsV in vivo has been
indicated by certain studies on experimental animals
(Ginsburg and Lotspeich, 1963; Ginsburg, 1965). Studies on 
catheterized rabbits have shown that about 107. of the 
administered AsV was reduced and then excreted in the urine 
as AsIII during the first 4 hours after administration. 
Vahter and Envall (1 983 ) estimated that at least 507. of the 
AsV given is reduced in the rabbit ( 407. of the dose excreted 
as DMA + 107 excreted as AsIII), although only a part of it 
remains unmethylated. Oxidation of arsenite in vivo has been 
reported in dogs (Ginsburg, 1965), more recently Vahter and 
Envall (1983) have shown that it also occurs in mice. There 
is no information available on the influence of metabolism to 
methyl analogues on further tissue distribution.
1 . 1 . 4  A r s e n i c  t  o  >< 1  c: 1 1  v  .
The toxicity and LD values observed for arsenic
50
compounds vary greatly depending on the chemical form and
oxidation state of the chemical involved: the toxicity of the
trivalent compounds is much greater than that in the
pentavalent form. For example, the oral LD for AsV in rats
50
and mice has been found to be about 100 mg/kg and that for 
AsIII about 10 mg/kg. Toxicity is also highly dependent on 
the mode of administration, and the animal species studied. 
These differences may be explained, at least partially, by
differences in the methylation of the inorganic As by
different species of animals (Vahter, 1981). The solubility 
of an As compound also has a bearing on its oral toxicity as
shown by the fact that the more soluble sodium arsenite is
approximately 10 times more toxic than arsenic trioxide. 
Subacute and chronic exposures generally affect the same 
organ systems as those affected by acute As exposure, 
however, the changes observed are often more subtle or
modified.
Hepatic effects. The liver is an organ that 
accumulates arsenic during exposure to this element (Vahter 
and Norin, 1980) and lesions have been observed in animals 
following short and long-term exposure. Ishinishi et al. 
(1980) administered arsenic trioxide for seven months in the 
drinking water (the highest level being 62.5 mg/1), the
treatment was then withdrawn and the animals were sacrificed 
4 months later. Although no effects were observed in growth 
and general condition, slight liver injury with dose- 
dependent proliferation of the bile duct and chronic angitis
in the Glisson capsule were found. Shibuya (1971) reported
that impaired liver function, including delayed excretion of 
bromosulphthalein and increased serum transaminases occurred 
in rabbits given intravenous injections of arsenious acid in 
doses of 0.6 mgAs/kg, 3 times a week for 3 months. Mahaffey 
et al. ( 1 981) observed mild hepatic parenchymal cell swelling 
and decreased serum levels of alkaline phosphatase and 
glutamate oxalate transaminase in rats exposed to 50 mg/1 of 
AsV in the drinking water for 10 weeks. Watanabe et al. 
(1979) reported that after exposure of rats to 340 mg/kg of
arsenic trioxide in the diet for 3 weeks, no changes occurred
in serum enzymes or in the histology of liver, kidney and 
spleen. Schroeder et al. (1968) after treating rats with 
arsenic trioxide for at least two years, did not find any 
significant sign of toxicity. Liver mitochondria from rats or 
mice exposed to arsenate in drinking water at concentrations 
of 0, 20, 40 or 85 mg/1 showed mitochondrial swelling in
situ, which was accompanied by changes in mitochondrial 
respiration. Normal conformational (swelling and contraction) 
behaviour was also depressed in isolated mitochondria, as 
were a number of mitochondrial enzyme activities, including 
monoamine oxidase and cytochrome c oxidase (Fowler et al., 
1977, 1979). In mice similar alterations in mitochondrial
ultra structure accompanied by marked time-dependent changes 
in the inner structure of peroxisomes were reported by 
Mohelska et al. (1980).
Renal effects. The kidney is one of the primary organs 
in which arsenic accumulates, it also plays a major role in 
the excretion and metabolism of this metalloid (Ginsburg, 
1965; Brown et al., 1976; Vahter, 1981). Indications of 
impaired renal function, including decreased urea clearence 
and increased serum creatinine have been reported in rabbits 
given i.v. injections of arsenious acid 3 times a week for 3 
months (Shibuya, 1971). Rats given AsV in the drinking water 
(40, 85 or 125 mg/1) for 6 weeks, showed increased kidney
weights in relation to body weights. Ultrastructural studies 
in these animals revealed alterations in the proximal tubule 
cells consisting of swollen mitochondria and increased 
numbers of dense autophagic lysosome-type bodies. In 
addition, mitochondrial respiratory function was decreased 
(Brown et al., 1976). An interesting aspect of Brown's study 
was that the changes observed were confined to the proximal 
tubule cells, which is the major site of As transport in the 
kidney. The authors suggest that it is possible that the 
specific effect of in. vivo AsV exposure on the proximal 
tubule cell is due to a higher As concentration in these 
cells, and not to a special sensitivity to the AsV ion. 
Mitochondrial swelling is a feature of trace metal toxicity 
and is probably one of the earliest signs of renal toxicity 
(Squibb and Fowler, 1983). The changes in mitochondrial
ultra structure produced by AsV were accompanied by a marked 
increase (6-fold) in renal copper concentration and by a
small (5*/), but significant decrease in liver copper
concentration . The authors suggested that a functional Cu 
toxicity plays a role in the observed mitochondrial effects 
(Mahaffey et al. 1981). In a study by Brazy et al. (1980), 
AsV was found to inhibit the transport of sodium, phosphate 
and glucose in the renal tubules. This inhibition was 
associated with an increased oxygen consumption and a 
decreased NADH fluorescence (indicative of NAD oxidation) 
similar to that obtained by addition of ouabain. From these 
results, the authors proposed that the dominant effect of AsV 
was an inhibition of the oxidative phosphorylation process.
Testicular effects. There is little information
regarding the effects of As on testis. Bencko et al. (1968) 
have exposed hairless mice to arsenic trioxide in the 
drinking water at doses of 5 or 50 mg/l. No effects were seen 
at the lower dose, but at the highest level a marked 
degeneration in the germinal epithelium of testis was 
observed. Treu et al. (1974) reported an outbreak of 
poisoning due to ingestion of arsanilic acid in boars. 
During the acute phase 7 out of 16 died and all showed signs 
of gastrointestinal and neurological toxicity. However, long 
after other signs of toxicity disappeared, 3 boars showed 
adverse effects on sexual behaviour, two developed orchitis, 
epididymitis, and two showed low sperm counts and
morphological abnormalities. The authors suggested that the 
disturbances in sexual behaviour were due to central or 
peripheral nerve damage, but that the effects on semen
quality are more likely to be a direct effect on testis or
epididymis.
Acute toxicity in humans. The fatal dose of ingested 
arsenic trioxide for man has been reported to range from 1 to
2.5 mg/kg (Vallee et al., 1960). The first lesion to appear
is profound gastrointestinal damage resulting in severe 
vomiting and diarrhoea. Acute renal damage with microscopic 
hematuria accompanied by electrocardiographic disturbances is 
another common finding. Peripheral nervous disturbances, 
primarily of a sensory type, become manifest between 1 and 2 
weeks after ingestion. The hematopoyetic system is also
affected, showing pancytopenia (W.H.O., 1981).
Chronic toxicity in humans. Skin lesions have been
attributed to chronic exposure to inorganic arsenic. They 
include pigmentation changes, hyperkeratosis in palms and
soles, Bowen's Disease and basal and squamous cell
carcinomas. Peripheral vascular lesions consisting in 
thromboangiitis obliterans and gangrene were also observed 
(Tseng, 1977). It has been reported that after treatment with 
Fowler’s solution, some cases of portal hypertension without 
signs of liver cirrhosis were observed (Martindale, 1977).
Peripheral neuropathy has been reported to occur after long­
term occupational exposure. (W.H.O., 1981). An excess of
18
deaths due to respiratory cancer and an increased mortality
from cardiovascular disease has been observed in
epidemiological investigations on smelter workers (Axelson et 
al., 1978). ’
1.1.5 Pos sible molecular mecha nisms of toxicity.
Arsenic III. The most important mechanism by which
AsIII is considered to exert its toxic effects is through
interaction with active cellular sulfhydryl groups. This was 
discovered during the early 1900s and still forms the basis 
of the current understanding of AsIII action (Squibb and
Fowler, 1983). Most of the early work was carried out on
isolated enzymes, and most effects were inhibitory; Webb 
(1966) has published a comprehensive list of the enzymes 
affected. The mechanisms by which arsenicals inhibit enzyme 
activities varies for different enzyme systems. In some cases 
the enzyme activities can be restored by addition of excess 
glutathione, suggesting that the inhibition of activity is 
due to the reaction of As with a single SH group in the
enzyme. However, this simple mechanism clearly does not hold
for all enzymes, the activity of some As-inhibited enzymes is 
not restored by addition of simple monothiols, instead, 
dithiol compounds are more effective in restoring enzyme 
activity implying As binding to more than one -SH group.
Although in many cases the effect of arsenic on enzyme
19
activity appears to be due to direct interaction of As with 
enzyme sulfhydryl groups, there are other possible means by 
which it could inhibit enzyme function. Arsenic could for
example, react with SH groups of substrates, coenzymes or
intermediates. Phelps and Hatefi (1981), based on competition 
studies, concluded that the arsenical binding to the vicinal 
dithiol groups of beta-hydroxybutyrate dehydrogenase
interfered with coenzyme (NAD/NADH) binding and catalysis, 
but did not affect substrate/product binding. In an
interesting study, Johnson and Rajagopalan (1978) have 
proposed that the reaction of AsIII with the molybdenum 
centre of xanthine oxidase causes an inhibition of electron 
transfer and substrate hydroxylation during the enzyme 
catalyzed reaction, without any effect on substrate binding. 
These authors suggested that the site of interaction at the 
Mo centre was either an SH group liganding to the Mo atom, a 
persulfide residue associates with the Mo or the Mo atom 
itself.
Arsenic V . Although considerable attention has been 
paid to AsIII mechanisms of toxicity, direct reaction of 
inorganic pentavalent arsenic ion within tissues should not 
be discounted. The arsenate ion is isosteric and 
isoelectronic with phosphate (Sisler, 1956). A considerable 
number of in vitro studies have demostrated that arsenate can 
subtitute for phosphate in enzyme catalyzed reactions. 
Gresser (1981) has recently demonstrated that ADP-arsenate is 
indeed syntesized from ADP and arsenate (10 mM) by succinate-
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energized submitochondrial particles. The ADP-arsenate formed 
rapidly hydrolyzes or can react with glucose to form 
glucose-6-arsenate. The adverse effects of arsenate 
substitution for phosphate are thought to arise from the fact 
that arsenical esters are inherently unstable compared to the 
corresponding phosphate esters (Squibb and Fowler, 1983).
1 . 2 Selenium.
1.2.1 Historical aspects.
Historically, interest in selenium first arose from 
its toxic effects, particularly in relation to animal 
husbandry. Then, for many years the emphasis was placed on 
its possible carcinogenesis, and eventually, recognition that 
certain animal diseases could be attributed to a deficiency 
of Se in the diet, served to foe us attention on the 
beneficial effects of this trace element (Schroeder et al. , 
19 7 0).
1.2.2 Sources and ocurrence of selenium in the 
environment.
Chemically, Se is a period IV metalloid and belongs 
to the subgroup VIb of the period system which also includes 
oxygen, sulphur, tellurium and polonium. The atomic number of 
Se is 34, its atomic weight 78.96. Its valence states are -2, 
+4 and +6, it is more toxic in lower valence than in higher 
valence states. It has three allotropes. Elemental Se is not 
soluble in water. Selenites and selenates are soluble in 
water (Glover et al. 1979).
Selenium occurs in the earth's crust, typically in 
concentrations from 0.05 to 0.09 mg/kg. The occurrence of Se
in soils is a topic of considerable interest particularly in 
view of its toxic effects on cattle through plants which can 
accumulate the element from seleniferous soils. On the other 
hand, there are diseases prevalent in animals on a selenium 
deficient diet produced by grazing in areas in which the
soils are low in selenium (Cooper et al., 1974). As recently 
shown, Keshan Disease, a cardiomyopathy of children and young 
women in China, occurs exclusively in regions where Se levels 
are extremely low. Thus, it is the first human disease shown 
to be related to Se deficiency. Other factors may be involved 
in the disease, but Se deficiency plays a major role (Burk, 
1983).
Selenium has been identified as a minor constituent in 
water. The levels in surface and ground waters range from 0.1 
to about 400 ug/1. However, depending on geological
characteristics they may reach concentrations up to 6 mg/1 
(Glover et al., 1979).
The main sources of industrial production are the
selenides of lead, copper, mercury and nickel. The use
pattern of Se in the period 1975 - 1978 has been reported as 
follows: glass industry, 27/; semiconductor technology and
electrical engineering, 23/; chemicals for duplicating 
machines, 23*/.; inorganic pigments, 14*/.. Inorganic salts are 
used in several countries as feed additives. Selenium sulfide 
preparations for external application are used in
dermatology. Labelled selenomethionine is used for scanning
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of organs and tissues (N.A.S., 1976).
1.2.3 Metabolism of selenium.
Gastrointestinal absorption. Sodium selenite (SelV) is 
readilly absorbed from the gastrointestinal tract of rats, 
with most estimates of absorption exceeding 80'/. Brown et al. 
(1972), studied the absorption of labelled selenite from rats 
that had been fed with Torula yeast diets containing several
levels of SelV; between 95 and 100'/. of the administered Se
was absorbed, this being independent of the different levels 
of Se in the diet. Cary et al. (1973), reported that the 
absorption of Se from diets supplemented with 
selenomethionine, selenite or seleniferous corn averaged 807. 
and was not affected by the Se source. The site of absorption 
was investigated by Whanger et al. (1976) using ligated
segments of the digestive tract of rats, the absorption of 
selenite or selenomethionine was greatest in the duodenum, 
followed by jejunum and ileum. _I_n vitro work with everted 
intestinal sacs from golden hamsters indicated that
selenomethionine, but not selenite or selenocysteine, was 
actively transported against a concentration gradient 
(McConnell and Cho, 1965).
Tissue distribution. After absorption, a substantial 
fraction of Se is bound to albumin and globulins. In mice and 
rats, selenium rapidly enters the erythrocytes where it is
metabolized and then gradually released back into the plasma 
(McConnell, 1941; Sandholm, 1973). Studies on several animal 
species indicate that Se in red cells is associated with 
glutathione peroxidase, a Se containing-enzyme (Hoekstra, 
1975). Studies on animals kept on adequate or high Se diets 
have shown that the highest concentrations of Se are reached 
in liver and kidney following either single high-level 
exposure or long-term exposure to physiological levels of Se 
compounds. Spleen, lung, myocardium, skeletal muscle and 
brain contained decreasing amounts. (Martin and Gerlach, 
1972). Brown and Burk (1973) studied the distribution and 
retention of Se in the tissues of rats given SelV after being 
maintained on a Se-deficient (Torula yeast) diet for one 
month; female rats consistently retained larger amounts of
radioactivity in all tissues except the brain and
reproductive organs than did the males. However, a marked
uptake and retention of Se was noted in the reproductive 
organs of males. The testes and epididymis retained about 427. 
of the total body burden 3 weeks after administration.
Elimination. Selenium may be eliminated from the body 
by the three major excretory pathways urine, feces and
expired air, however, under most dietary conditions and at 
most dose levels, urinary excretion is the most important 
route of elimination. Burk et al. (1972) reported that 
the urinary excretion of Se is reduced at high doses, 
possibly due to an increase of Se in the expired air. The
oxidation state of the administered Se also affects the
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extent of the urinary excretion, Hi rooka and Galambos (1 906) 
compared the disposition of selenite and selenate
administered intraperitoneally. Approximately 517. of the 
selenate was excreted in the urine, while only 377. of 
selenite was eliminated in the 24 hour period. Se from 
selenomethionine is probably less readily excreted in the 
urine than that from selenite. The trimethylselenonium ion 
accounted for about 40 7. of the total dose of selenite given
parenterally, but increased to 567. when the element was given 
orally to animals that had previously been ingesting large 
amounts of Se in the diet (Palmer et al., 1970).
In some of the above mentioned studies, fecal 
excretion accounted for about 107. of the intraperitoneally
administered Se. However, other studies indicated that as 
much as 307 of a subcutaneous dose of selenate or selenite 
was present in the feces arid gastrointestinal contents of 
rats at 24 hours (Ganther and Baumann, 1962). It appears that 
biliary excretion amounts to only 27. of the administered 
dose (Levander and Baumann, 1966). However, the amount of Se 
excreted in the bile is greatly increased when arsenic 
compounds are administered concurrently with Se (Levander and 
Baumann, 1966). In addition, under conditions of chronic oral 
exposure, fecal elimination plays a more prominent role in 
the disposition of Se.
In contrast to arsenic, the respiratory excretion of
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volatile Se (dimethylselenide) can be an important 
elimination route, and depending on the dose it can reach.up 
to 30*/ of the administered dose. It appears that after doses 
below 0.1 mg/kg respiratory excretion is minimal ( 1 and at 
doses of 1 mg/kg it is about 10*/ (Olson et al. , 1 963 ).
Biotrans formation. Methylation yielding
dimethylselenide, dimethyldiselenide and trimethyIselenonium 
ion, appears to be the major pathway of Se metabolism. The 
highest methylating activity has been found in liver and 
kidney (Hsieh and Ganther, 1977) The formation of 
dimethylselenide involves a reduction from the + 4 oxidation 
state of selenite to the - 2 level followed by methylation of 
the selenide. Both the 105,000 g supernatant fluid and the 
washed microsomes were able to form dimethylselenide, but 
neither was as active as the 9,000 g supernatant fraction. 
Glutathione was required for the formation of 
dimethylselenide and could not be replaced by other thiols. 
Hsieh and Ganther (1977) found that the soluble fraction of 
homogenates contained glutathione reductase and another 
NADPH-dependent disulfide reductase, both presumably involved 
in the reduction of selenite to selenide, and a 
methyltransferase with a molecular weight of about 30,000. In 
contrast, the microsomal fraction had only methyltransferase 
activity and apparently methylated hydrogen selenide 
nonenzymatically in the presence of high GSH levels. The 
microsomal methyltransferase was exceedingly sensitive to 
inhibition by arsenite, which is known to inhibit the
formation of dimethylselenide in vivo: the nature of this
inhibition was not stated in the publication. It remains to
be established whether the soluble and microsomal Se- 
methyltransferases are unique enzymes specific for Se or if
they are similar to the known S- or O-methyltransferases. The
reduction reaction selenite to selenide has been shown to
operate in red blood cells, for example, Gasiewicz and Smith
(1978) presented evidence that hydrogen selenide was the 
final product of selenite metabolism by rat erythrocytes. The 
biochemical mechanisms involved in the formation of the
urinary metabolite trimethylselenonium have not been 
investigated thoroughly. It would seem reasonable to assume 
that trimethylselenonium is formed from dimethylselenide by 
the addition of a third methyl group, however, Obermeyer et 
al. (1971) found that less than 0.57. of i.p administered 
labelled dimethylselenide was excreted in rat urine within 24 
hours. On the other hand, following the administration of 
trimethylselenonium 9 7 of the dose was excreted in the
expired air of the rats within 6 hours. This findings seem 
incompa tible with a s traightforwa rd precursor-product 
relationship.
1.2.4 Toxicity of selenium.
A few minutes after subcutaneous or peroral 
administration of high doses of selenium to dogs, the signs 
observed include vomiting, garlic odor of the breath, tetanic
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spasms and death from respiratory failure (Franke and Moxon,. 
1937). Pathological changes include congestion of the liver 
with areas of focal necrosis, congestion of the kidney, 
endocarditis, myocarditis, petechial hemorrhages of the 
epicardium and atony of smooth muscles. The organ most 
affected by Se is the liver, which initially undergoes a 
reversible fatty degeneration, but if the exposure 
continues over a long period, cirrhosis is likely to occur. 
In the kidney there is commonly mild tubular degeneration. 
The spleen becomes enlarged and the stomach and intestinal 
tract show hemorrhages. Smith et al. (1973) reported that the 
minimum lethal dose of Se as sodium selenite or selenate in
rabbits, rats and cats was between 1.5 and 3.0 mg/kg,
regardless of whether the compounds were administered orally,
subcutaneously, intraperitoneally or intravenously. This 
effect probably reflects the rapid and complete absorption of 
soluble Se compounds either from the site of injection or 
from the gastrointestinal tract. Halverson et al. (1966)
found that the addition of Se (6.4 mg/kg) to the diet of rats
caused significant growth depression, liver cirrhosis and 
splenomegaly, whereas diets containing 8 mg/kg or more caused 
additional effects such as anemia, pancreatic enlargement, 
elevated serum bilirubin levels and after 4 weeks death. In 
contrast, levels of 4.8 mg/kg or less had no apparent effects 
on rats after 6 weeks. Jacobs and Forst (1981), using
selected serum enzyme levels and histopathology as 
indicators, suggested that rats can be exposed to sodium
selenite via drinking water (1 to 4 mg/1) for up to one year
without apparent signs of toxicity.
1.2.5 Carcinogenic a nd anticarcinogenic effects of 
selenium.
The first report concerning the carcinogenic effects 
of selenium was that of Nelson et al. (1943) who fed rats 
with diets containing Se as seleniferous corn or wheat. From 
126 exposed rats, 73 survived less than 18 months and showed 
no evidence of liver tumours. From the remaining 53 that 
survived 18 to 24 months, 11 developed liver-cell adenoma or 
low grade carcinoma without metastasis in cirrhotic livers. 
No tumours developed in livers that were not cirrhotic. 
Seifter et al. (1946) found multiple thyroid adenomas and
liver hyperplasia in rats fed bis-4-acetylaminophenyl 
selenium dehydroxide (0.05%) for 105 days. Based largely upon 
these studies, Se was included as a carcinogen in the Delaney
Clause of the Food Additive amendment of 1958. However, two
studies that specifically looked for carcinogenic effects of 
Se on mice (Schroeder and Mitchener, 1972) and rats (Harr et
al., 1967) failed to observe significant differences in the 
number of malignancies between Se-treated groups and
controls.
In contrast, Shamberger (1970) reported that topical 
administration of Se solution (0.0005/) reduced the number of 
tumours produced by the concomitant application of croton oil
and 7,12-dimethylbenz(a )anthracene (DMBA) dr 3-
methylcholanthrene (MG). Harr et al. (1972) reported that
mammary adenocarcinomas and/or hepatic carcinomas developed
more slowly in groups of animals treated with 150 ppm of 2-
acetylaminofluorene (AAF) and 0.5 - 2.5 ppm of sodium
selenite than in those treated with AAF plus 0 - 0.1 ppm of
Se; the reduction was 85 - 95/ after 200 days of exposure to
the AAF, but only 20 to 30/ after 320 days of exposure. Harr
et al. (1973) in a corollary to the above study also reported
that the concentration of Se in the liver of rats fed
selenite-supplemented diets was inversely correlated with the
incidence of hepatic and mammary tumours. Dietary sodium
selenite was also reported to reduce the number and the size
of liver tumours induced by repeated small doses of aflatoxin
B (Grant et al., 1977). Selenium supplementation inhibited 
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DMBA-induced mammary gland tumorigenesis in mice and rat 
(Medina and Shepherd, 1981; Welsch et al., 1981). Ip (1981) 
studied the preventive effect of Se on the initiation and 
promotion of mammary carcinogenesis, by supplementing the 
diets of rats with Se before, during or after DMBA exposure. 
He concluded that while Se can inhibit both the initiation 
and promotion phases of carcinogenesis, a continuous intake 
of Se was necessary to achieve maximal tumorigenesis 
inhibition. Its efficacy was attenuated when it was given 
long after carcinogenic injury. The intraperitoneal injection 
of various chemical forms of Se at several times after 
inoculation of mice with Erlich ascites tumour cells has also 
been shown to prevent the development of tumours, but one
week delay after the inoculation reduced the effectiveness 
of this Se effect (Greeder and Milner, 1 980) . It is clear 
that administration of Se compounds in the diet or in water 
is an effective inhibitor of carcinogenesis produced by a 
number of.chemical carcinogens; however, despite extensive 
study, the mechanism by which selenium prevents tumour 
formation in the above studies has not yet been elucidated. 
This subject is further discussed in Chapter 4.
1 .3 Heme metabolism.
1.3.1 Outline of the pathway.
The synthesis of heme in mammalian cells involves 
cooperation between mitochondrial and cytoplasmic 
compartments. The synthesis of delta-aminolevulinic acid 
(ALA) is a mitochondrial process, but its subsequent 
conversion into coproporphyrinogen occurs in the cytoplasm. 
The last steps (from coproporphyrinogen to heme) again take 
place within the mitochondria. The stages in the heme 
metabolism pathway are outlined in Fig. 1.1 (Connelly, 1983). 
The initial step is the condensation of glycine and succinyl
coenzyme A by the enzyme ALA synthetase to form ALA in the
mitochondria. The ALA then passes into the cytosol where ALA 
dehydratase (ALAD) catalyzes the condensation of -4^ vo. 
molecules of ALA to form the pyrrole porphobilinogen (PBG) . 
Four molecules of this monopyrrole are condensed by the 
concerted activity of two cytoplasmic enzymes: 
uroporphyrinogen I synthetase (URO-I-S) and uroporphyrinogen 
III cosynthetase (URO-111-CoS), forming the first porphyrin 
ring in the pathway, uroporphyrinogen III. Another 
cytoplasmic enzyme, uroporphyrinogen decarboxylase (UROD), 
converts the four acetic acid side chains of the 
uroporphyrinogen III to methyl groups to yield
coproporphyrinogen III. The coproporphyrinogen III enters
the mitochondria where coproporphyrinogen oxidase oxidatively
decarboxylates the two propionic acid side chains on rings A 
and B to vinyl groups forming protoporphyrinogen IX. 
Protoporphyrinogen oxidase is then responsible for removing 
six hydrogen atoms to yield protoporphyrin* IX. The final 
step in heme biosynthesis is the insertion of ferrous iron 
into protoporphyrin IX to form protoheme (heme) by the
mitochondrial enzyme heme synthetase (ferrochelatase). Heme 
is then incorporated into various apoproteins of the cell, to 
form biologically active hemoproteins.
Hemoprotein degradation takes place in a number of 
tissues, the heme is released and it is cleaved at the alpha- 
methene bridge carbon atom by microsomal heme oxygenase to 
produce biliverdin IX-alpha and carbon monoxide. The
biliverdin is then reduced to bilirubin IX-alpha by the
cytoplasmic enzyme biliverdin reductase. Bilirubin is 
transported from its sites of formation to the liver where 
the carboxyl groups on the propionic acid side chains are 
conjugated with glucuronic acid, glucose, xylose etc. The 
conjugated compounds are then excreted in the bile and thence 
into the gut where additional modifications are performed by 
gut bacteria. Recent reviews on this subject are those of 
Sassa and Kappas (1981), Ibraham et al. (1983) and Maines 
( 1 984a) .
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Fig. 1.1 Heme synthesis and degradation (taken from Connelly, 1983).
1.3.2 D e l t a - a m in olevul in ic acid synthetase
Some characteristic of the enzvme. All the evidence to
date is consistent with the formation of ALA, catalyzed by
ALAS, being the rate-limiting step in heme biosynthesis. 
ALAS is synthesized on the ribosomes in the cytoplasm and is 
then transported to the mitochondria. Normally, the activity 
of the enzyme in mitochondria is very low and in the cytosol
is barely detectable. It appears that ALAS is either free in
the mitochondrial matrix or loosely bound to the inner
mitochondrial membrane. However, in animals treated with 
porphyrinogenic drugs, where ALAS activity is much higher 
than normal, a significant proportion (35/) of the total 
activity is present in the cytoplasm, much more than can be 
accounted for by mitochondrial damage (Hayashi et al. 1969). 
This cytosolic enzyme may represent newly synthesized ALAS on 
the way to being incorporated into the mitochondria (Kikuchi 
and Hayashi, 1981). Both mitochondrial and cytoplasmic 
enzymes have been shown to be synthesized on cytoplasmic 
ribosomes (Tait, 1978).
ALAS has one of the shortest half-lives yet reported
for any mammalian liver enzyme. In adult rat liver, the
half-lives of both the mitochondrial enzyme and its mRNA has 
been found to be about 1 hour (Tsuchudy et al., 1965); those 
of fetal rat liver are about 34 minutes (Woods, 1974). 
Adult rat liver cytoplasmic enzyme has a half life of 20
minutes in the absence of hemin, and 120 minutes in its 
presence (Hayashi et al. 1972). This short life permits 
regulation of the enzyme activity by control of its synthetic 
mechanism.
Nakakuki et al. (1980) have reported that rat liver 
cytosolic ALAS consists of a dimer of identical subunits 
having a molecular weight of 51,000 plus two catalytically 
inactive subunits having molecular weights of 79,000 and 
120,000.
Catalytic mechanism. The formation of ALA from 
glycine and succinyl-CoA is accompanied by loss of the 
carboxyl group of glycine as carbon dioxide and the 
liberation of CoA. The participation of pyridoxal phosphate 
in ALA synthesis is well established and the first stage in 
the catalytic reaction may be envisaged as a transimination 
between enzyme-pyridoxal phosphate and glycine to form an 
enzyme-pyridoxal phosphate-glycine Schiff base complex, thus 
forming a stable carbanion with loss of a proton. According 
to Jordan and Shemin (1972), this is followed by 
condensation in which the electrophilic acyl-C atom of 
succinyl CoA acts as an electron acceptor to form alpha- 
amino-beta-oxoadipic acid. The decarboxylation occurs 
simultaneously or shortly thereafter.
Induction of ALAS. It has been postulated that the 
control of hepatic ALAS activity by heme repression requires 
the existence of a regulatory heme pool and that most, if not 
all, of the chemicals which cause increased ALAS activity do 
so by primarily or secondarily decreasing the regulatory heme 
pool (Meyer, 1982). Some mechanisms by which chemicals do
this are:
1) Increase in heme breakdown: In the case of 2-
allyl-2-isopropylacetamide (AIA) and other allyl-containing 
compounds, the loss of liver-heme is due to increased
destruction and conversion into abnormal porphyrins or green 
pigments (De Matteis et al. 1982). The endoplasmic reticulum 
is the most important site of heme destruction, and the 
effect seems to be confined to the cytochrome P-450 heme 
without affecting the apoprotein, which is therefore able to 
accept newly formed heme. The new heme is also diverted into 
this degradative pathway and hence the "free heme" pool is 
lowered producing a marked increase in ALAS activity (De
Matteis,1978).
2) Inhibition of heme synthesis: In the case of 3,5- 
diethoxy carbonyl-1,4-dihydrocollidine (DDC) and griseofulvin 
there is some degree of liver heme destruction, but 
inhibition of heme synthesis is probably more important in 
causing the loss of heme and the stimulation of ALAS 
activity. This was shown in experiments where a rapid loss
in heme synthetase activity was caused by DDC before any 
increase in either ALAS activity or in liver porphyrin 
concentration had occurred (Abbritti and De Matteis, 1983).
3) Induction of apoproteins: Among the reactions that
compete for heme in the cell are the syntheses of 
apoproteins, among which synthesis of the apoproteins of 
cytochrome P-450 account for the major part of the total 
hepatic heme synthesized. The concentration of P-450
increases in response to various lipophilic drugs, and is 
regularly accompanied by increased ALAS activity. The 
secondary rise of ALAS activity following apocytochrome P-450 
induction by these compounds may be seen as a coordinated 
adaptive response providing the additional heme for 
hemoprotein synthesis, although the precise manner by which 
induction of apocytochrome and heme synthesis are coordinated 
remains to be elucidated (Meyer, 1982).
4) Combined mechanisms: In contrast to a large number
of drugs and chemicals that induce cytochrome P-450 and 
secondarily lead to a controlled and coordinated induction of 
ALAS, a small number (e.g. DDC) affect heme synthesis in such 
a way as to produce porphyria characterized by a massive 
increase in ALAS and marked hepatic overproduction, 
accumulation and excretion of heme precursors.
1.3.3 Heme oxvaenase.
The mechanisms by which heme and hemoglobin are 
converted to bile pigments in vivo remained controversial 
until 1968, when Tenhunen et al. (1968, 1969) showed that the
microsomal fraction of rat liver, kidney and bone marrow 
possesses a mixed-function oxidase enzyme, heme oxygenase, 
which cleaves the alpha-methene bridge of heme. This heme 
oxygenase system catalyses the degradation of heme to yield 
biliverdin IX-alpha and consumes NADPH and molecular oxygen.
Mechanism of heme degradation via the heme oxvaenase 
svstern. This system consists of heme oxygenase and NADPH- 
cytochrome P-450 reductase, the latter serving as the 
electron donor for the reaction. The mechanism is similar to 
that of the cytochrome P-450 dependent hydroxylation
reactions in microsomes, the heme oxygenase reaction requires 
NADPH and molecular oxygen, indeed it was thought at one time 
that the system involved a cytochrome P-450 as a terminal
oxidase (Tenhunen et al. 1968). However, purification of the 
heme oxygenase by Yoshida and Kikuchi (1979) demonstrated 
that it is independent of any type of cytochrome P-450.
The purified heme oxygenase from rat liver has a
minimum molecular weight of 32,000 (Yoshida and Kikuchi,
1979). It is not a hemoprotein by nature, but it binds heme 
to form a 1:1 complex (Yoshida and Kikuchi, 1978a). In the
heme oxygenase reaction, heme acts as both the substrate and 
coenzyme and the heme oxygenase protein provides a suitable
site for the rapid autocatalytic oxidation of the bound heme. 
The heme binding environment of the heme oxygenase protein 
may be similar to those of hemoglobin and myoglobin with heme 
binding to heme oxygenase through a coordination linkage with 
an aminoacid residue of the protein (Kikuchi and Yoshida,
1980).
The possible chemical and reaction sequence of heme 
degradation, according to Kikuchi and Yoshida (1983), is 
summarized as follows : as a preliminary step, protoheme
binds to the HO protein to form a ferric heme-HO complex. 
Then the heme is reduced to ferrous heme by the NADPH- 
cytochrome P-450 reductase system, followed by binding with 
molecular oxygen to form the oxygenated heme-HO complex this 
initiates the subsequent heme degradation. For the onset of 
the reaction, a reducing equivalent is indispensable (Yoshida 
et al., 19 80a), and the first step of heme oxidation is
assumed to be hydroxylation at the protoheme alpha-methene 
carbon producing alpha-hydroxyheme. The molecular oxygen 
which is bound to heme on HO is probably reduced to a 
‘peroxo* form of dioxygen and this activated form of dioxygen 
is then utilized directly to oxidize the heme moiety.
Although protoheme has four methene carbons which link four
pyrrole rings in the porphyrin moiety, the activated oxygen 
attacks specifically the alpha-methene of heme (Noguchi et
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a l ., 1 9 8 2 ) .
The most difficult unsolved problem in the HO reaction 
is the nature of the chemical sequence from hydroxyheme to 
iron-biliverdin complex involving carbon monoxide liberation. 
It is thought that alpha-hydroxyheme is further oxidized to 
the so called 688 nm substance thereby consuming a reducing 
equivalent. This substance shows an absorption maximum at 
688 nm and is presumed to be an intermediate whose chemical
structure has not been fully elucidated (Yoshida et al.,
1980b). The alpha-methene carbon of the porphyrin is
liberated as carbon monoxide at this step. Conversion of the 
688 nm substance to the biliverdin-iron complex, which still 
remains attached to the HO protein, also requires oxygen and 
reducing equivalents suggesting that another hydroxylation 
reaction is involved in this step. The release of iron from 
the biliverdin-iron complex is facilitated in vitro by the 
addition of either desferrioxamine, a ferric iron chelator, 
or the NADPH-cytochrome P-450 reductase system, indicating 
that for the release of iron from the biliverdin-iron chelate 
in vivo, the iron may have to be reduced to the ferrous state 
by the NADPH-cytochrome P-450 reductase system (Yoshida and 
Kikuchi,1978c).
Induction of heme oxvqena se activity bv 
xenobiotics. Sibahara et al.(1979) and Kikuchi and Yoshida 
(1983), studied the cell-free synthesis of HO directed by 
polysomes isolated from pig alveolar macrophages or rat liver
obtained from animals treated with cadmium and bromobenzene.
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A combination of ( C) or ( H)-labeled leucine and 
antibodies (IgG) specific to pig spleen HO and rat liver HO
was used. In both, macrophages and rat liver, free polysomes 
were the major site of HO synthesis. The ability to conduct 
HO synthesis was greatly increased in the induced systems
and it was proportional to the HO activities observed in the
livers from which the polysomes were prepared. This was 
taken as an indication that all these inducers enhanced the 
synthesis of HO mRNA, which in turn increased HO synthesis.
Stimulation of hepatic HO by hemin and non-heme 
substances was first demonstrated by Tenhunen et al. (1970b). 
Since then a number of reports have appeared dealing with HO 
stimulation by hemin or various non-heme substances in liver. 
The mechanism of induction, however, has eluded convincing 
explanation and different hypotheses have emerged. One 
hypothesis expresses the concept that the induction of HO
reflects the intermediate action of endogenous heme, 
specifically that of derived from P-450 degradation. Evidence 
in favour of this hypothesis is provided by the finding that 
stimulation of liver HO follows administration of exogenous 
heme (Tenhunen et al., 1970), and also by the finding that 
drugs like AIA, which preferentially destroy rapidly turning 
over liver heme, cause a 50I decrease in liver HO activity 
(Maines and Kappas, 1975). A question that still remains to 
be answered is whether the stimulation of the enzyme produced
by several non-heme chemicals is also mediated by heme (De
Matteis, 1 9 62). Bis sell and Hammaker (1 976a, b; 1 9 7 7 )
reported that endotoxin administration produced an increase
in the heme saturation of TP, and that the loss of
radioactivity from prelabelled P-450 heme and the exhalation 
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of CO were noted before the stimulation of HO. In all 
these respects, endotoxin resembled administration of 
exogenous heme. On this basis these authors concluded that 
HO-inducing agents act by primarily producing a release of 
heme from P-450 which in turn induces HO. Similarly, CS
2
administration caused a rapid release of heme from the
1 4
microsomes and significant conversion of 5-amino (4- C)
levulinate into bile bilirubin, as well as HO stimulation.
These results suggested that the main target of CS was the
2
protein moiety, rather than the heme moiety, of the 
cytochrome. A lesion of the apoprotein may be expected to 
reduce the affinity for heme, with some of the P-450 heme 
being released and also with less of the newly formed heme 
being accepted and stabilized in a hemoprotein structure. 
The net result being a substrate-mediated HO induction 
(Jarvisalo et al., 1978).
According to Maines (1984), the possibility of P-450 
heme regulating both the activity of ALAS and HO is an 
attractive concept which fits both the experimental data on 
the response of these enzymes to exogenously administered 
heme, as well as, providing an uncomplicated explanation for 
how homeostatic control of ALAS and HO is maintained. The
difficulty arises when attempts are made to explain the 
induction of HO by hormones, starvation and metals, and to 
rationalise HO induction in extrahepatic systems, which
possess low concentrations of P-450.
It has been reported that insulin and epinephrine
administration moderately induced HO in rat liver. At the 
same time they caused a transient maximal saturation of TP 
with heme. Insulin produced a small transient increase in 
ALAS activity, whereas epinephrine transiently reduced it to 
about 507. of control. However, the content of P-450 was not 
appreciably decreased (Kikuchi and Yoshida, 1983). The 
question thus remains, as to whether the source of heme which 
appeared to have entered into the "regulatory heme" pool was
from P-450 or not. It has been reported that a single
subcutaneous injection of bromobenzene caused a progressive 
and extensive increase in HO activity, with TP heme 
saturation reduced to nearly zero at 12 h or later after 
injection. ALAS activity was transiently reduced to 607. of 
control and afterwards it returned to control values. The P- 
450 content was also gradually decreased. However, the 
activity of HO still continued to increase linearly even 12 
hours after injection (Guzelian and Elshourbagy, 1979; 
Kikuchi and Yoshida, 1983). It is also known that a number 
of transition elements and heavy metals, including Co, M n , 
Fe, Ni, Cu, Zn, Cd, Hg, Pb, Sn, Pt, Sb, Se and some 
organometallic compounds, are powerful inducers of HO.
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Besides producing an initial inhibition in ALAS activity, 
followed by a rebound increase, these elements decrease the 
heme saturation of TP and the cytochrome P-450 concentration 
(Maines and Kappas, 1975, 1 976a, 1 976b, 1 977a; Eaton et al. ,
1 980 ; Sunderman et al., 1983; Rosenberg et al., 1984). The
above mentioned reports led Kikuchi and Yoshida (1983) to
suggest that the release of P-450 heme and the subsequent 
increase in the "free heme” pool size is not a common 
underlying mechanism for the induction of HO. According to 
Maines (1984a), these results attest to the unlikelihood that 
the most effective inducers of HO, metal ions and
bromobenzene, mediate their action on HO via their effect on 
the cellular "free heme" pool.
The following discussion attempts to summarize the 
current hypotheses on the mechanisms of induction in the 
above mentioned cases. De Matteis (1982) has suggested the 
possibility that HO stimulation caused by starvation, iron
and metals could be substrate-mediated via a microsomal 
lesion produced through the action of peroxides. There is
evidence that in vitro. starvation and iron increase the 
peroxidative damage of the microsomal membranes and that
sulfhydryl reagents, such as heavy metals, can convert P-450 
to P-420, resulting in less heme being retained or accepted 
due to a loss of a stable apoprotein structure, which in turn 
would lead to an increase in HO activity. Attention is drawn 
by De Matteis (1982) to the work of Bakken et al. (1972), 
Penning and Scoppa (1977), and Burk and Masters (1975), which
respectively explored the influence of cyclic AMP, lipid 
peroxidation and selenium deficiency on the relationships 
between P-450 and HO induction, providing indirect evidence 
in favour of this attractive hypothesis.
Another hypothesis, particularly as it pertains to the 
action of metal ions, has been suggested by Maines and Kappas 
(1976b). They have hypothesized that the irreversible 
interaction of metal ions with specific receptor sites, 
containing key sulfhydryl groups, may trigger cellular events 
leading to HO induction. They also suggest that a direct 
relationship exists between the cellular content of SH and 
the ability of metals to affect enzyme synthesis. If the 
endogenous content of SH groups is increased by the oral 
administration of cysteine, before the injection of metals, 
the HO inductive action is blocked. Conversely, the HO 
effect can be magnified by depleting the cellular content of 
SH groups prior to the metal administration (Maines and 
Kappas, 1977b). Recent studies indicate that not only metal 
ions, but other agents which increase HO activity, also 
alter the cellular levels of GSH suggesting that 
perturbations in the ratio of GSSG/GSH constitute a common 
basis by which agents of great diversity induce HO activity 
(Chung and Maines, 1981; Chung et al., 1982). An -SH- 
containing protein which would appear to be a good candidate 
for functioning as an HO activity regulator is biliverdin 
reductase (BR) which is highly sensitive to SH reagents
(Kuttyand Maines, 1984).
The possibility that metal ions act via the formation 
of metallophyrin complexes has also been suggested. There is 
evidence supporting the formation of Zn- and Co­
protoporphyrins in vivo (Sinclair et al. 1982). However, it 
has been suggested that no other metal ion forms a stable 
protoporphyrin chelate complex in biological systems (Maines, 
1984a).
In summary, the induction of hepatic HO involves two
apparently different mechanisms; one, heme mediated and other
possibly independent of heme mediation. The moderate
increases in HO activity produced by the administration of
CS , endotoxin, insulin and epinephrine are likely to be 
2
mediated by heme in view of the observations that the 
administration of these agents produced an increase in the 
heme saturation of TP. On the other hand, the extensive 
increase in HO activity observed after the administration of 
metal ions and bromobenzene, seem to be independent of 
mediation by heme, since there was no indication of increases 
in the "free heme" pool as judged from the heme saturation of 
TP (Kikuchi and Yoshida, 1983). However, the precise 
mechanism of HO induction by these inducers is not yet clear.
1 . 3 . 4  T r y p t o p h a n  p y r r o l a s e
Tryptophan pyrrolase also known as tryptophan
oxygenase (TP) is the heme-dependent liver cytosol enzyme
that catalyzes the oxidative cleavage of the pyrrole ring of 
L-tryptophan to produce N *-formylkynurenine in the first and 
rate-limiting step of the kynurenine-nicotinic acid pathway 
of tryptophan degradation (Badawy, 1979).
Some characteristics of the enzvme: Liver is the only
mammalian organ known to contain TP activity, and this enzyme
may be considered as a specific marker for hepatic tissue
(Knox and Mehler, 1950; Rose, 1972). It has been reported 
that TP consists of four subunits (43,000 molecular weight) 
which are nonidentical and separable into two distinct 
species on polyacrylamide gel; the molecular weight of TP is 
about 167,000, comprising 2 moles of heme and 2 moles of 
copper per mole of tetrameric enzyme (Schutz and Feigelson,
1 972; Brady et al. , 1972 ) .
In the liver of man, rat and certain, but not all, 
other animal species (Badawy and Evans, 1974), the enzyme 
exists in at least two forms. The already active reduced 
holoenzyme does not require the addition of hematin for 
demonstration of its activity in vitro, whereas the heme-free 
predominant form (apoenzyme) does (Feigelson and Greengard, 
1961a). The activation of the rat liver enzyme in vitro
consists of two steps, both of which require the 
participation of tryptophan. The inactive apoenzyme is first 
conjugated with hematin, this reaction requires a small 
concentration of L-tryptophan, although some of its congeners 
can replace it. The oxidized holoenzyme formed by 
conjugation is then reduced by ascorbic acid, this reaction 
also requires tryptophan which can not be replaced by its 
congeners. The reduced holoenzyme that is formed is active 
in the catalytic reaction, this reaction also specifically 
requires L-tryptophan as its substrate (Knox, 1966).
Catalytic mechanism. The preponderant existent
evidence suggest that at the active site one substrate,
tryptophan, binds to the cuprous moiety and the other
substrate, oxygen, binds to the heme iron. It seems possible
that in the activated transition complex either or both
substrates may serve as bridging ligands between the heme and
copper moieties, bringing the system into the appropriate
electronic conformation. This generates enzyme-bound
electrophilic tryptophan and nucleophilic 0 species which
2
then interact to form the reaction product, formylkynurenine 
(Feigelson and Brady, 1974).
Regulation of trvotopha n pyrrolase activity. Knox 
(1951, 1955) was the first to demonstrate the enhancement of
rat TP activity by both corticosteroids and tryptophan 
Glucocorticoid hormones act directly upon the isolated
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perfused liver, as well as upon fetal liver cells in organ 
culture to increase the levels of TP, thus indicating that 
the hepatocyte is a direct target cell for these hormones
(Feigelson and Brady 1974). The increased production of
enzyme protein occurs in a process distinct from substrate 
induction and does not involve prior saturation of apo-TP 
with its heme cofactor. The hormonal mechanism involves the 
induction of apoenzyme synthesis, probably by increasing the 
amount of TP mRNA (De Lap and Feigelson, 1978). The
substrate mechanism consists of decreased degradation of pre­
existing apo-TP in the presence of a normal rate of
synthesis. It is thought that tryptophan stabilizes the 
enzyme (Badawy and Evans, 1975). There is also evidence to 
suggest that tryptophan may in addition enhance the synthesis 
of liver heme (Badawy and Evans, 1973a). However, further 
work is clearly required to elucidate the mechanism (s) by 
which tryptophan exerts its effects. The existence of a 
cofactor mechanism in the regulation of TP activity has been 
suggested by Badawy (1978) on the basis that the 
administration of 5-aminolevulinate or hematin increases the 
saturation of apo-TP with its heme activator (Badawy and 
Evans, 1973b, 1975), in a way resembling tryptophan
administration, however, neither compound stabilizes TP. It 
has been suggested that reciprocal control mechanisms between 
hemoprotein and ALAS are involved in the coordinate 
synthesis of the heme and apoenzyme moieties of TP (Marver et 
al., 1966). It has also been shown (Badawy, 1977a,b), that
saturation of the apoenzyme is sensitive to treatments that
affect the heme biosynthetic pathway.
Relationships between TP and the "free heme" pool. 
The existence of an interrelation between heme concentration 
and ALAS and HO activities at the cellular level has led to 
the concept of a regulatory "free heme pool" (Granick et al., 
1975). Although, it has not been possible to define the 
identity and intracellular localization of this pool, it 
could be visualized as a small concentration of free or 
loosely-bound heme with a rapid rate of turnover into which
newly synthesized heme is fed and out of which heme is drawn
for either the synthesis of hemoproteins or for degradation 
(De Matteis, 1 975 ) .
The theoretical size of the "free heme" pool comes 
from the work of Granick et al. (1975). In his study, avian 
embryo liver cells in culture were treated with AIA, after 
which several concentrations of hemin were added. The hemin 
concentration that inhibited the increase in the
protoporphyrin yield by 507. was 0.05 to 0.1 uM and this was
taken as an indication of the "free heme" pool size.
According to Granick's hypothesis, this minute amount 
of free heme (0.17. of the total hemoprotein-heme of the 
hepatic parenchyma cell) would be most suitable to control 
the rate of heme metabolism. If the heme generated in the 
mitochondria caused the "free heme" to increase beyond 100
nM, the formation of ALAS would be repressed, the increased 
heme would be degraded more rapidly by HO and, more slowly, 
it would induce HO. In contrast, when "free heme" decreased 
below 50 nM the synthesis of ALAS would not be repressed, 
more of this enzyme would be made, and therefore, more heme 
would be produced. It was also suggested that the heme 
combines with some apoprotein to modulate the translation of 
ALAS. As discussed previously, there is evidence suggesting 
that TP activity is subject to regulation by its cofactor 
heme (Druyan and Kelly, 1972), and that the heme saturation 
is also affected by changes in heme metabolism; the heme 
saturation of apo-TP is decreased by agents that destroy heme 
or inhibit its synthesis, whereas the opposite is true for 
treatments increasing the utilization or the synthesis of 
this pigment (Badawy and Evans, 1973a). It has been 
calculated (Badawy, 1978) that during the early depletion of 
TP by DDC plus phenylbutazone, there is a heme loss of 0.093 
uM from the cytosol. This loss represents the largest 
depletion of TP under conditions of potentiated experimental 
porphyria, and is similar to the concentration (0.1 uM) 
suggested by Granick et al. (1975) for the readily 
exchangeable "free heme". The above considerations have led 
Badawy (1978) to suggest that TP utilizes the "free heme" 
pool involved in the regulation of heme biosynthesis, and 
that this enzyme may play an important role in the regulation 
of heme biosynthesis.
1-3.5 Epoxide Hvdrolase.
Epoxide hydrolase (EH) is the microsomal enzyme that 
catalyzes the hydration of epoxides to trans -1, 2-
dihydrodiols. Its role with regard to normal mammalian 
function is presently unclear although a number of endogenous 
steroids and lipids have been found to serve as substrates. 
Epoxides of cholesterol and fatty acids may be formed during 
lipid peroxidation and EH could conceivably protect the cell 
against possible deleterious effects of these lipid epoxides 
(Watabe et al., 1980). Considerably more attention has been 
given to the role of EH in metabolizing xenobiotic compounds 
of toxicological potential. Many chemical substances are
aromatic or olefinic compounds which can be metabolized by
the microcrosomal P-450 system producing reactive epoxides 
and arene oxides. Since certain of these compounds have 
toxic, mutagenic and carcinogenic properties, the ability of 
epoxide hydrolase (EH) to convert epoxides to chemically less 
reactive trans-dihydrodiols is an important detoxication 
mechanism. However, it has also been shown that P-450 and EH 
convert certain polycyclic aromatic hydrocarbons to more 
reactive bay region diol epoxide derivatives (Lu and Miwa, 
1980). Thus, depending on the particular metabolic pathway, 
EH can either play the role of activator or inactivator of
the mutagenicity of polycyclic aromatic hydrocarbon 
derivatives.
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Some characteristics of the enzvme. The purified 
microsomal enzyme contains a single polypeptide with a 
molecular weight of 50,000 in the presence of sodium 
dodecylsulfate; the aminoacid analysis indicate that it has a 
relatively high content of tryptophan and tyrosine, and that 
it does not contain a prosthetic group such as heme or flavin 
(Lu et al. , 1 975 ) .
Although the substrate specificity of EH is very 
broad, it is highly regiospecific with monosubstituted 1, 1-
and cis -1, 2- disubstituted epoxides which contain large
lipophilic groups being the most readily hydrated (Oesch, 
1973). The available evidence indicates that EH-catalyzed 
hydration occurs by nucleophilic attack at the least hindered 
epoxide carbon atom by an incoming hydroxyl ion resulting in 
ring opening away from this ion and the formation of trans- 
dihydrodiol product (Lu and Miwa, 1980).
Induction of the enzvme. EH is induced by the 
administration of certain xenobiotics, traditionally the most 
popular inducing agent has been phenobarbitone (Guengerich, 
1982). In earlier studies, 3- methyl- cholanthrene has been 
reported to be more potent than phenobarbitone (Oesch, 1973), 
but the effect seems to be variable and in some cases non­
existent (Jerina et al., 1977). EH is also induced by 
polyhalogenated biphenyls (Oesch et al., 1977). In general, 
compounds that induce EH also appear to induce P-450 and
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other drug metabolizing enzymes, but it is thought that these 
enzymes are under separate genetic control (Oesch et al,. 
1 973 ) .
Epoxides which are good substrates of EH are not good 
inducers, possibly due to their fast hydration by the enzyme 
(Schmassmann et al. 1978). Schmassmann and Oesch (1978) 
studied trans-stilbene oxide as an example of a substance 
that can induce EH without inducing P-450 enzymes. Although 
it strongly induced EH, the activity of four monooxygenase 
parameters was not changed, but the activity of 7- 
ethoxycoumarin O-deethylation was increased by a similar 
degree to EH, and the benzo[a]pyrene metabolite pattern was 
drastically changed (Bucker et al., 1979). Thus, at this time 
there appears to be no xenobiotic that will specifically 
alter EH activity.
1 . 4 Effects of arsenic and selenium on heme met aboli s m .
1.4.1 Effects of arsenic on heme metabolism.
Woods and Fowler (1977b, 1978) exposed rats and mice
to (AsV) in concentrations of 20, 40 and 85 mg/1 in drinking
water. At the end of the exposure period, a non dose-related
decrease in ALAS activity was observed. A marked dose-related
decrease in heme synthetase activity was also observed. HO
activity was not determined. In rats, the activities of ALA
dehydratase and uroporphyrinogen synthetase were not
significantly altered. In contrast, the activity of
uroporphyrinogen synthetase was increased in a dose-related
manner in mice. Dose-related increases in urinary
porphyrins, without significant changes in urinary excretion
of ALA or porphobilinogen, were also observed. Cytochrome P-
450 concentration and aminopyrine demethylase activity were
not significantly altered. Subsequent studies (Fowler and
Mahaffey, 1978) showed that the combination of lead plus AsV
produced an additive effect on coproporphyrin, but not
uroporphyrin excretion. Woods et al. (1981) reported that the
-3
addition of HgCl , AsV, AsIII and other metals (10 M),
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reduced the activity of uroporphyrinogen decarboxylase in 
vitro: further addition of reduced glutathione or
dithiothreitol completely prevented the effect.
Martinez et al. (1983) administered AsIII via drinking 
water in concentrations of 5, 50 and 100 ppm for up to 7
weeks to female rats. A dose-related increase in urinary 
uroporphyrin excretion was observed after one week of 
treatment. As the treatment continued, a gradual decrease in 
the response was observed, such that at the end of treatment 
only the rats exposed to the highest level showed significant 
uroporphyrinuria. These changes in the magnitude of the 
response were interpreted as part of an adaptive process 
which may limit the usefulness of uroporphyrin excretion as a 
biological index of As toxicity.
Sardana et al. (1981) reported that AsIII (25 to 100 
umol/kg) produced dose-related increases in hepatic ALAS and 
HO activities accompanied by corresponding reductions in P- 
450 content. AsV (25 to 100 umol/kg) did not increase hepatic 
HO, but a small increase in renal HO was observed. 
Administration of the parasiticidal agents melarsoprol 
(organic AsIII) and tryparsamide (organic AsV) also increased 
hepatic HO activity. However, Sardana et al. (1982) reported 
that in chick embryo liver cells, both AsIII and melarsoprol 
were powerful HO inducers while AsV and tryparsamide failed 
to do so.
These effects and their implications are discussed in 
detail in the following Chapters.
1.4.2 Effects of selenium on heme metabolism.
Maines and Kappas (1976a) reported that sodium 
selenite administered subcutaneously to rats (10 to 100 
umol/kg), produced non dose-related increases in ALAS 
activity and dose-related increases in HO activity. A dose- 
related inhibition in ethylmorphine N-demethylase activity 
was also observed. No significant reductions in P-450 content 
or changes in hepatic porphyrin concentration were noted. 
These findings were observed 14.5 hours after treatment. 
Eaton et al. (1980) reported that doses of 13 and 25 umol/kg 
increased HO activity. However, only the highest dose reduced 
P-450 concentration in 25'/.. Sardana et al. ( 1 982 ) reported 
that addition of sodium selenite to cultured chick embryo 
cells (concentration not stated) did not increase HO 
activity.
Schnell et al. (1983) reported that 72 hours after
i.p. administration of 2.4 mg/kg of sodium selenite there was
a significant decrease in ethylmorphine N-demethylase
activity ( 287.) and cytochrome P-450 content (187.). No change
in aniline hydroxylase or NADPH cytochrome c reductase was
observed. Exposure to selenite in the drinking water (1, 2 or
4 mg/1) for 30 days produced no alterations in any of the
parameters measured. The addition of selenite to microsomes
-3
(final concentration 10 M) obtained from untreated rats 
resulted in 407 inhibition of aniline hydroxylase and
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ethylmorphine N-demethylase activities. However, no change 
was observed in P-450 concentration. Reiter and Wendel (1985) 
reported that exposure to SelV in the diet (10 ppm) for 6 
months produced no significant effects on HO activity or in 
aminopyrine-N-demethylase. However, a 502 reduction in P-450 
concentration and ethoxycoumarin O-deethylase activity was 
observed.
These effects and their implications are discussed in 
detail in the following Chapters.
Aims of this study This work was undertaken to study 
some effects of arsenic and selenium on heme metabolism with 
reference to : 1) the time-course and dose relationships of
As effects on the hepatic "free heme" pool, as measured by 
the heme saturation of tryptophan pyrrolase; 2) some aspects 
of the target organ selectivity of AsIII and AsV, with 
special reference to testicular effects; 3) The comparison 
between the effects of As and Se on cytochrome P-450 and P- 
450-dependent monooxygenases. The overall objective being to 
gain some insight on the effects of these metalloids on heme 
metabolism which might be related to the genesis of overt 
toxic effects.
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CHAPTER TWO 
MATERIALS AND METHODS
2 . 1 CHEMICALS.
Sodium arsenite and sodium arsenate, Suprapur grade, 
were supplied by Merck GmbH (Darmstadt, West Germany). Sodium 
selenite and cadmium chloride were obtained from British Drug 
Houses Ltd. (Poole, Dorset).
NADH, NADPH, glycine, ATP, sucrose, EDTA, sodium 
succinate, biliverdin, pyridoxal-5'-phosphate, bilirubin and 
Tris (Trizma) were all purchased from Sigma London Chemical 
Co. Ltd. (Poole, Dorset).
14 3
[2.3- C ] succinic acid, [7- H] styrene oxide and 5- 
14 2
amino [4- C] levulinic acid hydrochloride were supplied by
Amersham International pic (Amersham, Buckinghamshire).
Hemin, ALA and L-tryptophan were supplied by British 
Drug Houses Ltd. (Poole, Dorset).
Sodium dithionite and Folin-Ciocalteu phenol reagent
were obtained from Fisons Scientific Equipment Ltd.
(Loughborough, Leicestershire).
Styrene oxide was purchased from Aldrich Chemical Co.
Ltd. (Poole, Dorset).
Ethoxyresorufin (50 uM in methanol) and resorufin 
(10uM in ethanol) were purchased from Pierce and Warriner 
Ltd. (Chester, Cheshire).
The Dowex AG 50W-X8 resin in the sodium form, 200 
4 0 0 mesh, was obtained from Bio-Rad Co. (Richmond, 
California).
Carbon monoxide and oxygen were supplied by British 
Oxygen Co. (London).
All other reagents were of Analar grade or equivalent.
2.2 ANIMALS AND TREATMENTS.
2.2.1 Animals.
Male Wistar Albino rats, of the University of Surrey
strain (180-210g), were obtained from the University of
Surrey Animal Unit. The rats were housed in cages with
sawdust bedding (Lee and Co., Chertsey, Surrey), and were
allowed food (LAD-1, K + K, Croydon) and water ad. libitum ,
except when indicated. A 12 h light/dark cycle was operated
o
( 0700-1 900 light), at a temperature of 22 C and 507. humidity.
2.2.2 T reatments.
Food deprivation
In the acute studies, animals were allowed access to 
food and water ad. libit urn for 24 hours, then deprived of food 
for the following 24 hours and subsequently treated. food 
deprivation was continued until the animals were sacrificed. 
In the subchronic study, food was witheld for 24 hours before 
sacrifice.
Control animals
Control animals received 0.1 ml of sodium chloride 
0.97. (w/v) by subcutaneous injection in the loose tissues of
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the abdominal region. Animals were killed by cervical 
dislocation 16 h after the injection, except were indicated.
Treated animals
The elements were administered as a solution in 
distilled water and injected subcutaneously in the loose 
tissues of the abdominal region, the cervical region was also 
used when two different metalloids were injected. The doses 
of sodium arsenite (AsIII) were 12.5, 25, 50, 75 and 100
umol/kg Those of sodium arsenate (AsV) were 25, 50, 100, 150
and 200 umol/kg. Those of sodium selenite (SelV) were 2.5, 5,
10, 20 and 40 umol/kg. Those of cadmium chloride were 7 and
20 umol/kg. Animals were sacrificed by cervical dislocation 
16 h after the injection. Alternatively, for time course 
studies, animals were killed at various time intervals. In 
the subchronic study, the animals were exposed to AsIII in 
the drinking water at a concentration of 50 mg/1 for period 
of 5, 10, 20 and 30 days, and sacrificed as described above.
2.3 PREPARATION OF SUBCELLULAR FRACTIONS FROM LIVER,
KIDNEY AND TESTIS.
This method is based on that of de Duve et al. (1959).
Principle. The differential centrifugation of tissue
homogenates separates the components of interest into 
fractions which can then be analysed for their enzyme
content, revealing the association of particular enzymes with 
cellular structures.
Reagents
20 mM Tris-HCl buffer, pH 7.4, containing 250 mM
sucrose.
20 mM Tris-HCl buffer, pH 7.4, containing 250 mM
sucrose and 5.4 mM EDTA.
Method
Livers were perfused in situ through the portal vein 
with ice-cold 0.9X NaCl until bleached of hemoglobin. Liver 
and other organs excised at sacrifice were blotted dry and 
weighed. After scissor- mincing they were homogenised in 3 
volumes of ice-cold 20 mM Tris-HCl buffer, pH 7.4, containing 
sucrose (250 m M ), using three strokes of a Potter-Elvejhem 
glass-teflon homogeniser, with a pestle rotating at 2400
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r . p . m .
A sample of the homogenate was retained for further
analysis, and the remainder was centrifuged in 50 ml
polycarbonate tubes at 10,000 x g for 20 minutes, using an 8
x 50 ml aluminium head rotor in an MSE "High Speed 18"
o
refrigerated centrifuge at 4 . The supernatant was decanted
and recentrifuged at 40,000 rpm (105,000 x g) for one hour, 
using an 8 x 35 titanium angle head rotor in an MSE "Prepspin 
50" refrigerated centrifuge.
The supernatant obtained (cytosol) was retained for
further analysis, and the pellet was resuspended in ice-cold
20 mM Tris-HCl, pH 7.4, containing sucrose (250 m M ), using a
Potter-Elvehjem homogeniser. The resulting suspension was
recentrifuged at 40,000 rpm for 1 hour. The washed microsomal
pellet was finally resuspended in ice-cold 20 mM Tris-HCl
buffer, pH 7.4, containing sucrose (250 m M ) and EDTA (5.4
m M ), to a concentration equivalent to 1.0 g wet weight of
tissue per ml. The microsomal suspension was either assayed
immediately or stored in 1.5 ml aliquots in polycarbonate
o
sample cups at -20 C.
2.4 A S S A Y  OF S O L U B L E  E N Z Y M E S .
2.4.1 Trvptophan Pyrrolase.
This method is based on that of Badawy and Evans
(1975).
Principle. The product of tryptophan oxidation by TP, 
formylkynurenine, is hydrolyzed by formylase normally present 
in excess in liver. The kynurenine formed is determined by 
its absorption at 365 nm. It can be measured either in the 
absence (holoenzyme activity) or in the presence ("total 
enzyme" activity) of added hematin. The apoenzyme activity is 
calculated by difference.
Reagents
0.1 M Potassium phosphate buffer, pH 7.4, containing 
sucrose (250 m M ). In the subchronic study, this buffer was 
substituted by 20 mM Tris-HCl buffer at the same pH and 
sucrose concentration.
0.03 M L-tryptophan.
0.2 M Sodium phosphate buffer, pH 7.0.
0.6 M Sodium hydroxide.
0.9 M Trichloroacetic acid.
0.36 mM Hematin hydrochloride in 0.1 M sodium
hydroxide (1.17 mg/5 ml).
Method.
Samples of the homogenate (4.5 ml) were diluted with
4.5 ml of the homogenising buffer. They were added to the
incubation mixture containing 3 ml of tryptophan (0.03 M), 9
ml of 0.2 M sodium phosphate buffer pH 7.0 and 15 ml of
distilled water. The mixture was divided into two aliquots,
and 0.1 ml of the hematin solution was added to one aliquot,
to give a final concentration of 2 uM. Samples (3 ml) of
o
the assay mixture where incubated at 37 C for 0, 15, 30, 40,
50 and 60 minutes with shaking in stoppered tubes in an
atmosphere of 0 . The reaction was stopped at each of the
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above time-intervals by the addition of 2 ml of 0.9 M
trichloroacetic acid; the tubes and contents were shaken for
a further 15 min and then centrifuged at 2,000 rpm for 20
min. To 2.5 ml of the supernatant, 1.5 ml of 0.6 M were
added. The kynurenine present was determined at 365 nm in a
Perkin-Elmer Lambda 5 spectrophotometer, and the
concentration was calculated using an extinction coefficient 
-1 -1
of 4540 M cm . T P  activity was calculated from the increase
in the E with time during the linear phase and expressed 
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as umol of kynurenine formed/g (wet weight) of liver.
2.4.2 ALA Synthetase,
This method is based on that of Condie and Tephly 
(1978), as modified by Oe Matteis (1981).
Principle. ALAS catalyzes the condensation of glycine and
succinyl-CoA to form ALA. Its activity is determined in rat
1 4
tissues by measuring the incorporation of C C]succinate into
1 4
ALA and by isolating the C C]ALA on Dowex 50 ion-exchange 
columns. This is essentially the method described by Ebert et 
al. (1970), but modified by the authors mentioned above.
Reagents.
Reaction Cocktail (Tris-glycine-EDTA):
1 M Tris-HCl, pH 7.2 (90 ml).
1 M Glycine (120 ml).
0.1 M EDTA (90 ml).
1.6 mM Pyridoxal phosphate.
The pH was adjusted to 7.5 with 1 M NaOH. This
o
solution was prepared fresh each week and stored at 4 C. 
Pyridoxal phosphate (7.9 mg/20 ml) was added to the cocktail 
on the day of the experiment.
4 mM Sodium succinate.
1 4
[2,3- C Isuccinic acid was dissolved in 4 mM 
2
succinate to achieve a specific activity of 2.73 uCi/umol.
1 4
5-amino [4- C] levulinic acid hydrochloride was 
dissolved in 10 mM HC1 to achieve a specific activity of 1 
uCi/ml.
Carrier ALA: 16.3 mg/10 ml 0.1 M HC1.
1.8 mM ATP (5 mg/ml).
25/ (w/v) Trichloroacetic acid.
17. (w/v) Trichloroacetic acid.
1 M Acetate buffer, pH 4.6.
0.1 M Acetate buffer pH 3.9.
Methanol - 0.1 M acetate buffer pH 3.9 mixture (2:1,
v/v).
1 M HC1.
10 mM HC1.
1 M Sodium acetate.
Equilibrated ethylacetate: Equal volumes of 1 M
acetate buffer (pH 4.6) and ethylacetate were mixed. The 
layers were allowed to separate and the top layer was 
collected.
Preparation of cation exchange resin.
Dowex 50 resin (A6 50W-X8, H form) 200-400 mesh, was
converted to the sodium form by heating 2-3 times in 2 M NaOH 
o
at 50 C until no colour was observed in the wash. The resin
was then washed extensively with water and equilibrated with
0.1 M acetate buffer, pH 3.9. The resin was added to
chromatographic columns (20 cm x 1 cm). A resin column of 2
71
cm in height was used.
Method .
An aliquot (0.5 ml) of a 107 (w/v) whole organ
homogenate was added to the incubation mixture containing 250
14
ul of the reaction cocktail, 100 ul sodium [2,3 C] 
succinate, 150 ul ATP. The combined reagents were incubated 
without shaking for 1 h. At the end of the incubation period, 
250 ul of trichloroacetic acid (25*/) were added to stop the 
reaction, followed by 50 ul of carrier ALA.
I solation and counting of ALA.
Following centrifugation, supernatant separation and
pellet resuspension in 1.57. TCA , the supernatants were
pooled and added to the chromatographic column. The sample
was allowed to flow through and the columns were washed
successively with 20 ml of 0.1 M acetate buffer (pH 3.9), 20
ml methanol-0.1 M acetate buffer, pH 3.9 (2:1 v/v), and 10 ml
of 0.01 M HC1. The ALA was then eluted with 5 ml of 1 M
sodium acetate, pH 8.5. As a standard, samples containing 5- 
14 14
amino [4- C] levulinic acid instead of [2,3- C ] succinic
2
acid were run through the same process. Over 907. of the ALA
applied to the columns was recovered by these isolation
procedures.
An aliquot (0.5 ml) of the eluate was taken for
counting. In a stoppered tube, 4.5 ml 1 M acetate buffer (pH 
4.6), 1.5 ml 1M HC1 and 100 ul of acetyl acetone were added
to the remaining 4.5 ml of eluate. The tubes were stoppered 
tightly- and boiled for 20 minutes, allowed to cool and added 
with 4.5 ml of equilibrated ethyl acetate. The mixture was 
shaken and allowed to separate. 2 ml of the ethyl acetate 
phase were counted.
Enzyme activity was expressed as pmol of ALA formed 
per mg of homogenate protein per hour.
2.4.3 Biliverdin reductase.
This method is based on that of Krasny and Holbrook
(19 7 7).
Principle. Biliverdin reductase is the cytosolic enzyme that 
catalyzes the reduction of the central alpha-methene bridge 
of biliverdin to bilirubin. The enzyme activity is measured 
spectrophotometrically by following the rate of bilirubin 
formation at 468 nm.
Reagents.
20 mM Tris-HCl buffer, pH 7.4, containing sucrose (250 
m M ) and EDTA (5.4 m M ).
60 uM Biliverdin.
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27 mM NADPH.
Cytosol ~ 2 0 mg protein/ml.
Method.
To an appropriate amount of cytosol in a test tube
(usually 1 ml for liver, 1.5 ml for kidney and 3 ml for
testis), were added 100 ul of biliverdin solution, and
corresponding amounts of Tris-HC1/sucrose buffer to make a
total volume of 3 ml. The suspension was gently agitated to
mix the contents and then divided equally between two 1.5 ml
optical cuvettes having a 1 cm light path. The cuvettes were
o
preincubated for 5 minutes at 37 C in a constant temperature
cuvette chamber. The reaction was then initiated by addition
of 30 ul of NADPH to the sample cuvette and the same volume
of buffer to the reference cuvette. The rate of bilirubin
formation was determined by continuously recording for 5
minutes the increase in optical density at 468 nm. Enzyme
activity was calculated using a millimolar extinction
-  1 -  1
coefficient of 30 mM cm and expressed as nmol of bilirubin 
formed per hour, per mg of cytosolic protein.
2 . 5 A S S A Y  OF  M I C R O S O M A L  E N Z Y M E S .
2.5.1 Heme oxygenase.
This method is based on that of Tenhunen et al.
(19 6 9).
Principle. The microsomal heme oxygenase catalyzes the 
oxidative cleavage of the heme (ferriprotoporphyrin) ring at 
the alpha-methene bridge, to form the linear tetrapyrrole 
biliverdin IX. The initial product formed from HO
(biliverdin) has a broad absorption peak with a maximum at 
670 nm with a low extinction coefficient and is not an 
optimal reaction product to assay spectrophotometrically. For 
this reason, a source of NADPH-dependent biliverdin reductase 
is added in excess to the incubation mixture to
quantitatively convert the biliverdin formed during the
reaction to bilirubin, which is then measured 
spectrophotometrically, by following the rate of formation of 
bilirubin at 468 nm.
Reagents.
20 mM Tris-HCl buffer, pH 7.4, containing sucrose (250 
mM) and EDTA (5.4 m M ).
1.7 mM Hematin hydrochloride dissolved in 0.1 M 
sodium hydroxide.
27 mM NADPH.
Microsomal suspension, ~ 2 0 mg protein/ml.
Cytosol ~ 20 mg protein/ml.
Method.
To an appropriate amount of microsomal suspension in a
test tube (usually 0.5 ml for liver and testis, and 1 ml for
kidney) were added respectively 2.5 or 2.0 ml of TrisHCl
buffer, pH 7.4, containing sucrose (250 m M ) and EDTA (5.4
mM), 0.5 or 1 ml of cytosol and 44 ul of hemin hydrochloride,
to make a total volume of 3.5 ml. The suspension was gently
agitated to mix the contents and then divided equally between
two optical cuvettes having a 1 cm light path. The cuvettes
o
were preincubated for 5 min at 37 C in a constant temperature
cuvette chamber. The reaction was then initiated by addition
of 20 ul of NADPH to the sample cuvette and the same volume
of buffer to the reference cuvette. The rate of bilirubin
formation was determined by continuously recording (5 to 10
min) the increase in optical density at 468 nm. Enzyme
activity was calculated using a millimolar extinction
- 1  - 1
coefficient of 30 mM cm and expressed as nmol of bilirubin 
formed per hour per mg of microsomal protein.
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2.5.2 Epoxide H v d r o l a s e .
This method is based on that of Oesch et al. (1971).
Principle. Microsomal epoxide hydrolase catalyses the
hydration of both alkene and arene oxides to the
corresponding trans-dihydrodiols. The activity was determined
3 3
by measuring the conversion of [7- H]-styrene oxide to [7- -
H]-styrene glycol.
Reagents.
0.5 M Tris-HCl buffer, pH 9.0.
40 mM C7-3-H]-styrene oxide (156.7 uCi/mmol) in 
acetonitrile.
Method.
To an appropriate amount of hepatic microsomal
suspension in a Sovirel tube (usually 100 ul) were added 100
ul of 0.5 M Tris-HCl buffer (pH 9.0) and distilled water to
give a final volume of 380 ul. The tubes were preincubated in
o
a shaking water bath (120 cycles/min) at 37 C for 5 minutes.
3
The reaction was started by adding 20 ul of [7- -H]-styrene
oxide working solution (2.0 mM, 125 nCi). After 7 minutes of
o
incubation at 37 C, the reaction was terminated by the
o
addition of 9 ml of petroleum ether (boiling range 40-60 C).
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The incubates were extracted on a rotary mixer, then
centrifuged for 3 minutes at 1000 rpm. The aqueous and
organic layers were separated by freezing in a
cardice/ethanol bath and the upper organic layer was -
discarded. To the remaining aqueous phase, 9 ml of petroleum
ether were added and the process of tumble mixing and layer
separation was repeated. Two ml of ethyl acetate were added
to the remaining aqueous phase and tumble mixed for 1 0
3
minutes in order to extract the reaction product, [7- H]-
styrene dihydrodiol. Aqueous and organic phases were
separated by centrifugation at 2000 rpm for 5 minutes and 0.5
ml aliquots of the ethyl acetate layer were removed for
scintillation counting. Blanks containing boiled microsomes,
3
and [7- H]-styrene oxide standards were also prepared.
2.5.3 Hepatic cytochrome P-450 .
This method is based on that of Omura and Sato (1964).
Principle. Sodium dithionite when added to a microsomal 
suspension reduces the cytochrome P-450. The subsequent 
gassing of the sample with CO results in a CO-complex of
reduced cytochrome P-450, which has a maximal spectral
absorption at 450 nm.
Reagents.
Carbon monoxide.
Sodium dithionite, solid.
6 6 mM Tris-HCl buffer, pH 7.4.
Method.
Aliquots of microsomal suspensions were diluted to
about 2 mg protein/ml with 6 6 mM Tris-HCl buffer, pH 7.4. A
few crystals of sodium dithionite were added, mixed and the
solution divided equally between two cuvettes. Following the
establishment of a baseline of equal light absorbance between
400 and 500 nm, carbon monoxide was bubbled through the
sample cuvette for 30 seconds, and the resulting difference
spectrum was recorded. The amount of cytochrome P-450
present in the sample was calculated using the peak
absorbance at 450 nm minus the absorbance at 490 nm, using an
- 1  -  1
extinction coefficient of 91 mM cm
2.5.4 Hepatic cytochrome Jb .
5.
This method is due to Omura and Sato (1964).
Principle. The addition of a source of reducing equivalents,
NADH, to the contents of the sample cuvette containing a
catalytic amount of NADH-cytochrome b reductase, results in
5
the reduction of cytochrome b with an associated change in
5
spectra between 409 and 424 nm.
Reagents.
6 6 mM Tris-HCl buffer, pH 7.4.
11.5 mM NADH.
Method .
Aliquots of microsomal suspensions were diluted to
about 2 mg protein/ml with 6 6 mM Tris-HCl buffer pH 7.4, and
were divided equally between two cuvettes. Following the
establishment of a baseline of equal light absorbance between
400 and 500 nm, NADH was added to the sample cuvette to give
a final concentration of 0.45 mM and the resulting difference
spectrum was recorded. The concentration of cytochrome b was
5
calculated by measuring the change in absorbance between 424
-  1 -  1
and 409 nm using an extinction coefficient of 185 mM cm
2.5.5.Renal cytochromes P-450 and fc> .
5
This method is based on that of Orrenius et al.
( 1 973 ) .
Principle. According to Orrenius et al. (1 9 7 3  ), the 
classical method for estimation of cytochromes P-450 and b
5
gives inaccurate results if hemoproteins which have C0- 
induced absorbance bands in the 450-490 nm wavelength region 
are present in great quantities in the microsomal suspension. 
At least two such proteins, hemoglobin and mitochondrial 
cytochrome oxidase, are present in kidney microsomes.
Reagents.
20 mM Tris-HCl buffer, pH 7.4, containing sucrose 
( 2 5 0 mM).
300 mM Sodium succinate.
16.7 mM NADH
Carbon monoxide.
Sodium dithionite, solid.
Method.
Aliquots of microsomal suspensions were diluted to 
about 2 mg protein/ml with 200 mM Tris-HCl buffer, pH 7.4 
containing 250 mM sucrose. 100 ul of 300 mM sodium succinate 
were added to 3 ml of microsomal suspension, mixed and 
bubbled with CO for 30 seconds. The mixture was incubated at 
room temperature until maximal mitochondrial pigment 
reduction was achieved. Following the establishment of a 
baseline of equal light absorbance between 400 and 500 n m , 2 0  
ul of 16.6 mM NADH were added to the sample cuvette and the 
resulting difference spectrum was recorded. A few crystals of 
sodium dithionite were added to the sample cuvette and the
resulting difference spectrum was again recorded. The amounts
of cytochromes P-450 and b present in the sample were
5
calculated using extinction coefficients of 91 and 185 mM 
1 - 1  
cm respectively.
2.5.6 Ethoxvcoumarin O-deethvlase.
This method is based on that of Ullrich and Weber
( 1972 ) .
Principle. 7-ethoxycoumarin is metabolised by hepatic 
microsomes to a single major fluorescent product, 7- 
hydroxycoumarin (umbelliferone). The rate of reaction may be 
measured by monitoring the linear increase in fluorescence 
with time.
Reagents.
6 6 mM Tris-HCl buffer, pH 7.4.
1 mM 7-Ethoxycoumarin.
1 mM 7-Hydroxycoumarin.
6.2 mM NADPH.
Method.
1 0 0 ul of microsomal suspension (about 2 0 mg 
protein/ml), 250 ul of 7-ethoxycoumarin (1 m M ) and 2.15 ml of
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6 6 mM Tris-HCl buffer, pH 7.4 were mixed in a fluorescence
o
cuvette and allowed to equilibrate to 3 7 C for 5 minutes in 
the thermostatted cuvette holder of a Perkin-Elmer LS-5 
fluorescence spectrophotometer. The baseline was recorded and 
20 ul of 6.2 mM NADPH was added to the cuvette and mixed. The 
increase in fluorescence at 450 nm was monitored for at least 
3 minutes, using an excitation wavelength of 370 nm. 
Standards of 7-hydroxycoumarin were added to calibrate the 
reaction.
2.5.7 Ethoxvresorufin O-deethvla se.
This method is based on that of Burke and Meyer
( 1 975 ) .
Principle. Hepatic microsomes metabolise 7-ethoxyresorufin to 
a single fluorescent product, resorufin. The rate of the 
reaction may be measured by monitoring the linear increase in 
fluorescence with time.
Reagents.
6 6 mM Tris-HCl buffer, pH 7.4.
50 uM 7-ethoxyresorufin in methanol.
10 uM resorufin in ethanol.
31 mM NADPH.
Method.
50 ul of microsomal suspension (about 2 0 mg
protein/ml), 10 ul of 50 uM 7-ethoxyresorufin and 2.45 ml of
6 6 mM Tris-HCl buffer, pH 7.4, were mixed in a fluorescence
o
cuvette and allowed to equilibrate to 37 C for 5 minutes in 
the thermostatted cuvette holder of a Perkin-Elmer LS-5 
fluorescence spectrophotometer. The base line was recorded 
and 20 ul of 31 mM NADPH were added to the cuvette and mixed. 
The increase in fluorescence at 586 nm was monitored for at 
least 3 minutes, using an excitation wavelength of 510 nm. 
Standards of resorufin were added to calibrate the reaction.
2.6 PROTEIN ASSAY IN TISSUE SUBFRACT I ONS.
This method is based on a modification of that of 
Lowry et al. (1951 ) .
Principle. Two reactions are involved in this method:
a) an initial interaction of protein and Cu(II) in alkali; b) 
a reduction of the phosphotungstic and phosphomolybdic acids 
to molybdenum blue and tungsten blue, both by the Cu-protein 
complex and by the tyrosine and tryptophan of the protein. 
The latter two aminoacids give colour in the absence of 
Cu(II), but the rest of the protein gives no colour without 
Cu(II). About 75'/ of the colour is dependent on the Cu (11) .
Reagents .
0.5 M NaOH.
1'/ (w/v) Copper sulphate pentahydrate.
2/ (w/v) Sodium potassium tartrate.
0.05 M NaOH, containing 2/ (w/v) sodium carbonate. 
Folin-Ciocalteu phenol reagent, diluted with water 
( 1 : 2 ,  v / v ) .
Bovine serum albumin in 0.05 M NaOH (250 ug/ml).
Method .
Samples of the homogenates were predigested with 0.5 M
NaOH. The samples of tissue subfractions were diluted with 50 
mM NaOH to give appropriate protein concentrations. The 
protein standard was diluted with 50 mM NaOH to give 
concentrations of 50, 100, 150, 200 and 250 ug/ml. Copper
sulphate, sodium potassium tartrate and sodium carbonate in 
NaOH were mixed in a ratio 1:1:100 (v/v) immediately before
use. The protein standards, samples and blanks (0.5 ml) were 
mixed with the sodium carbonate reagent (5 ml) and allowed to 
stand for 10 minutes at room temperature. Diluted Folin- 
Ciocalteau phenol reagent (0.5 ml) was added, and the 
solutions were mixed immediately. After standing for a 
minimum of 30 minutes at room temperature, the absorbance at 
750 nm was recorded using a Perkin-Elmer Lambda 5 
spectrophotometer.
2.7 STATISTICS.
The results obtained were reported as the mean 
plus/minus one standard deviation. Statistically significant 
differences between individual treatments and control were 
determined by the standard "t" test. The value of p < 0.05
was regarded as denoting significance.
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CHAPTER THREE 
SOME EFFECTS OF ARSENIC AND
SELENIUM ON HEPATIC HEME METABOLISM
3 . 1 INTRODUCTION.
Arsenic and selenium are common environmental agents 
which have been shown to produce hepatotoxic effects in 
various species following acute or subacute exposure (Fowler 
et al., 1979; Fishbein, 1977). Exposure to these metalloids
is also known to alter the activities of some enzymes in the 
heme synthesis pathway (Maines and Kappas, 1976a; Woods and
Fowler, 1978; Sardana et al., 1981).
/
This Chapter describes the acute effects of these 
metalloids on the heme saturation of TP, a sensitive 
indicator of "free heme" pool changes (Badawy, 1979). They 
are discussed in relation to the concomitant effects on the 
activities of ALAS and HO, respectively the rate limiting 
enzymes of heme synthesis and catabolism. The differences in 
potency between two different oxidation states of arsenic, 
AsIII and AsV, are also studied. A comparison between the 
effects of single and continuous administration of AsIII is 
made and the possible appearence of tolerance to its toxic 
effects is examined.
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3.2 RESULTS.
3.2.1 Effects of sodium arsenite (AsIII).
a) Tryptophan pyrrolase.
The effects of 5 different dose levels ranging from
12.5 to 100 umol/kg at 24 hours are shown in table 3.1, and
the effects of a single dose at different times (2 to 24
hours) are shown in table 3.2. The AsIII was administered by 
subcutaneous injection.
Dose response study. At dose levels above 12.5 
umol/kg, there was a progressive decrease in the heme
saturation of TP (Table 3.1). At the lowest dose (12.5
umol/kg) both calculated apoenzyme values and holoenzyme
activity were increased. Above 50 umol/kg a progressive
decrease in holoenzyme activity was observed and the
calculated values of apoenzyme were increased. Although the 
holoenzyme/apoenzyme ratio changes were more pronounced, they 
closely paralleled those observed in the heme saturation 
percentage.
Time course studv: during the first 4 hours after
100 umol/kg treatment with AsIII, a small but significant 
increase in the degree of heme saturation was observed. This 
was followed by a gradual decrease which was still falling
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when the last observation was made at 2A hours (Table 3.2). 
During the first A hours, "total enzyme", holoenzyme 
activities and apoenzyme values, were markedly reduced by 
amounts which resulted in the transient increases in heme 
saturation shown in table 3.2. The holoenzyme activity 
continued to be depressed for the remaining period, whereas 
"total enzyme" activity and apoenzyme values returned to near 
control values.
b) ALA synthetase.
The dose response data are shown in table 3.3. The 
enzyme activity showed a dose-dependent increase, being 
significant at doses of 50 and 75 umol/kg of AsIII. At a 
dose of 75 umol/kg, the enzyme activity was about twice that 
of the control level.
c) Heme oxygenase.
The increase in this enzyme activity was progressive 
and pronounced at all dose levels above 12.5 umol/kg (Table 
3.3). The increment in activity appeared to follow the 
increase in dosage. At the highest dose (100 umol/kg) a 12- 
fold increase over control values was observed.
d) Biliverdin reductase.
No change of activity was observed at any dose level
Table 3.3 Effects of sodium arsenite (AsIII) on hepatic 
ALA synthetase, heme oxygenase and biliverdin reductase.
AsIII 
(umol/kg)
ALA
Synthetase1
Heme
Oxygenase 2
Biliverdin 
Reduc tase3
Control 134.8 ± 28.2 1.70 ±0.25 20.5 ± 3.7
12.5 134.6 ± 23.A 1.71 ±0.31 19-2 ± 2.A
25 153.A ± 26.2
*
3.90 ± 0.A2 19-3 ± A.A
50
*
187.6 ± 20.0
*
9 .28 ± 0.12 21.9 ± 5 . 8
75
X
265 - A ± 16.6 1A.09 ± 0.62 20.2 ± 5.A
1 00 N.A.
*
20.67 ± 0.88 18.8 ± 3.2
1 pmol ALA/mg homogenate protein/h.
2 nmol bilirubin/mg microsomal protein/h.
3 nmol bilirubin/mg cytosolic protein/h
All above given as' X ± S.D. (n = 17 for controls, n = 3 for 
other data). These effects were studied at 16 hours after 
subcutaneous administration of AsIII.
* Differs from control data, p < 0.05.
N.A. Data not obtained.
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( table 3.3).
c) Cytochromes P-450 and b .
5
There was a progressive decrease in P-450 concentration 
at all dose levels above 25 umol/kg. At the highest dose 
(100 umol/kg) the concentration was reduced to 44*/ of the 
control level (Table 3.4). No effect on cytochrome b
5
concentration at any dose level was observed (Table 3.4).
Figure 3.1 summarizes the effects of AsIII on some 
indicators of heme status.
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Table 3.A E ff e c t s 
cytochromes P-A50 and
of s o d i u ;n a r s e n i t e 
b5.
(AsIII) on hepatic
AsIII- 
(umol/kg)
Cytochrome
P-4501
Cy tochrome 
b5 1
Control 0.63 ± 0.08 0.29 ± 0.03
12.5 0.58 ± 0.05 0.27 ± 0.01
25
*
0.51 ±0.09 0.28 ± 0.04
•50'
*
0.42 ± 0.07 0.26 ± 0.04
7 5
*
0.37 ± 0.07 0.24 ± 0.02
1 0 0
*
0.28 ± 0.06 0.26 ±0.03
1 nmol/mg microsomal protein.
All above given as X ± S.D. (n = 17 for controls, n = at 
least 3 for other data). These effects were studied at 16 
hours after AsIII administration.
* Differs from control data, p < 0.05.
N.A. Data not obtained.
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Fig. 3.1 Effects of sodium arsenite (AsIII) on some 
indicators of cellular heme status. The effects were 
studied at 16 hours after subcutaneous administration 
of AsIII.
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3.2.2 E f f ec t s  of s o d i u m  a r s e n a t e  (A s V ) .
a) Tryptophan pyrrolase.
Dose response study. The effects of 5 different dose 
levels ranging from 25 to 200 umol/kg at 24 hours are shown 
in table 3.5. AsV was administered by subcutaneous injection.
At dose levels above 25 umol/kg, there was a progressive 
decrease in the heme saturation of TP (Table 3.5), 
accompanied by corresponding increases in apoenzyme values.
The holoenzyme/apoenzyme ratio followed closely the changes 
in the extent of heme saturation.
Time course study. Four hours after treatment the 
heme saturation of TP was reduced to 67'/ of its control 
value, and remained at about this level for the rest of the 
observation period (Table 3.6). A small increase in "total 
enzyme" activity was observed.
b) ALA synthetase.
A dose-dependent increase in this enzyme activity was 
observed (Table 3.7), but only at dose levels above 100 
umol/kg of AsV was the increase significant. The highest dose 
( 2 0 0  umol/kg) increased the activity to almost twice the 
control value.
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Table 3.7 Effects of sodium arsenate (AsV) on hepatic ALA 
synthetase, h e m e  o x y g e n a s e  a n d  b i l l v e r d i n  reductase.
AsV
(umol/kg)
ALA
Syn thetase1
Heme
O
Oxygenase
Biliverdin
Reductase3
Con trol 134.8 ± 28.2 1.70 ±0.25 20.5 ± 3.7
25 N.A. 1 .68 ±0.13 18.2 ± 1.9
50 142.8 ± 22.4 1.73 ±0.10 20.6 ± 4 . 3
100 133.4 ± 13.0
V
1.64 ±0.16 20.8 ± 3.7
* *
1 50 190.2 ± 20.0 2.68 ±0.11 19*2 ± 2.6
200 259.6 ± 62.6 5.05 ± 0.55 20.0 ± 4.8
1 pmol ALA/mg homogenate protein/h.
2 nmol bilirubin/mg microsomal protein/h.
3 nmol bilirubin/mg cytosolic protein/h.
All above given as X± S.D. (n = 17 for controls, n = at 
least 3 for other data). These effects were studied at 16 
hours after subcutaneous administration of AsV.
* Differs from control data, p < 0.05.
N.A. Data not obtained.
c) Heme oxygenase.
A dose-related increase in HO activity was observed 
(Table 3.7). No effects were observed at doses below 150 
umol/kg of AsV; the highest dose (200 umol/kg) produced a 3- 
fold increase in activity.
d) Biliverdin reductase.
No change of activity was observed at any dose level 
(Table 3.7).
e) Cytochrome P-450 and b .
5
No effects were observed on P-450 concentration at
doses below 150 umol/kg (Table 3.8). However, the highest
dose reduced the concentration to 131 of control values.
There was no change of cytochrome b concentration at any
5
dose level (Table 3.8).
\
Figure 3.2 summarizes the effects of AsV on some 
indicators of heme status.
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T able 3.8 8 f f e c t 
hepatic cytochromes
s of sod i u rn 
P-450 and b^.
arsenate (AsV) on
AsV
(umol/kg)
Cy tochrome 
P-4501
Cy tochrome 
^5 1
Control 0.63 ± 0.08 0.29 ± 0.03
25 0.65 ± 0.05 0.30 ± 0.04
50 0.62 ± 0.06 0.28 ± 0.05
1 00 0 . 60 ± 0.05 0.31 ± 0.04
1 50 0.5 7 ± 0.04 0.28 ± 0.03
200
*
0.46 ± 0.05 0.29 ± 0.02
1 nmol/mg microsomal protein.
All above given as X ± S.D. (n = 17 for controls, n = at 
least 3 for other data). These effects were studied at 
16 hours after subcutaneous administration of AsV.
&
Differs from control data, p < 0.05.
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Fig. 3.2 Effects of sodium arsenate (AsV) on some 
indicators of cellular heme status. The effects were 
studied at 16 hours after subcutaneous administration 
of AsV.
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3.2.3 Ef fect s .of s.odium seleni te .
a) Tryptophan pyrrolase.
Dose-resoonse study. . The effects of 5 different dose
levels administered subcutaneously and ranging from 1.25 to 
20 umol/kg at 16 hours are shown in table 3.9. At dose levels 
above 2.5 umol/kg, there was a progressive decrease in the 
heme saturation of TP, with the highest dose (20 umol/kg)
decreasing the heme saturation to half the control value
(Table 3.9). Although the holoenzyme/apoenzyme ratio changes 
were more pronounced, they closely followed those observed in 
the degree of heme saturation. Doses of 40 umol/kg and higher 
were lethal to all animals within 1 2 hours.
b) ALA synthetase.
A dose-related increase in the activity of this enzyme
was observed (Table 3.10); the highest dose (20 umol/kg)
produced a 2 -fold increase.
c) Heme oxygenase.
A marked dose-dependent increase in HO activity was 
also observed (Table 3.10), the highest dose produced an 
increase of almost 4 times the control values.
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Table 3.10 Effe cts of sodium selenite'iSelV) on hepatic
ALA synthetase, heme oxygenase and biliverdin reductase.
SelV
(umol/kg)
ALA
Syn thetase 1
Heme
Oxygenase2
Biliverdin
3
Reductase
Con trol 134.8 ± 28.2 1 .70 ± 0.25 20.5 ± 3.7
5
*
194.8 ± 22.2
*
2.74 ± 0.25 19-1 ± 1 . 1
10 231.4 ± 38.6
*
4.19 ± 0.38 21 . 4 ± 5.0
2 0
*
296.8 ± 23.8 6 . 92 ± 0.59 19-1 ± 2-7
1 pmol ALA/mg protein/h.
2 nmol bilirubin/mg microsomal protein/h.
3 nmol bilirubin/mg cytosolic protein/h.
All above given as X ± S.D. (n = 17 for controls, n = at 
least 3 for other data). These effects were studied 16 
hours after subcutaneous administration of SelV.
* Differs from control data, p < 0.05.
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d) Biliverdin reductase.
No change of activity was observed at any dose level 
(Table 3.10).
e) Cytochromes P-450 and b .
5
In marked contrast with the effects seen after treatments
with AsIII and AsV, no significant effects on P-450
concentration were observed at any dose level. Also no
effect on b was noted (Table 3.11).
5
Figure 3.3 summarizes the effects of SelV on some 
indicators of heme status.
T a b l e  3.11 E f f e c t s  of s o d i u m  s e l e n i t e  on h e p a t i c
cytochromes P-450 and b^.
SelV
(umol/kg)
Cytochrome
P-4501
Cy tochrome
Con trol 0.63 ± 0.08 0 . 29 ± 0.03
5 0.55 ± 0.09 0.32 ± 0.05
10 0.57 ± 0.10 0.29 ± 0.02
oCM 0.56 ± 0.05 0.32 ± 0.05
1 nmol/mg microsomal protein.
All above given as X ± S.D. (n = 17 for controls, n = at 
least 3 for other data). These effects were studied at 
16 hours after subcutaneous administration of SelV.
* Differs from control data, p < 0.05.
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Fig, 3.3 Effects of sodium selenite (SelV) on some 
indicators of cellular heme status. These effects were 
studied at 16 hours after subcutaneous administration 
of SelV.
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3.2.4. Effects of the combi ned administration o f AsIII 
and SelV
a) Tryptophan pyrrolase.
The effects of 4 different doses of AsIII, ranging 
from 12.5 to 75 umol/kg, plus 5 umol/kg of SelV at 16 hours 
are shown in table 3.12. AsIII was injected subcutaneously in 
the abdominal region and SelV immediately afterwards in the 
cervical region.
At all dose levels of AsIII plus 5 umol/kg of SelV 
there was a progressive decrease in the heme saturation of TP 
(Table 3.12). The decrease produced was more pronounced (p < 
0.05) than that observed with AsIII alone (Table 3.1). The 
holoenzyme/apoenzyme ratio followed closely the heme 
saturation percentage changes. The administration of 12.5 
umol/kg of AsIII plus 20 umol/kg of SelV resulted in a 
response similar to that observed after the administration of 
SelV alone (20 umol/kg).
b) Heme oxygenase.
The increase in this enzyme activity was greater (p <
0.05) than that observed after the administration of either 
AsIII or SelV alone (Tables 3.3 and 3.13). At the lowest 
dose a 2 -fold increase over control values was observed,
Ta
bl
e 
3.
12
 
Ef
fe
ct
s 
of
 
th
e 
co
mb
in
ed
 
a
d
m
i
n
i
s
t
r
a
t
i
o
n
 
of
 
so
di
um
 
ar
se
ni
te
 
(A
sI
II
) 
an
d 
so
di
u:
: 
se
le
n
i
t
e
 
(S
el
V)
 
on
 
ra
t 
li
ve
r 
t
r
y
p
t
o
p
h
a
n
 
p
y
r
r
o
l
a
s
e
1
.
110
45
CO
E
o
Q.
O
a:
c
o
•H
4J
(0
E
Z5
4-5
to
00
co
4-5
O
a)
E
>.
N
E
0
O
rH
O
Zu
0)
E
>,
N
E
0)
Oa.
<c
0 
00 —  
bO 
+ ^
M  O 
M  E 
10 ZJ 
< —
o
+1
o
vo
O'
ro
+i
ro
r-
ro
+1
vo
vo
o
+i
co
C\J
o
E
4->
c
o
o
vO CM ro CM r—
o V, ' r~>
o o O O o
+1 +1 +1 +1 +1
O ' o <r r- in
ro ro CM «— CM
• . • « •
o o o o o
CVJ
ro
+1
r-
CM
in
+i
in
r-
o
+i
c—
CM
*
O' cn
o o
+i +i
CO CO
• •
<r vo
in
+
in
CM
ro
+1
<r
ro
CM
o
CM
+ 1
vO
ro
o
+i
in
CM
vo
+l
ro
co
in
+
o
in
CM
CM
+1
o
cr>
+1
co
vo
+1
vo
in
in
+
o
o
in
co
+i
co
O'
vo
+i
vo
+i
vo
CT>
in
+
o
in
C"-
CM
o
+i
O'
O'
+i
CM CM
o O O
+1 +1 +1
ro o <r
r_
co
o
+1
r-
in
o
CM
+
in
cm
0 'O 
> r_ 
•H
0
•HCl-4 
0 ?  
_  4-5 
4-> M
-E
bO ® 
•H E  
0 0 
2 2
4-> tO 
0  4->
3 u 
0 
Cm  
'tw
0
bO
E
0
a
•a
0
E
E
O
Cm
_ CO co
J_5 #r“* 
0 M O
■H "O t !
e
0 E 
E  a> 
Z3 £  
E  4-5
o 0
E CO0
Cm O-E .
o Cm 4-5
in.c <T
o
f o
I—1 II o
o EE E O VZJ •H
•*4J cxCOCOCOcoi—i Eo4-5 (0
x> E CO 4-50 4-5 •H COCOE E •aCO0 OO
•HE f—(E •a oa E cd EX A 4-5cuU
Cm
coZJ EO0e <r o0 OtoCME EII CO OCO 4-5 E0 c ZJ Cm
•pH O-P JO CO
•rH , ZJ E> Q CO 0
•H . Cm
4-> COE CmO 0 •pH<53+1 4-5 Q
ix
Cmr- cd X
Ill
while a 9-fold increase was produced by the highest dose. 
The increase in activity produced by an AsIII dose of 12.5
plus 20 umol/kg of SelV (Table 3.13) was similar to that
produced by 20 umol/kg of Se alone (Table 3.10).
d) Biliverdin reductase.
No change of activity was observed at any of the 3
dose levels tested.
e) Cytochromes P-450 and b .
5
No change in P. 450 concentration was observed when
doses of AsIII (12.5 umol/kg) plus SelV (5umol/kg) or AsIII 
(12.5 umol/kg) plus SelV (20 umol/kg) were administered 
(Table 3.13). However, a reduction to 7 1*/ of control values 
was produced by the highest dose (AsIII 75 ug/kg plus SelV 5 
umol/kg); This reduction was less than that observed after 
the administration of AsIII alone (Table 3.4). No effect on
cytochrome b concentration at any dose level was observed.
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3.2.5 Effects of cadmium chloride .
a) Heme oxigenase.
The effects of two dose levels, 7 and 20 umol/kg, at 
16 hours were examined. Cd was administered by subcutaneous 
injection. A 7-fold increase in HO activity was observed at 
the higher dose ( 2 0 umol/kg), no significant change was 
observed at the lower dose (Table 3.14).
b) Biliverdin reductase.
No significant change in the activity of this enzyme 
was observed at any dose level (Table 3.14).
c) Cytochromes P-450 and b .
5
At the highest dose, P-450 content was reduced to 80/. 
of control values. No significant change was observed at the 
lower dose (Table 3.14). No effect on cytochrome b
5
concentration at any dose level was observed (Table 3.14).
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3.2.6 Effects of 3 0 day administration of sodium 
arsenite (AsIII) in drinking water (50 ppm).
Water consumption and estimated AsIII intake. A 
decrease in water consumption was observed in treated 
animals. The reduction was from approximately 130 ml/kg/day 
(range 110 - 150) in the control group, to approximately 62 
ml/kg/day (range 55 - 69) in treated animals. From these 
data, the daily AsIII intake in the treated group was 
estimated to be about 24 umol/kg/day (range 21 - 27
umol/kg/day).
a) Tryptophan pyrrolase.
The control values showed no significant changes 
during the 30 day period of study. After 5 days of treatment, 
the degree of heme saturation of TP was reduced to 777. of 
control values. This reduction was mantained without 
significant change when the treatment was continued for 1 0 , 
20 and 30 days (Table 3.15). The holoenzyme/apoenzyme ratio 
followed closely the changes in heme saturation percentage. 
There was a progressive increase in "total enzyme" activity 
and in calculated apoenzyme values, which was significant (p 
< 0.05) after 10 days of treatment; the maximum increase was 
observed after 30 days treatment (30 and 50/., respectively).
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b) ALA Synthetase.
ALAS activity showed an increase of 602 over control
values at day 5 and day 10 of treatment, after which a small
decrease was observed; at day 20 and 30 the activity was 
still 30-402 above control values (Table 3.16).
c) Heme oxygenase and biliverdin reductase.
No change of activity was observed for either enzyme
at any of the treatment periods studied (Table 3.16).
d) Cytochromes P-450 and b .
5
No change in either of these parameters at any 
exposure period was observed (Table 3.17).
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Table 3.16 Effects of 30 day administration of sodium 
arsenite (AsIII) in drinking water (50 ppm) on rat ALA 
synthetase, heme oxygenase and biliverdin reductase.
Days of 
Treatmen t
ALA
Syn the tase 1
H erne
Oxygenase2
Biliverdin
Reductase3
Control
CMcoCM+iCO<rmT— 1 .70 ± 0.25 20.5 ± 3.7
5,
*
221 .A ± A A.0 1.80 ± 0.1 A 19-3 ±1.8
10
*
220.8 ± 19-8 1.86 ± 0.23 18.2 ±3.0
20
* *
175-0 ± 36.0 1 .73 ± 0.30 19.9 ± A. 8
30
at
192.8 ± A 1 . 8 1.-79 ± 0 . A 6 17.5 ± A . A
1 pmol ALA/mg homogenate protein/h .
2 nmol bilirubin/mg microsomal protein/h.
3 nmol bilirubin/mg cytosolic protein/h.
All above given as X ± S.D. (n = 17 for controls, n = at 
least A other data).
* Differs from control data, p < 0.05 ; ** 0.05 < p < 0.1.
T a b l e  3 . 1 7  E f f e c t s  o f  30 d a y  a d m i n i s t r a t i o n  of s o d i u m
a r s e n i t e  (A s  1 1 1 ) in d r i n k i n g  w a t e r  (50 p pm) on r a t
h e p a t i c  c y t o c h r o m e s  P - 4 5 0  a n d  b^.
As 111 C y t o c h r o m e  C y t o c h r o m e
( D a y s  o f  P - 4 5 0 1 b . 1
t r e a t m e n t )
C o n t r o l  0 . 6 3  ± 0 . 0 8  0 . 3 1  ± 0 . 0 3
5 0 . 6 8  ± 0 . 0 9  0 . 3 4  ± 0 . 0 3
10 0 . 6 5  ± 0 . 0 7  0 . 2 9  ± 0 . 0 5
20 0 . 5 9  ± 0 . 0 4  0 . 3 2  ± 0 . 0 3
30 0 . 6 9  ± 0 . 0 7  0 . 3 4  ± 0 . 0 3
^ m o l / m g  m i c r o s o m a l  p r o t e i n .
All a b o v e  g i v e n  as X ± S . D .  (n = 1 7  f o r  c o n t r o l , n = a t  l e a s t  
4 f o r  o t h e r  d a t a ).
* D i f f e r s  f r o m  c o n t r o l  d a t a ,  p < 0 . 0 5  .
3.3 DISCUSSION.
3.3.1 Assessment of acute effects of As and Se on cytosolic 
heme status . using tryptophan pvrrolase as an index-.-
TP is a heme-dependent enzyme that in most animal 
species is normally 35 to 45/. saturated with heme (Marver et 
al. , 1 966; Seglen and Jervel 1 969 ). Circumstances which
increase cellular "free heme" produce rapid changes in the 
enzyme activity by converting the remaining inactive heme- 
free apoenzyme to the active heme-containing holoenzyme
(Wetterberg et al., 1969). Conversely, reductions in cellular 
heme decrease the heme satura tion of TP (Feigelson and
Greengard, 1961b; Badawy, 1977a). In the studies reported 
here, the responsiveness of TP was employed as an indicator 
of changes in heme metabolism/availability produced by As and 
Se administration.
Effects on the degree of heme saturation. The results 
of this study showed that the overall response to AsIII, AsV 
and SelV acute treatments was a dose-related decrease in the 
degree of heme saturation of TP, thus clearly indicating that 
these elements decreased the content of cytosolic heme in 
liver cells. The ability of As and Se to markedly reduce the 
proportion of TP saturated with heme is consistent with their 
abilities to rapidly and potently induce HO as shown in the 
present study and previously reported by Maines and Kappas
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(1976a) for acute doses of SelV, and by Sardana et al. (1981) 
for acute doses of As. The rapidity with which TP responds to 
the changes in heme metabolism produced by As and Se is in 
agreement with the suggestion of Badawy (1977b) that TP
utilizes a pool of "free heme" which has a rapid turnover
rate.
AsIII, AsV and SelV all produce a similar effect on TP
i.e. a decrease in the heme saturation. However, there are
marked differences in the potencies of these elements; on a
molar basis, SelV was 10 times as potent as AsV, and 4 times
as potent as AsIII. AsIII was about 2.5 times more potent
than AsV (Fig. 3.4). Badawy (1977a) has reported that the
subcutaneous injection of only 2.5 umol/kg of CdCl or 12.5
2
umol/kg of CuCl reduced the heme saturation of TP to about
2
50/ of control values, whereas 250 umol/kg of Fe, Ni, M n , Li 
and Co salts were required to achieve that effect. In the 
present study, 20 umol/kg of SelV reduced the heme saturation 
to 50/ of control values indicating that Se is among the more 
potent elements that reduce the heme saturation of TP.
The difference in potency between AsIII and AsV is not 
surprising since AsIII is generally considered to be more 
toxic than AsV (Byron et al., 1967; Nakamuro and Sayato, 
1981). Several factors may account for this: 1) the
retention of As in the body has been shown to be dependent on 
the valence form, AsIII being retained more effectively than 
AsV (Vahter, 1981); 2) the binding of AsIII to hepatic
As
V 
y 
= - 
0.
09
x 
+3
8.
8 
; 
r 
= 0
.9
9
Se
lV
 
y 
= - 
0.
99
x 
+ 
37
.7
 
; 
r 
= 0
.9
4
As
II
I 
y 
= - 
0.
23
x 
+ 
36
.5
 
; 
r 
= 0
.9
6
122
o  to  
S- CU 
4-5 3  
C i—
O  rd O >
o
o
C\J
oo
oin
oCM
o
in
o
4-5
>0
X>
oJO
CO
cu
to
oo
4 -
o
c
o
•r—
4-> 
rd5- 3 
4-> 
rd  
to
CU
E
CU
CU
-C
4->
c •
0 c
0
to •r—
4-5 4-5
O rd
0) u
4- 4-5
4- to
Lul •p -
c
••r—
■ E
H  -O
■ rd
> to
1— 1 O
CU O
oo CU
c
• 0 rd
c 4-5
rd CJ
0
JO
2 nto
> S-
to cu
<C 4->
4-
O rd
2 to
S-
3
1—1 0
1— 1 JC
1—1
CO to
< 1—
4- 4-5
O rd
to  * o
CU CU
■1— •r—
0  - o
c O
CU 4-5
4-5 to
O
O l CU
CO
CU rd
> r—
•r— O
4-5 i -
rd i -
1— >0
QJ Q.
OL
C
rd
«d- sz• Q.
CO O
4-5
• CL
CO >>
*1— S-
U - 4-5
OJ
*dl 4 0 a6e^U9 ou0 d uoL^BJn^es 01110^
123
cellular constituents is more pronounced than that of AsV 
(Vahter and Marafante, 1903). 3) it has been shown that AsV
is reduced to AsIII before being methylated (a detoxication 
mechanism) and it has been suggested that AsV toxicity is due 
to its conversion to AsIII (Me Bride et al., 1978; Vahter and 
Envall, 1983). The latter suggestion is still the subject of 
debate The possibility that the two valence forms may have 
different mechanisms of toxicity has also been suggested 
(Thompson, 1948; Mitchell et al., 1971). AsIII is thought to 
exert its toxic effects through interactions with active 
cellular sulfhydryl groups, whereas arsenate could act by 
substituting for phosphate in enzyme catalyzed reactions. The 
difference in potencies between SelV and AsIII is more 
difficult to explain, because Se is not considered to be a 
porphyrinogenic element (Maines and Kappas, 1976a). The 
difference in porphyrinogenic potential of AsIII and SelV 
could affect their different abilities to induce HO (Fig.
3.10). This possibility is further discussed in Section 
3.3.3.
Possible mechanisms of As and Se effects on 
cellular heme status. It is known that acute and subchronic 
As exposure alter the activities of some enzymes in the heme 
synthesis pathway. Sardana et al. (1981) have reported that 
acute administration of AsIII produces a biphasic effect on 
ALAS activity, namely, an initial decrease followed by a 
rebound increase. Woods and Fowler (1977b, 1978) have
reported that subchronic exposure (6 weeks) to AsV in the
drinking water resulted in decreases .in ALAS and heme
synthetase activities in rats and mice. Accompanying these 
alterations were dose-related increases in urinary porphyrin 
excretion. Similar increases in urinary porphyrins were 
observed after 7 days exposure to AsIII (Martinez et al.,
1983). Furthermore, both AsIII and AsV produced in vitro a 
significant inhibition of uroporphyrinogen decarboxylase 
(Woods et al., 1981). The results reported here show that an 
acute dose of As produced a marked increase in HO activity. 
Thus, cellular heme status is a major target by virtue of the 
inhibitory effect of As on two enzymes involved in heme 
synthesis and its inducing effect on HO, which increases 
heme degradation. A result of the effects on ALAS, 
uroporphyrinogen decarboxylase, and heme synthetase is the 
excess production of heme intermediates leading to porphyria.
The mechanisms underlying the acute effects of Se are 
less clear. Although it seems to have the same biphasic 
effect as AsIII on ALAS described above, it has no effect on 
the cellular content of porphyrins (Maines and Kappas, 
1976a). However, there is no available information on the
effects of Se on uroporphyrinogen synthetase and 
uroporphyrinogen decarboxylase. Se is a potent inducer of HO, 
but it has been suggested that is not a direct inducer, and 
that it mediates HO induction through increased production 
and availability of cellular "free heme" (Maines and Kappas, 
1976a). However, if this were the case, either no effect or
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an increased heme saturation of TP should have been found in 
the present study. Thus, the increase in HO activity (Table
3 .1 0 ) is a possible cause of the observed decrease in the 
heme saturation of TP, although the mechanism proposed by 
these authors to explain HO induction may be open to 
alternative interpretation.
Earlv effects of As III. The time-course study showed 
a small but significant (p < 0.05) increase in the degree of 
heme saturation of TP during the first four hours after 100 
umol/kg AsIII treatment (Table 3.2 and Fig. 3.5). This was in 
contrast to the pronounced decrease observed 2 4 hours 
after the same treatment. This rapid effect is in agreement 
with previous reports (Feigelson et al., 1959; Badawy and
Evans, 1975) indicating that TP-apoenzyme is one of the most 
rapidly turning over and, hence, one of the most responsive 
of hepatic proteins. The holoenzyme has a half life of 7.4 
hours, whereas that of the apoenzyme has been reported to be 
2.3 hours (Correia and Burk, 1978). This transient response 
to AsIII, if the effects on heme saturation are considered in 
isolation, could be interpreted simply as indicative of an 
increase in the "free heme" pool size, however, if we 
consider the marked decrease in "total enzyme", holoenzyme 
and calculated apoenzyme activities at these early times 
(Fig. 3.5), it is clear that the increase in heme saturation 
is mainly due to drastic reductions in "total enzyme" 
activity. Since such changes are generally considered to 
reflect changes in apoenzyme synthesis, the use of the heme
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Fig. 3,5 Time-course of sodium arsenite (AsIII) effects on 
tryptophan pyrrolase activities. AsIII was administered 
subcutaneously.
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saturation of TP alone as an index of increase in "free heme 
pool size is misleading. Interestingly, the subsequent 
decrease in heme saturation is concurrent with the recovery 
from the:effects on holoenzyme and "total enzyme" activities 
(Fig. 3.5).
A possible explanation of the transient increase in 
the degree of heme saturation is that AsIII, either by direct 
inhibition of apoenzyme synthesis, or via an allopurinol-type 
of inhibition (see below), reduces the number of apo-TP 
molecules saturated with heme, thereby increasing the "free 
heme" pool size. This increase would explain the early 
inhibition of ALAS activity produced by AsIII (100 umol/kg) 
reported by Sardana et al. (1981), for it is generally held 
that the size of the "free heme" pool regulates ALAS 
activity (Fig. 3.9; Section 3.3.2). There have been other 
instances in which metals, early on, increase( the heme 
saturation of TP. Badawy (1977a) reported that one hour 
after an i.p. dose of aluminium (150 mg/kg; 240 umol/kg), the 
heme saturation reached 80/., apparently due to a two fold 
increase in holoenzyme activity without changes in "total 
enzyme" activity. Indications of a similar "early" effect of 
cobalt, without further explanation, were also reported by 
Kikuchi et al. (1982).
How could interference of AsIII with TP occur ? The 
inhibition of "total enzyme" activity produced by AsIII
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appears to be similar to that observed two hours after the 
administration of allopurinol. This agent has been shown to 
interfere with the conjugation of apo-TP with its heme 
prosthetic group; the interference being reversed by excess 
hematin (Beking and Johnson, 1967; Badawy and Evans, 1973b). 
It would be desirable to have some experimental evidence 
regarding this point. If AsIII produced an allopurinol type 
of inhibition it would be dependent on the As concentration 
reached in the cytosol. Thus, the addition of excess hematin 
(in vitro) should be able to restore the "total enzyme" 
activity to control values and could also prevent the 
increase in both holoenzyme and "total enzyme" activities 
produced by tryptophan. Alternatively, it has been suggested 
that arsenicals affect protein and aminoacid metabolism 
leading to depressed protein synthesis through interference 
with the availability of certain aminoacids, and possibly by 
direct actions on the aminoacid's synthetic pathways (Webb, 
1966). Therefore, it is possible that the above changes could 
have resulted from AsIII inhibition of the synthesis of the 
apoprotein moiety.
The time-course of AsV effects showed that in contrast 
to the early inhibition of "total enzyme" activity produced 
by AsIII, AsV produced a small but significant (p < 0.05)
increase in total enzyme activity accompanied by a decrease 
in holoenzyme activity, which resulted in a reduction of the 
heme saturation to 70/. of its control values (Fig. 3.6); 
these changes remained without significant variations between
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4 and 16 hours after AsV administration. Possible 
explanations for this difference include : 1) Most enzyme
inhibitions produced by As are presumably due to the 
arsenical reacting with SH groups at or near the active site 
of the enzyme; pentavalent arsenicals generally produce much 
less inhibition than the corresponding trivalent compounds, 
as would be expected from the fact that they do not react 
readily with SH groups (Webb, 1966). 2) the dose of AsV used 
in this part of the study was comparatively low ( 1 0 0  umol/kg) 
as witnessed by the fact that it failed to produce 
significant effects on other enzymes measured, whereas that 
of AsIII was comparatively high (100 umol/kg), approaching 
lethal doses and producing large effects on other enzymes.
Further considerations of the effects on "total 
enzyme" activity. So far, most experimental work devoted to 
studying the relationships between TP activity and heme 
metabolism alterations has been focused on the heme 
saturation value, and has attached much less importance to 
the other parameters measured. However, the possibility that 
some metals could affect the apoenzyme moiety of TP is 
apparent from the above discussion. Data reported in this 
study on the effects of AsIII and AsV at 24 hours (Tables 3.1 
and 3.5 ; Figs. 3.5 and 3.6), and also by Badawy (1977a, 
1978), on the effects of AIA and DDC show that "total enzyme" 
activity is increased under some conditions. Thus, it is 
clear that heme saturation can be reduced either by
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Fig. 3.6 Time-course of sodium arsenate (AsV) effects on 
tryptophan pyrrolase activities. AsV was administered 
subcutaneously.
decreasing the holoenzyme activity, or by enhancing that of
the "total enzyme", or by exerting both effects. A likely
explanation for the effects on "total enzyme" activity is
provided by the work of Knox (1951) and Knox and Auerbach
(1955) who studied the role of the adrenals. These authors
showed that TP activity is enhanced by the administration of
corticosteroids and stress-producing agents. Schimke et al.
(1965) and De Lap and Feigelson (1978) have shown that this
increase involves induction of apoenzyme synthesis, due to
increases in the amount of TP mRNA. Furthermore, acute and
subacute administration of AsIII and CdCl have been shown to
2
alter carbohydrate metabolism, probably via effects on the 
adrenal glands causing the release of epinephrine and
corticosteroids (Ghafghazi and Mennear, 1973; Ghafghazi et 
al., 1980). Thus, it is possible that some metals increase 
"total enzyme" activity via an effect on the adrenals, a
mechanism which has also been put forward to explain AIA- 
induced TP activity (Feigelson and Greengard, 1961b).
In view of the above effect, how valuable is the
measurement of heme saturation as an index of "free heme 
pool" size ? One problem in the study of the regulation of 
hemoprotein synthesis is lack of knowledge of the means of 
integration between apoprotein synthesis and that of its 
prosthetic group heme. It has been claimed that changes in 
one constituent lead to adjustments in the synthesis of the 
other (Tait, 1978). To assess the heme saturation as the sole 
variable, it is obviously necessary to prevent changes other
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than those caused by an altered heme availability. Prior 
starvation of experimental animals has been used to raise 
optimally the "total enzyme" activity by an hormonal 
mechanism, thus forestalling any enhancement by agents which 
act by this mechanism (Badawy, 1978 and 1981). However, in 
some experiments with metallic and other compounds (Badawy, 
1977a), it seems that either starvation is not enough or that 
the enhancement is not solely due to the hormonal mechanism 
discussed previously. It has been suggested that corticoids 
induce apo-TP synthesis and increase the holoenzyme activity 
in proportion to the rise in total activity, so that the heme 
saturation remains essentially constant (Feigelson and Brady, 
1974; Morgan and Badawy, 1980). This consideration is not 
applicable to substrate or cofactor-type enhancement of TP 
activity, which produces a large increase in holoenzyme 
activity with little or no synthesis of apoenzyme and a rise 
in the heme saturation. Therefore, if an effect on "total 
enzyme" activity is observed, it is important to identify the 
mechanism which is responsible, in order to interpret the 
heme saturation data.
The degree of heme saturation of TP has been expressed 
in the literature either as holoenzyme/apoenzyme ratio or as 
percentage of the holoenzyme activity against that of "total 
enzyme". Badawy (1978) prefers to use the concept of 
holoenzyme/apoenzyme ratio rather than the percentage because 
higher doses of compounds are required to produce a 50*/
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decrease in the latter, a finding that the present study 
confirms. However, the possible effects of AsIII and other 
metals on apoenzyme synthesis, indicates the importance of 
expressing the degree of heme saturation of TP as percentage 
instead of holoenzyme/apoenzyme ratio. This gives separate 
consideration of the effects of chemicals on parts of the TP 
system other than heme availability.
3.3.2 Effects of acute administration of As and Se on ALA 
Svnthetase activity.
ALAS is thought to play a key role in the regulation 
of heme synthesis for two main reasons: 1) its activity
appears to be rate limiting in the pathway; 2) it is the site 
where heme exercises a negative feedback control on its own 
synthesis (De Matteis, 1975).
The results of this study show that the overall 
response to acute administration of AsIII, AsV and SelV was a 
dose-related increase in hepatic ALAS activity (Tables 3.3, 
3.7 and 3.10). A comparison with literature data, indicate 
that after Fe-dextran (Ibraham et al., 1979) and Co (Maines 
and Kappas, 1976b), Se and As are among the most potent 
inducers of ALAS. However, there were marked differences 
between As and Se potencies; on a molar basis, SelV was 8 
times as potent as AsV, and about 3.5 times as potent as 
AsIII. AsIII was about 2.5 times more potent than AsV (Fig. 
3.7).
Possible mechanisms of As and Se effects on ALA 
Synthetase activity. The main regulatory aspects of heme 
synthesis, utilization and degradation were brought together 
in a model centered on the feedback control exercized by heme 
at the ALAS level (De Matteis, 1975; Granick et al., 1975). 
Currently the chemically mediated increase of ALAS in liver
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is supposed to be mainly due to a reduction in the "free heme" 
pool (see Section 1.3.2), which can be elicited by one or 
more of the following mechanisms : 1) inhibition of heme
synthesis; 2) increase in the rate of heme utilization; or 3)
increase in the rate of heme degradation. As discussed in 
Section 3.3.1, there is evidence that arsenic affects 
mechanisms 1 and 3, inhibiting heme synthetase activity,
producing porphyria and increasing HO activity. Se, however, 
has no effect on the cellular content of porphyrins, but it
is a potent HO inducer.
Effects of As and Se on the relationships between the
heme saturation of TP and ALA Synthetase activity. Welch and
Badawy (1980), have reported that ALAS activity is enhanced
when the heme saturation of TP is reduced by treatments that
decrease cellular heme content. On the other hand, ALAS
activity has been reported to be decreased when the heme
saturation of TP is increased after hematin administration 
(Welch and Badawy, 1980; Yamamoto et al., 1981). These 
findings led these authors to suggest that an inverse
relationship exists between ALAS activity and the degree of 
heme saturation of TP. In the present study the relative 
potencies of As and Se on ALAS activity were similar to those 
on the heme saturation of TP, suggesting that the mechanism 
of both effects is similar. In order to explore the effects 
of the acute administration of AsIII, AsV and SelV on the 
relationships between the "free heme pool" and ALAS activity, 
two factors were investigated: 1) a dose-response study with
the effects measured 16 hours after treatment; 2) the time- 
course of AsIII effects.
As and Se produced a dose-related decrease in the 
percentage of TP saturated with heme, accompanied by dose- 
related increases in ALAS activity; the correlation 
coefficient (r) between these effects was better than - 0.94 
for each metalloid indicating that ALAS activity was 
inversely proportional to the TP heme saturation. These "r" 
values (see also figure 3.8) suggested that if ALAS activity 
were dependent on the "free heme" pool size, as measured by 
the heme saturation of TP, a good correlation would be 
expected between these parameters, regardless of the 
metalloid used to produce the effects. The combined 
correlation coefficient obtained for these data, when the 
effects of the 3 salts were considered, was - 0.86, 
supporting this proposition. Two models may be used to 
explain these data, a linear model ( y = 406.2 - 7.88x ; r = 
-0.86 ) or an exponential model ( lny = In 546.9 - 0.040x ; r
= -0.86 ). Unfortunately there are insufficient data,
especially at the lower TP heme saturation values, to decide 
between these models. The findings indicate: 1) that As and
Se reduce the size of the regulatory "free heme" pool, 
causing a positive feedback control of ALAS activity. 2) 
that most chemicals which increase ALAS activity, may do so 
by decreasing the regulatory "free heme" pool (Meyer, 1982). 
3) that if the exponential model is the one which represents
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Fig. 3.8 Relationships between the heme saturation 
of tryptophan pyrrolase and ALA synthetase activity. 
The effects were studied 16 hours after subcutaneous 
administration of the metalloids.
this relationship, there may be circumstances in which no 
further depletion of the heme saturation of TP could be
achieved while maintaining a concurrent increase in ALAS
activity.
The time-course studies reported by Sardana et al. 
(1981) of the effects of a single dose of AsIII (100
umol/kg), showed that this metalloid produces a decrease in 
ALAS activity 1 hour after treatment, followed by a rebound 
increase which reached a peak at 8 hours before returning to 
control levels at 24 hours (Fig. 3.9). This biphasic effect 
is characteristic of the administration of a number of
transition and heavy metals (De Matteis and Gibbs, 1976;
Maines and Kappas, 1977b). The time-course of the effects on 
the heme saturation of TP reported in the present study 
showed a small but significant increase during the first four 
hours after treatment (AsIII; 100 umol/kg), followed by a 
gradual decrease which at the end of the observation period 
(24 hours) corresponded to a heme saturation of 407. of 
control values (Fig. 3.9). Kikuchi et al. (1982), have
reported similar time-courses for the effects of Co on ALAS 
and TP administration i.e. an initially increased ALAS
activity declining rapidly after 12 hours, while the heme 
saturation of TP continued to decrease; however, in their 
publication the values of "total enzyme" and holoenzyme 
activity were not given. The effects observed between 1 and 8 
hours after AsIII administration support the suggestion that 
an inverse relationships exist between ALAS activity and heme
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Fig. 3.9 Time-course of sodium arsenite (AsIII) effects 
(100 umol/kg body wt.) on ALA synthetase activity (o) and 
the heme saturation of tryptophan pyrrolase (©). The data 
on ALA synthetase were taken from Sardana et al. (1981).
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saturation of TP. Although ALAS activity was still above 
control values, its declining trend in the presence of a 
parallel decrease in the heme saturation of TP is difficult 
to explain (Fig. 3.9). This indicates that the relationship — 
between these parameters is not a simple inverse one, and 
that there are conditions in which it does not hold. Further 
experiments are needed to: 1) investigate the time-course of
the production of porphyria and the inhibition of heme 
synthetase activity produced by AsIII, to assess the likely 
causes of reduction in the "free heme" pool size which result 
in changes in ALAS activity and heme saturation of TP. The 
information obtained in this proposed experiment may allow 
the reconciliation of the information from the dose-response 
studies. It is possible that ALAS activity may reflect more 
accurately the changes in the "free heme" pool than the heme 
saturation of TP, or alternatively, ALAS activity may be 
controlled by a heme pool not measured by TP; 2) study the 
possibility of TP playing a more active role in the 
regulation of ALAS, rather than being a passive indicator of 
heme availability. and 3) explain some other circumstances 
in which the above relationship does hot hold. In particular 
an assessment is needed of: a) the effects and time-course of 
other potent ALAS inducers on TP e.g. administration of Fe- 
dextran, which according to Bonkowsky et al. (1981) produces 
a 4-fold increase in ALAS activity; b) the mitochondrial 
and cytosolic ALAS activities and their corresponding 
relationships to TP heme saturation after metal treatment.
Although most e x p e r imental  evidence indicates that 
ALAS activity is regulated by heme availability, alternative 
mechanisms unrelated to heme repression, have also been 
proposed to explain ALAS induction. They include direct 
effects on the nucleus to increase induction-specific RNA 
(Tyrrell and Marks, 1972), effects on ALAS translation and 
alterations in the enzyme’s half life (Sassa and Granick, 
1 970 ) .
3.3.3 F f fe ct s of the ac ut e administration of As and Se on 
heme oxvaena se activity.
Heme oxygenase plays a key role in mammalian heme 
catabolism and it is widely accepted that in physiological
conditions its activity is controlled by the amount of heme
available for catabolism (Pimstone et al. , 1971).
The results of this study show that the overall
response to acute administration of AsIII, AsV and SelV was a
dose-related increase in hepatic HO activity (Tables 3.3, 3.7 
and 3.10), thereby, enhancing the heme degradation rate. This 
confirm earlier reports of Sardana et al. (1981) and Maines 
and Kappas (1976a). AsIII has also been reported to increase 
HO activity in cultured avian liver cells, whereas SelV 
failed to elicit this response (Sardana et al., 1982). There 
are marked differences in the potencies of these metalloids; 
on a molar basis, SelV was marginally (1.3 times) more potent 
than AsIII, and 15 times as potent as AsV. AsIII was 12 
times more potent than AsV (Fig. 3.10). These relative 
potencies were markedly different from those described for 
the effects on ALAS and TP (Section 3.3.2). The main change 
was a marked increase in the ability of AsIII to induce HO, 
suggesting the possibility that more than one mechanism may 
be involved in the induction of heme oxygenase.
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Po s s i ble mechani sms o f As and Se effect s on HO 
activity. Although the ability of hemin and some xenobiotics 
to induce HO activity has been known since 1970 (Tenhunen et 
al., 1970), the mechanisms of induction have eluded 
explanation and different hypotheses have emerged. In general 
terms, it could be said that these hypotheses are based on 
the effects that a particular inducing agent has on enzymes, 
such as heme saturation of TP and cytochrome P-450 
concentration, which are recognized as indicators of cellular 
heme status. According to Kikuchi and Yoshida (1983), hepatic 
HO induction may occur by two apparently different 
mechanisms. The first type of mechanism is epitomised by the 
induction caused by carbon disulphide, endotoxin, insulin and 
epinephrine. This induction is considered to be mediated by 
heme because these agents each produce a significant increase 
in the heme saturation of TP, and a moderate increase in HO 
activity, comparable to that caused by small doses of hemin 
(3 umol/kg). The second type of mechanism is characteristic 
of the induction produced by cadmium, cobalt and 
bromobenzene and seems to be independent of heme mediation, 
since these agents reduce the heme saturation of TP and cause 
a far more extensive HO induction than that observed after 
the administration of 30 umol/kg of hemin.
In the case of As and Se, the dose-response data 
obtained 16 hours after treatment provided indirect evidence 
to suggest that the increase in HO cannot be explained in
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terms of the first mechanism i.e. the regulatory "free heme" 
pool model because: 1 ) There . were no ind i.cation s of
increases in "free heme pool" size, as measured by the heme 
saturation of TP, which could trigger a positive feedback on 
HO. On the contrary, it appears that one reason for the 
reduction in heme saturation was the increased HO activity 
(Fig. 3.11). 2) the concomitant increase in ALAS activity is
further indication of cellular heme depletion.
A particular point of interest arises in the case of 
AsIII, where data on the time-course of the effects on ALAS 
and TP are available; namely if the early increase in the 
degree of heme saturation of TP observed in the present study 
[together with the inhibition of ALAS activity observed 2 
hours after AsIII treatment (Sardana et al. 1981)] could be 
interpreted as indicative of an increased "free heme" pool 
size (Section 3.1.1; Fig. 3.5), then this transient increase 
would stimulate the synthesis of HO-specific mRNA, which 
according to Kikuchi and Yoshida (1983) has a long half-life 
(4 hours). Because HO has a 6 hours’ half-life a sustained 
increase in HO activity could occur, which in turn would 
reduce the heme saturation of TP. Thus, at the end of the 
observation period (16 hours), the picture would be that of 
an increased HO activity accompanied by a reduction in the 
heme saturation of TP. However, the increase in heme 
saturation values was far below the saturation produced by a 
3 umol/kg hemin injection which only produced a 3-fold 
increase in HO activity in the experiments of Kikuchi and
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Fig. 3.11 Relationships between the heme saturation of 
tryptophan pyrrolase and heme oxygenase activity. AsIII 
(o), AsV (o) and SelV (□). The effects were studied 16 
hours after subcutaneous administration.
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Y o shida(1983).
Alternatively, it may be postulated that it is heme 
utilization by TP and not the degree of heme saturation that 
is related to HO induction. If this is the case, then the 
early increase in the heme saturation of TP is due to the
reduction in the "total enzyme" and holoenzyme activities, 
the net effect being to reduce the number of apo-TP molecules 
saturated with heme, thus allowing the unused heme to
increase the "free heme" pool size. Further experiments are 
needed to explore this possibility.
A comparison between doses of AsIII, AsV and SelV 
which were equally effective in producing a 502 decrease in 
the heme saturation of TP at 16 hours after treatment showed 
that the AsIII dose increased HO activity almost twice as 
much as that of SelV or AsV (Fig. 3.11). This suggests that
the increase in HO activity produced by these metalloids is a
property partly or totally independent of the "free heme" 
pool size, as measured by the heme saturation of TP. It also 
raises a question: where does the heme metabolized by excess
As 111-induced HO comes from ? It remains to be established 
whether HO activity is directly affected by these metalloids, 
or indirectly through degradation of P-450. Possibly, P-450 
serves to influence the size of a specific subcompartment of 
the heme pool.
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A comparison between the increase in ALAS and HO
activity produced by AsIII at 16 hours after treatment (Fig.
3.2 and 3.12) showed that the increase (with respect to
control values) in HO activity was always greater than that 
produced in ALAS activity. The highest dose (75 umol/kg) 
produced a 2-fold increase in ALAS activity, while HO
activity was increased 8-fold. This disparity between the 
effects on ALAS and HO activities and the fact that 8
molecules of ALA are required to form one molecule of heme 
clearly illustrates the lack of parallelism between heme 
synthesis and degradation.
It is known that between 15 and 20 transition 
elements, heavy and organometallic compounds are HO inducers 
(Maines and Kappas, 1977a; Eaton et al., 1980; Rosenberg et 
al., 1984). From data reviewed by these authors and those 
reported here, it could be said that besides increasing HO 
activity, all elements tested so far that increase ALAS 
activity, decrease TP heme saturation and reduce P-450
concentration. Se is notable because it does not seem to
reduce P-450 content. The possible role of P-450 in HO
induction is briefly discussed in the following Section.
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Fig. 3.12 Effects of sodium arsenite (AsIII) on the 
relationships between the heme saturation of tryptophan 
pyrrolase and ALA synthetase and heme.oxygenase activities. 
The effects were studied 16 hours after subcutaneous 
administration of AsIII.
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3.3.A Effects of As and Se on cytochrome P-450 concentration.
It has been suggested that HO -inducing agents might 
act by first labilizing the heme moiety of P-450, the 
released heme then acting as the inducer for HO (Bissell and 
Hammaker, 1976 a, b; Lim et al. 1980). The acute 
administration of AsIII and AsV produced a dose-related 
decrease in P-450 concentration, AsIII being 3 times more
potent than AsV. This difference in relative potency was
similar to that observed in the effects on TP and ALAS.
Possible mechanisms of As effects on cytochrome P-450. 
De Matteis (1982), has reviewed evidence indicating that in 
vitro, metals could produce peroxidative damage to microsomal 
membranes leading to decreased affinity of the P-450 
apoprotein for heme, and suggested that if these agents 
produced similar effects in vivo, this would lead to a
substrate mediated HO induction. Recently, Klimczac et al. 
(1984) showed that lipid peroxidation produced by Cd in vivo 
is concurrent with the reduction of P-450 content, and 
increases in ALAS and HO activities. Although no direct 
information is available regarding the effects of As on lipid 
peroxidation, Squibb and Fowler (1983) have reviewed 
information indicating that As administration reduces 
catalase activity. Thus, it is possible that P-450 loss
produced by As could be explained by this mechanism. Further 
work is necessary to explore this possibility.
Although published literature favours an association 
between lipid peroxidation and P-450 loss, no evidence is 
available to support the suggestion that an increase in "free 
heme" pool due to P-450 breakdown had taken place before the 
increase in HO activity. Furthermore, Drummond et al. (1982) 
reported that SKF 5 2 5A protects the integrity of P-450 
throughout the immediate period (0 - 16 h) after the
administration of Co, Sb, AsIII and other metals, without 
affecting the extent of HO or ALAS induction; thus, providing 
evidence that P-450 degradation is not an essential event for 
metals to initiate HO induction. This raises the question : 
is heme the stimulus for HO induction ? and if so, where 
does it come from when P-450 is protected by SKF 525A ? Does 
it come from an isoform of P-450 not protected by SKF 525A or 
from another heme pool(s), microsomal or cytosolic ? It would 
be helpful to know the effect of SKF 525A on the heme 
saturation of TP in As treated rats.
The administration of Se produced a dose-related 
decrease in TP heme saturation and also resulted in dose- 
related increases in ALAS and HO activities. However, it did 
not seem to significantly affect the microsomal P-450 content 
(Tables 3.9, 3.10 and 3.11). These results confirm those
reported by Maines and Kappas (1976a). They have shown that 
hepatic total P-450 levels were refractory to a subcutaneous 
dose of 50 umol/kg at 14.5 hours after treatment, but found 
that the activity of ethylmorphine N-demethylase was reduced
by 507.. This finding was difficult to repeat in our hands,
since in our strain of rats such doses were lethal after a
short period. According to Luckey and Venugopal (1978) the
LD for sodium selenite in rats is about 43 umol/kg. Eaton 
5 0
et al. (1983) have reported that in two groups of animals 
treated with two consecutive i.p. injections of 13 umol/kg or 
25 umol/kg (at 12 and 36 hours before sacrifice), a 3-fold 
increase in HO activity was observed, while only the highest 
dose significantly reduced P-450 concentration; No effects on 
P-450 dependent enzymes were measured in this study. However, 
Schnell et al. (1983) reported that 72 hours after treatment 
with a single i.p. dose (23 umol/kg) of SelV, a 207 reduction 
in P-450 content and a 3 07 decrease in ethylmorphine N- 
demethylase activity were produced, but no effect on aniline 
hydroxylase activity was observed. The effects on HO activity 
were not determined by these authors. The above data suggest 
that there are doses of SelV which induce HO, but have no 
effect on P-450 concentration, and that this occurs between
14.5 and 24 hours after treatment. This would support the 
contention of Drummond et al. (1982) that P-450 heme 
degradation is not essential to initiate HO induction. 
However, it would be interesting to know what changes, if 
any, occur in HO activity at later times when the P-450 
concentration is reduced. Time-course studies on the effects 
of Se on these parameters are needed to resolve this.
Why does SelV administration not reduce P-450 content
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at times up to 24 hours ? Se has been shown to be necessary
to maintain the normal function of P-450 (Burk and Correia,
1981; Burk, 1983). Se also increases the levels of Se-
glutathione peroxidase which protects against lipid
peroxidation (Tappel, 1980), a possible factor in P-450
losses (De Matteis, 1 982 ). Furthermore, in vitro. and in
contrast to most metals, Se in concentrations ranging from 
-6 -3
10 to 10 M produced no effect on total P-450 content; 
however, a 257. decrease in aniline hydroxylase was observed 
in the same experiment (Schnell et al., 1983). Another
possibility is that SelV acts in a manner analogous to that
of SKF 525A, complexing with heme, thereby preventing the
degradatory effects of some compounds on P-450. However, Se
does not impair the ability of P-450 to bind CO, as SKF 525A
does (Buening and Franklin, 1976), which makes this
possibility unlikely.
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3.3.5 JLs blliverdin reductase an importa nt factor in 
the regulation of heme oxygenase activity Z
It has been suggested by Maines and Kappas (1977) that
the interaction of metal ions with specific receptor sites,
containing key sulphydryl groups, may trigger cellular events
leading to HO induction. According to Maines (1984), an SH-
containing protein which appears to be a good candidate for
functioning as the regulator of HO activity is biliverdin
reductase (BR). The hypothesis proposed was that the
activity of BR is inhibited upon exposure to agents with a
high affinity for SH groups. As a result, the enzyme would
be unable to remove the biliverdin formed by HO. Thus, HO
activity would be inhibited as the result of the hindered
dissociation of biliverdin from its heme-binding site. This
could trigger cellular events to accommodate the inhibited HO
activity, leading to increased HO production. The evidence
supporting this hypothesis comes from experiments in which
rats were treated with biliverdin (Kutty and Maines, 1984).
The response was an initial (within 3 h) inhibition followed
by a late (48 h) rebound increase in BR and HO activities.
However, there is little published information on the effects
of metals on this enzyme. Frydman et al. (1979) mentioned
that in rats dosed with 200 mg/kg (730 umol/kg) of CoCl an
2
increase in BR activity was observed, but no quantitative 
data were given; Kutty and Maines (1983) could not confirm 
these findings.
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The results of the present study showed no detectable 
effects of AsIII, AsV or SelV, at any dose level, on BR 
activity. These negative results argue against the 
hypothesis mentioned above, because As and Se are powerful HO 
inducers and markedly increased biliverdin production without 
significant changes in BR activity. Under physiological 
conditions biliverdin reduction is not the rate limiting step 
in heme catabolism and it appears that neither is this so 
under the altered conditions following As and Se poisoning. 
Therefore, it is highly unlikely that BR plays an important 
role in the HO induction produced by As and Se.
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3.3.6 Effects of the combined administration .of AsIII and 
SelV .
The simultaneous administration of AsIJI and SelV 
resulted in a dose-dependent decrease in the heme saturation 
of TP, as described by Albores (1984). However, the effect 
was significantly (p < 0.05) more pronounced than that
observed with AsIII alone (Tables 3.1, 3.9 and Fig. 3.12).
Only the effects of 3 combined doses on HO activity were
examined, however it was clear that this activity was
significantly higher (p < 0.05) than that produced by AsIII 
alone (Tables 3.3 and 3.13). The additive effects of AsIII 
and SelV on HO activity, plus the ability of As to inhibit
heme synthesis at other steps not affected by Se, might
explain the additive effects of these metalloids in 
decreasing the degree of heme saturation of TP. As in the
treatment with either AsIII or SelV alone, the combined
administration of these metalloids did not produce any 
significant effect on biliverdin reductase activity.
There were indications that SelV administration may 
protect against the P-450 degradation produced by AsIII 
(Tables 3.4 and 3.13). The levels of P-450 after AsIII 
treatment (75 umol/kg) were reduced to 597. of control values 
while those of AsIII (75 umol/kg) plus SelV (5 umol/kg) were 
reduced to 717 of control (0.1 > P > 0.05). Early and
Schnell (1981) have reported that i.p. administration of SelV
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(9.3 umol/kg) blocked the Cd-induced (3.8 umol/kg) reduction 
in P-450 and P-450 dependent monooxygenases. These data 
suggest that Se can prevent some manifestations of 
hepatotoxicity associated with the activity of the P-450 
dependent enzyme system; however, further experiments are 
needed to find the range of Se doses able to protect against 
this type of As hepatotoxicity. It is possible that the 
protective effect of Se against As-induced destruction of P- 
450 may involve the role of Se as a component of glutathione 
peroxidase (Hoekstra, 1975), which is particularly important 
for maintaining the integrity of cellular and subcellular 
membranes from the oxidative damage thought to be caused by 
metals (De Matteis, 1982). As selenium deficiency results in 
reduction of Se-dependent glutathione peroxidase activity 
(Burk, 1983), it would be interesting to know if Se 
administration increases its activity above control levels. 
The data from the present study indicate that Se may have a 
dual effect in As-induced hepatotoxicity. On one hand, it 
protects against the decrease in P-450 concentration, and on 
the other, it has additive effects increasing HO activity and 
further reducing the heme saturation of TP.
There is evidence that Se changes the biological 
effects of a number of heavy metals and render them less 
toxic (Nordberg, 1976). With respect to As and Se, it has 
been reported that they ameliorate each other's toxicities 
(Frost, 1983). The protective effects of As have been known 
since 1945 when Moxon et al. showed that As could prevent Se
poisoning when compounds of both elements were injected 
subcutaneously. Holmberg and Ferm (1969) showed that SelV 
decreased the teratogenicity of AsV in hamsters when injected 
simultaneously. However, there are some situations in which 
As increases Se toxicity. Obermeyer et al. (1971) have shown 
that poisoning by trimethylselenonium chloride, a compound of 
relatively low toxicity compared to many other Se compounds, 
is markedly increased by simultaneous injection with AsIII. 
Cabe et al. (1979) showed that in rats exposed to AsV (50 
ppm) plus SelV (10 ppm) via drinking water for 13 weeks the 
mortality rate was 70'/ compared to less than 10'/ in the rats 
exposed to AsV or SelV alone. As if this picture were not 
confused enough already, Levander, (1977) and Alexander 
(1980) have reported that AsIII potentiates the beneficial 
effect of SelV in protecting against methylmercury
toxicity. A general mechanism has been proposed to explain 
the mutually antagonistic abilities of As and Se. Levander 
and Baumann (1966) have suggested that Se and As react in the 
liver to form a detoxication conjugate which is then excreted 
into bile; the chemical nature of this conjugate has not yet 
been established. This is consistent with the fact that As 
and Se each increase the biliary excretion of the other. 
However, this explanation would not account for the additive 
effects observed in this study.
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3.3.7 Effects of 3 0 day exposure to AsIII.
Although the control values did not change
significantly during the 30 day period, TP "total enzyme"
activity and apoenzyme values were lower (Table 3.15) than
those obtained in the acute experiment series (Table 3.1).
However, the degree of heme saturation and the
holoenzyme/apoenzyme ratio did not significantly change. A
possible explanation for this reduction in TP activity is
that the incubation of homogenate samples in the 30 day study
was not done immediately after homogenization, as it was in
the acute experiment series, but was kept in the incubation 
o
mixture at 4 C for four hours before starting the incubation 
period. Badawy and Evans (1974) have suggested that delays in 
sample incubation may decrease enzyme activity. The main 
effects of continuous exposure to AsIII on TP were:
1) a progressive increase in "total enzyme" activity 
and in calculated apoenzyme values (Table 3.15). Although 
there is little published information which directly relates 
to the effects of As on TP apoenzyme synthesis, Ghafghazi and 
Mennear (1973) and Ghafghazi et al. (1980) have shown that 
the acute and subacute administration of Cd and AsIII affect 
the adrenal glands, releasing epinephrine and corticoids. 
This in turn leads to an increase in TP-apoenzyme synthesis 
as discussed in Section 3.3.1. Indirect support to this 
suggestion was given by the report (Cebrian et al., 1984)
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that administration of AsIII in drinking water (5, 50 and 100
ppm) produced a dose-related weight increase in the adrenal 
glands of female rats at the end of 8 weeks of treatment.
2) an initial decrease in the heme saturation of TP,
which did not subsequently change significantly during the
period of treatment (Table 3.15). This 257. decrease from 
control values indicates that continuous treatment with AsIII 
has reduced the availability of heme in liver cells. This 
effect was similar to that observed after the acute 
administration of 25 umol/kg. It also seems to indicate that 
a new equilibrium, at a lower level, between synthesis and 
degradation of heme has been reached during the 30 days of 
treatment.
There was a 607 increase in ALAS activity, during the
first 10 days of exposure and subsequently this level was
reduced to a 307 increase over control values (Table 3.16). 
This appears to be in response to the decreased heme 
availability shown by reduction in the heme saturation of TP. 
Although the increases were modest, they are within the range 
observed after acute treatment with doses higher than 50 
umol/kg of AsIII.
In marked contrast to the dose-related increases in HO 
activity and corresponding decreases in cytochrome P-450 
concentrations observed after the acute administration of
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AsIII (Table 3.3 and 3.4), no detectable effects on these
parameters were observed at any of the interim time points
during treatment (Table 3.16). A possible explanation for
this is that at the exposure levels selected for this
experiment (50 ppm; 24 umol/kg/day) AsIII does not reach the
endoplasmic reticulum in sufficient concentrations to produce
a significant effect. It should be noted that the binding of
As to microsomes is fairly weak in several animal species,
the exception being the marmoset monkey in which 507 of the
As present in the liver cell is bound to the microsomal
fraction (Vahter et al., 1982). The discrepancy between the
effects of acute and chronic treatments are not exclusive to
As. It is known that acute treatment with Co, Cd, Zn, Ni or
Hg markedly increase ALAS and HO activities and reduce P-450
contents. However, daily administration of Co(N0 )
3 2
(20mg/kg; 69 umol/kg), CdSO (10 mg/kg; 13umol/kg) and ZnSO
4 4
(20 mg/kg; 111 umol/kg) in drinking water for 30 days
produced only moderate increases in ALAS activity (30-407),
decreases in HO activity (30-407) and increased P-450
concentration (20-307). Similar treatment with NiSO (20
4
mg/kg; 71 umol/kg) or HgCl (5mg/kg; 18.4 umol/kg) produced
2
no detectable effects on any of these parameters (Kadiiska et
al., 1985). Se, which is a powerful HO inducer in acute
experiments, when administered for 6 months in the diet (10
ppm) did not induce HO; also in contrast to the absence of
effects after acute treatment, subchronic exposure produced
a 207 decrease in P-450 concentration (Reiter and Wendel,
1 985 ) .
In the present study, the acute subcutaneous 
administration of AsIII produced a marked increase in HO 
activity, which was considered to be a major corrtributing 
factor to the observed decrease in heme availability (see 
Section 3.1.1). However, in the 30 day study, where the dose 
of AsIII (50 ppm in the drinking water) was equivalent to 3.1 
mg/kg/day (24 umol/kg/day), the combination of increased ALAS 
activity, diminished heme availability and apparently normal 
rate of heme degradation, strongly suggests that an 
alteration in the heme synthesis pathway is produced after a 
relatively short time of exposure. Woods and Fowler (1978) 
and Martinez et al.(1983), showed that AsV and AsIII produce 
porphyria in rats, this would be expected to be associated 
with a reduction in the production of heme and hence, a 
decrease in heme availability. This pattern was observed in 
the present study.
Woods and Fowler (1978), have reported that exposure 
for 6 weeks to AsV at 20, 40 and 85 ppm in the drinking water
resulted in non-dose-related effects on ALAS activity; while 
no alteration ocurred in rats exposed to 20 ppm, a 20/. 
reduction in activity was observed at the 40 ppm level, but 
only a 13/ reduction was produced by the highest 
concentration. No effect was observed in mice at 20 and 85 
ppm exposure, but a 13/ reduction was observed at the 40 ppm 
level. No effects on ALA dehydratase were observed in rats
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or in mice. The activity of uroporphyrinogen I synthetase, 
was not affected in rats, but there was a dose-related
synthetase was also found, the maximum decrease ( 407.) was 
observed at the 85 ppm level. Accompanying these alterations 
in enzyme activity, there were substantial dose-related
elevations in the concentrations of urinary porphyrins. 
Martinez et al. (1983) have shown that AsIII administration 
in drinking water at 5, 50 and 100 ppm produced a dose-
related increase in uroporphyrin excretion after one week of 
treatment. Although there is agreement that As produces
porphyria, there is little information on the organs
affected? the report that in AsV-induced porphyria a
reduction in  ^ALAS activity was present (Woods and Fowler,
1978) is suggestive that other organs, specially kidney, may 
be affected and could contribute to the total excretion of 
porphyrins (see Chapter 5).
marked increase in uroporphyrin excretion was followed by a 
gradual decrease towards control levels, as the period of 
exposure continued (Fig. 3.14), this was interpreted as a
ALAS followed a similar pattern, giving support to the idea 
that an adaptive response to the toxic effects of AsIII on 
heme synthesis takes place. Other biochemical studies of As 
toxicity have also suggested the existence of an 
adaptation/compensation phenomenon. Schiller et al. (1978)
increase in mice. A dose-related inhibition of heme
In the study of Martinez et al. (1983), the initial
sign of adaptation. In the present study, the response of
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reported that an inhibition of pyruvate dehydrogenase induced 
by exposure to As for 3 weeks was not present after 6 weeks 
of continuous treatment. The exact mechanisms by which 
adaptation to As toxicity develops are not known; however-; 
the following possibilities have been mentioned: decreased
gastrointestinal absorption, changes in excretion rates, or 
alterations in the rate at which AsIII is converted to AsV in 
vivo (Squibb and Fowler, 1983).
CHAPTER FOUR 
SOME EFFECTS OF ARSENIC AND SELENIUM 
ON HEPATIC XENOBIOTIC METABOLISM.
4.1 INTRODUCTION
Some effects of arsenic and selenium on hepatic heme 
metabolism were described and discussed in Chapter 3. A 
prominent effect of the acute administration of these 
metalloids was an increase in the rate of heme degradation, 
which in turn affected either the specific activity or the 
absolute amounts of several heme-dependent enzymes. Among 
these enzymes the concentration of cytochrome P-450 was 
markedly reduced by both pentavalent and trivalent arsenic, 
whereas selenium did not seem to affect this enzyme system. 
Thus, it was considered of interest to study the effects of 
these metalloids on hepatic cytochrome P-450- dependent 
metabolism, since this enzyme system is involved in the 
biotransformation of many endogenous and exogenous 
substances.
It was also decided to study the effects of As and Se 
on epoxide hydrolase (EH), a microsomal enzyme concerned with 
the conversion of highly reactive epoxides and arene oxides 
to chemically less reactive dihydrodiols. This reaction has 
been recognized as an important metabolic step in the 
detoxication of these compounds (Lu and Miwa, 1980). It is
generally considered that compounds that induce EH will also 
induce P-450 and other P-450 dependent metabolizing enzymes 
(Guengerich, 1982). However, there are several furan 
derivatives that are good EH inducers, but either have no
significant effects on P-450 concentration (eg. dibenzofuran 
and dihydrobenzofuran) or decrease it (eg. furan and 
benzofuran), Connelly (1983). From Connelly’s data it is 
also apparent that some compounds (eg. isosafrole, 
benzofuran, dihydrobenzofuran and trans-stilbene oxide) that 
induce EH, induce concurrently heme oxygenase (HO). Although 
there is very little available information on the in vivo 
effects of inorganic compounds on EH activity, or on the 
possibility of As or Se or their metabolites forming 
epoxides, arsenic shares with furan and benzofuran HO 
inducing and P-450 depleting properties, and Se shares with 
dibenzofuran and dihydrobenzofuran the ability to induce HO 
without affecting P-450 content. On this basis it was decided 
to study the effects of AsIII and SelV on EH activity.
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4.2 RESULTS.
4.2.1 Effects of Arsenic.
The effects of 4 different dose levels of AsIII 
(ranging from 12.5 to 75 umol/kg) and 5 different levels of 
AsV (ranging from 25 to 200 umol/kg) at 16 hours were 
studied. Both salts of As were administered by subcutaneous 
injection. In the subchronic study, AsIII was administered 
via drinking water at a concentration of 50 mg/1.
a ) Ethoxvcoumarin and ethoxvresorufin 0-deethviases.
(i) Acute effects of AsIII. The activity of both these P-450 
dependent enzymes was decreased in a dose-related manner 
(Table 4.1). However, the effect was slightly greater for 
ERD; the reduction in activity was significant even at a 
lower dose; the highest dose (75 umol/kg) reduced the 
activity to 47/ of control. For ECO the activity was reduced 
to 66/ of control by 75 umol/kg of AsIII.
(ii) Acute effects of AsV. The observed effects were similar 
to those produced by AsIII administration, the activities of 
both enzymes were reduced, but only at doses higher than 100 
umol/kg (Table 4.2). Again, this reduction was slightly 
greater for ERD; the highest dose (200 umol/kg) reduced the 
ERD activity to 49/ of control, while ECD activity was
Ta
bl
e 
4.
1 
Ef
fe
ct
s 
of
 
so
di
um
 
ar
se
ni
te
 
(A
sT
II
) 
on
 
he
pa
ti
c 
ep
ox
id
e 
h
y
d
r
o
l
a
s
e
,
 
he
me
 
o
x
y
g
e
n
a
s
e
,
 
e
t
h
o
x
y
c
o
u
m
a
r
i
n
 
an
d 
e
t
h
o
x
y
r
e
s
o
r
u
f
i
n
 
O-
de
et
hy
 
1
a
s
e
s
, 
an
d 
c
y
t
o
c
h
r
o
m
e
 
P
-
4
5
0
.
172
CO co CC t-- c—
CD o o o o o
E . • • • •
r o o o o r-~,
x
-CJ +1 +1 +1 +1 +1
O o
O in cn vO r— CM t—
4-3 <r vO in in <r CO
>> 1 . • • • •
o  CL, o o o o o
C
•H
Cm CO
3 CD
i-. CO * at at
O CO o CO in vO o
CO «H • • • • ♦
CD >> co CM •»— o r—
j- x:
>1J-> +i +1 +i +1 +!
X CD
O CD CO r— CO T— in
-C XJ . • • • •
4-3 I co vO <r o CO
w o T_ r~ *—
c
•Hh
t- CD at at
CO CO co <r vO r— CM
E CO o o O o o
3 i—1 • • • • •
O >> o o o o o
O SZ
>. +1 +1 +1 +1 +1
X CD
O CD co o vO o in
jo *a co <r co CO CO
4-3 I . . . . .
cu o o O o o o
CM
0
CO
CO
c
0
0 fao 
E >> 
Cl) Xuz o
a)
TD
•H
x
o
a
w
CD
co
CO
i—i
o
X>
DC
bO
-X
M O 
M E 
CO 3
i n
co
o
+i
o
o-
o
co
+i
cr>
O
SX
4-3
C
O
o
co
o
+!
+i
c^-
i n
co
CM
<r
O
+1
O
cr»
co
cr>
o
+i
in
o
in
CM
CM
o
+i
co
c o
co
+i
o
<r
o
in
co
MO
o
+1
o
o
CM
+1
vO
CM
in
CO
4-3
CO
"O
u
(D
sz
4-3
o
C-,
o
Cm
M
M
M
CO
<s
Cm
o
r c
J O
s -
H 4-3 
CO 
-3 *H
0 c
•H
I E 
• a  
- co
..  w3
C  4-3
O 3 
O O 
JO 
i. 3
vO
CO
4-3 .
ii ^ in
" CO o
c c C  CO o
•rH . •H u
0 c 0 3 V
•r~i -J . • n
O 0 O c Q  sz cx
C-. 4-3 X •H rr\
cx O cx 0 } vO co
S-« 4-3 +1 T~ 4-3
1—1 CX i— i o CO
CO co J-4 4-3 •o
E 1—1 E a lx CO
O CO o rH
CO E CO •—i CO *o o
O O o cO CO 0
J-, CO u E •H 4-3
O o o O C  ’O c
•H u •H CO 0  3 O
E a E o >  40 U
•H S-. \ CO
faO E bO u •rn E
E E •H bO Q) O
N bO \ E U
C E C 0  0 Cm
•H •H bO >  2
E sz E E O CO
N \ X jQ co S-.
rH 1— 1 rH r— 1 CO ^ 0O o o o u Cm
• E E E E 0 Cm
C C CXC rH Cm •H
rH Cm Q
T--- CM CO <r •a: 0 at
Table 4 . 2 Effects of sodium a r sen ate (AsV) on hepatic 
cytochrome P-450, ethoxycoumarin and ethoxyresorufin 0- 
deethylases.
AsV Cytochrome Ethoxycoumarin Ethoxyresorufin
(umol/kg) P-4501 0-deethy1ase2 0-deethy 1ase3
Control 0.63 ± 0.08 0.38 ± 0.08 18.2 ± 3.0
25 0.65 ± 0.05 N.A. N.A.
50 0.62 ± 0.06 0.36 ± 0.07 19*6 ±2.5
100 0.60 ± 0 . 0 5  0.34 ± 0.08 20.7 ± 3.2
* * * 
150 0.57 ± 0.04 0.31 ± 0.02 14.3 ± 2.3
* x x
200 0.46 ± 0.05 0.23 ± 0.04 8.9 ± 1.0
1 nmol/mg microsomal protein.
2 nmol/mg microsomal protein/min.
3 pmol/mg microsomal protein/min.
All above given as X ± S.D. (n = 17 for controls, n = at least 
3 for other data). These effects were studied at 16 hours 
after subcutaneous administration of AsV.
* Differs from control data, p < 0.05
N.A. Data not obtained.
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reduced to 60'/. of control.
(iii) Effects of administration of AsIII daily for 30 days.
No significant effects on either ERD or ECD were observed at 
5, 10, 20 or 30 days of expousure (Table 4.3).
b ) Eooxide Hvdrola se.
No significant effects of acute administration of 
AsIII were observed at any dose level (Table 4.1).
c ) Heme oxvaenase and Cytochrome P-450.
The effects of AsIII and AsV on these parameters have 
been described and discussed in Chapter 3 i.e, acute As
treatment resulted in dose-related increases in HO and dose-
related decreases in P-450 concentration (Table 4.1), while 
exposure for 30 days to AsIII produces no significant changes 
in these parameters.
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Table A.3 Effects of 30 day administration of sodium 
arsenite (AsIII) in drinking water (50 ppm) on hepatic 
cytochrome P-450, ethoxycoumarin and ethoxyresorufin 0- 
dee thy1ases.
Days of Cytochrome Ethoxycoumarin Ethoxyresorufin
treatment P-4501 0-deethylase2 0-deethylase3
18.2 ± 3.0
20.4 ± 2.6 
15.9 ± 3.5 
15.7 ± 3.8
14.4 ± 1.5
1 nmol/mg microsomal protein.
2 nmol/mg microsomal protein.
3 pmol/mg microsomal protein.
All above given as X ± S.D. (n = 6 for control, n = at least
4 for other data).
^Differs from control data, p < 0.05 •
Control 0.63 ± 0.08 0.38 ± 0.08
0.68 ± 0.09 0.43 ±0.01
10 0.65 ± 0.07 0.41 ± 0.08
20 0.59 ± 0.04 0.37 ± 0.05
30 0.69 ± 0.07 0.39 ± 0.05
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4.2.2 Effects of S e l V .
The effects of 3 different doses of SelV at 16 hours, 
ranging from 5 to 20 umol/kg were studied. Se was 
administered by subcutaneous injection.
a ) Ethoxycoumarin and ethoxvresorufin O-deethvlases .
No significant effects of acute administration of SelV 
on the activity of either ERD or ECD was observed (Table 
4.4).
b ) Eooxide Hvdrolase.
A dose related increase in this enzyme activity was 
produced by SelV (Table 4.4). Doses below 10 umol/kg 
produced no significant changes, while the highest dose (20 
umol/kg) produced a 2-fold increase over control values.
c ) Heme oxygenase and cytochrome P-450.
After acute SelV treatment a dose-related increase in 
HO activity was observed, but P-450 content was unchanged 
(Table 4.4). These effects in relation to heme catabolism 
were described and discussed in Chapter 3.
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4.3 DISCUSSION.
4.3.1 Effects on mixed function oxidase activity.
There is some evidence that, under certain conditions, 
arsenic stimulates detoxicating enzyme activities in 
microorganisms (Legge, 1974), but little is known about this 
effect in mammals. Ribeiro (1971, as cited by Wagstaff,
1978) has reported that hexobarbitone sleeping time was 
reduced in mice pretreated with arsenic trioxide, but that 
rates of hexobarbitone oxidation or N-demethylation of 
aminopyrine were not altered in liver tissue from these same 
mice. These observations contrast with the results obtained 
in the present study in which the acute administration of 
AsIII and AsV resulted in a dose-dependent reduction in P-450 
concentration accompanied by dose-related decreases in the 
activity of ethoxycoumarin (ECD) and ethoxyresorufin (ERD) 0- 
deethylases. The 0-deethylation of 7-ethoxycoumarin has been 
shown to be inducible by both 3-methylcholanthrene (MC) and 
phenobarbitone (PB) in rat hepatic tissues (Ullrich et al. , 
1973; Sundheimer et al., 1983). In contrast, ethoxyresorufin 
0-deethylase activity is low in liver microsomes from control 
or phenobarbitone-treated rats, but it is induced 50 to 60- 
fold upon pretreatment with MC (Burke and Mayer, 1974, 1975).
ERD activity is considered a specific indicator of MC- 
inducible cytochrome P-450.
There are indications that the inhibitory effect of 
AsIII could be substrate dependent; the effect on ERD 
occurred at a lower dose, and the reduction in activity (with 
respect to control values of both enzymes) was 207. more
pronounced than that observed for ECD activity (Table 4.1).
Although the difference is quantitatively small, it is 
reproducible and suggests that AsIII has a differential 
effect on cytochrome P-450 composition in hepatic microsomes 
preferentially affecting the MC-inducible P-450 form (P — 448) . 
Further experiments are needed to determine fully whether
these observations represent a direct effect of AsIII on P- 
448 or are due to an effect on hemoprotein 
synthesis/degradation. In the first instance, it would be 
useful to study the in vitro effects of AsIII on the rates of 
benzo[a]pyrene hydroxylation, benzphetamine N-demethylation 
and acetanilide hydroxylation, followed by SDS-gel 
electrophoresis, these are well established procedures for 
identifying effects on particular forms of P-450 (Lu and 
West, 1979; Sundheimer et al.).
The acute administration of AsV also resulted in 
reduction of P-450 concentration and decreased ECD and ERD 
activities (Table 4.2). As observed with AsIII, the effect on 
ERD, was greater than that on ECD. However, AsIII 
was 2.5 times more potent than AsV in altering the activities 
of both demethylases (Fig. 4.1), this parallels the effects 
on cytochrome P-450 concentration.
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The acute administration of SelV produced no
significant changes in P-450 concentration or in ECD and ERD
activities (Table 4.'3). These results are consistent with 
those reported by Maines and Kappas (1976a), who found that 
high doses of SelV (50 umol/kg and higher) did not 
significantly reduce P-450 concentration 14.5 hours after
treatment. However, these results contrast with those
reported by Schnell et al. (1983) who found that an i.p. dose 
of 2.4 mg/kg (23 umol/kg) produced a 20/ reduction in P-450 
concentration, accompanied by a 30 '/. decrease in
ethylmorphine N-demethylase activity, without changes the
rate of aniline hydroxylation. This discrepancy may be 
related to differences in the period of Se administration, 
since Schnell’s measurements were made at 72 hours after
administering SelV, whereas in the present study and in that 
of Maines and Kappas (1976a) the measurements of P-450 and P- 
450 related monooxygenases were made much earlier (16 and
14.5 hours respectively after treatment). Time course studies 
on the effects of SelV on selected monooxygenases could
contribute to explaining the diferences mentioned above. A 
brief discussion on the absence of effects on P-450 
concentration and on the effects on HO activity was presented 
in Chapter 3.
In the present study, the administration of AsIII (50 
ppm) in the drinking water ‘ for 30 days produced no
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significant changes in P-450 levels or in ECD and ERD
f
activity at any of the intervals studied (after 5, 10, 20 and
30 days of treatment (Table 4.2). Although non-significant, 
there was a tendency towards an exposure-related decrease in 
ERD activity, suggesting that if the exposure had been 
continued, or higher levels used, a significant reduction 
could have been observed. Nonetheless, this contrasts with 
the marked reductions in P-450 content and in hepatic drug 
metabolism observed after the acute administration of AsIII. 
Our findings on the effects of continuous administration are 
in agreement with data reported by Woods and Fowler (1978), 
who found that 6 weeks of AsV treatment in drinking water 
(20, 40 and 85 ppm) produced no significant changes in P-450
concentration or in aminopyrine demethylase activity. 
However, the absence of effects mentioned above contrasts
with the data reported by Wagstaff (1978), who found that
administration of arsenic trioxide (100 and 1000 ppm) in a 
vitamin A supplemented diet to female rats produced a 20/ 
reduction in hexobarbitone sleeping time; the highest level 
(1000 ppm; ~ 500 umol/kg of rat/day) also produced an
increase in O-ethyl-O-p-nitrophenyl phenylphoshothionate 
detoxication and in the 0-demethylation of p-nitroanisole, 
both measured in the 9000 g supernatant. Besides the 
difference in sex and the vitamin A supplemented diet, no 
other explanation is at hand to account for the differences 
in the response to AsIII (present study), AsV (Woods and
Fowler, 1978) and arsenic trioxide. Schnell et al. (1978)
have ieported that cadmium, which is known to markedly reduce
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P-4 50 concentration and inhibit drug metaholism upon acute 
treatment (3 umol/kg, i.p.), did not produce changes in these 
parameters when it was subchronically administered via 
drinking water (100 and 200 mg/1) for up to 12 weeks. These 
authors were unable to satisfactorily explain their 
observations since they considered that the dose of Cd in the 
subchronic study was not large enough to induce sufficient 
metallothionein to inactivate the free Cd. Some 
considerations on the adaptation/compensation phenomena 
observed with As were made in Chapter 3.
4.3.2 Effects on epoxide hvdrolase.
The data presented in tables 4.1 and 4.4 indicate that 
As and Se share HO inducing properties, but differ in their 
ability to increase microsomal EH activity and in their 
effects on P-450 concentration and related monooxygenase 
activities. Thus, AsIII has no significant effect on EH 
activity but reduces P-450 content and the activity of P-450- 
related monoxygenases, whereas SelV induce EH but has no 
effect on P-450 and related enzymes. There is very little 
information on the effects of elements on EH that could be 
used as a reference for these effects. J_n vitro addition of 
metals (Cd, Zn and Hg) and organometallic compounds to 
microsomes has been shown to inhibit different drug 
metabolizing enzyme systems, including EH activity towards 
different substrates (Parkki, 1980, 1981). The hydration of
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styrene 7, 8-oxide was inhibited in an apparently 
noncompetitive manner, whereas the inhibition of
benzo[a]pyrene 4,5-oxide hydration with Cd was competitive 
(Parkki et al., 1980 ). The .in vitro addition of AsIII in 
concentrations up to 10 mM did not produce significant 
changes in EH activity (Parkki, 1981). However, it is 
difficult to extrapolate the significance of these results to 
studies made in vivo.
As yet we have no evidence to explain how Se induces 
EH, one might hypothesize a direct effect of Se on the EH 
receptor, in a way similar to that described for HO induction 
by metals (Kikuchi and Yoshida, 1983). Similarly, the reasons 
for the induction are uncertain. Is it possible that Se could 
form an epoxide which is a substrate for epoxide hydrolase ? 
To date, a separate EH receptor has not been described, and 
judging from the limited in formation available on the 
biotransformation of Se, it seems improbable that it could be 
transformed into an epoxide. The induction process may be 
complex for there have been several studies on the structure- 
activity relationships of EH inducers (Oesch, 1979; 
Seidegard, 1981; Connelly 1983) which have not produced 
conclusive evidence regarding the structural requirements for 
EH induction. It is of course possible that EH is coinduced 
in no more than fortituous association with other enzymes 
that are affected during a toxic process, or that EH 
induction is a particular response to certain forms of toxic 
or carcinogenic damage.
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Is there evidence to suggest that Se is an hepatic
carcinogen ? Several studies concerning the alleged
carcinogenicity of Se to laboratory animals are available: 
Nelson et al. (1943) fed diets containing 5, 7 or 10 ppm of
Se to rats for a life-time period and found that the liver 
suffered fatty degeneration and necrosis after a short period 
of exposure. However, when the exposure continued over a long 
period (1.5 years), cirrhosis in some animals was produced. 
Eleven out of 53 animals developed liver cell adenoma or low 
grade carcinoma without metastasis in cirrhotic livers,
whereas the control rats had neither liver tumours nor 
cirrhosis. Two studies that specifically looked for 
carcinogenic effects of Se in mice (Schroeder and Michener, 
1972) and rats (Harr et al., 1967, as cited by Glover et al.,
1979) failed to demonstrate any such effects. The overall 
conclusion could be that the neoplastic lesions, if any, are 
not present in the absence of severe hepatotoxic phenomena.
Is it possible that the Se-mediated increase in 
epoxide hydrolase could result from elevations in the 
concentration of bile components in liver? It has been 
hypothesized that as the increases in EH occur very shortly 
after exposure to hepatocarcinogens, such increase could be 
due more to the toxic effects of the compounds than to their 
carcinogenic properties (Dent and Graichen, 1982). Support 
for this hypothesis comes from acute studies with alpha and
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beta-naphthylisothiocyanates (ANIT and BNIT) (Leonard et al. , 
198 1 a, b) which showed that ANIT increased EH activity that 
correlated well with the extent of bile duct proliferation 
and elevated serum bilirubin. Conversely, BNIT which shares 
many toxicological properties with ANIT, did not produce 
bile duct proliferation and did not alter EH activity. 
Furthermore, bile duct ligation caused bile duct 
proliferation and increases in EH similar to those caused by 
ANIT. There is some evidence to suggest that Se treatment 
alters bilirubin metabolism. It has been reported (Halverson 
et al., 1966, 1970) that diets containing 6-8 ppm of sodium
selenite produced liver cirrhosis, splenomegaly, hemolytic 
anemia and elevated serum bilirubin levels in rats. 
Furthermore, the increase in HO activity with the consequent 
increase in bilirubin production observed at 16 hours after a 
single injection of sodium selenite reported in the present 
study, give some support to the assumption that Se treated 
animals have elevated concentrations of bile components, 
which in turn could induce EH activity. However, the 
mechanism by which bile components could induce EH has not 
been established.
Could epoxide hydrolase induction contribute to 
explaining the anticarcinogenic properties of selenium ? It 
is now generally accepted that Se, in addition to its 
possible carcinogenic properties, also has anticarcinogenic 
properties. This is supported by epidemiological evidence, 
animal experiments, and indirectly by bacterial mutagenicity
tests (Reddy and Massaro, 1983). In animal experiments, Se 
has been shown to counteract the induction of liver tumours 
by 2-acetylaminofluorene (Harr et al., 1972; Marshall et al.,
1979), by aflatoxins (Grant et al., 1977), and by 3-methyl-4- 
dimethylaminoazobenzene (Griffin and Jacobs, 1977).
Supplementation of the diet with Se also inhibited mammary 
gland tumours induced by 7,12-dimethylbenz(a )anthracene 
(DMBA) in mice and rats (Medina and Sheperd, 1981; Welsch
et al., 1981), while Se deficiency enhanced DMBA-induced
mammary tumorigenesis in rats having a high polyunsaturated 
fat intake (Ip and Sinha, 1981). It has also been shown that
Se reduces skin tumours due to 3-methylcholanthrene and 
benzo(a )pyrene (Shamberger, 1970). Se, however, may not be 
effective against all types of carcinogens, since it had no 
effect on the induction of tracheal cancer by 1-methyl-1- 
nitrosourea (Thompson and Becci, 1979), and it does not 
appear to be as effective against N-methyl-N-nitrosourea 
induced mammary tumours as it is against those induced by 
DMBA (Thompson and Becci, 1980).
Although the mechanism by which selenium functions as 
an anticarcinogen is not clear, it is known that compounds 
like aflatoxins, DMBA, and benzo(a )pyrene are transformed to 
epoxides in order to exert their carcinogenic effects 
(Heidelberger, 1975). Therefore, it is possible that the
induction of EH produced by the acute administration of Se 
could play a role in the protection afforded by Se against
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some chemical carcinogens, increasing the rate of metabolism 
of these highly reactive epoxides and reducing the
possibility of interactions with genetic material. Further 
experiments are needed to determine if during supplementation 
of the diet with Se, EH is maintained in an induced state. 
However, such a mechanism would not explain the protective 
effect of Se on 2-acetylaminofluorene or 3-methyl-4- 
dimethylaminoazobenzene tumours.
Other possible mechanisms to explain the 
anticarcinogenic properties of Se include: 1) The
antioxidant properties attributed to Se. As an antioxidant, 
Se could inhibit oxidative reactions required for
transforming procarcinogens into ultimate carcinogens or, 
more likely, autooxidative damage. However, by itself Se is 
not a good antioxidant, but it is a constituent of Se- 
dependent glutathione peroxidase which reduces
hydroperoxides, which otherwise might undergo autooxidation 
by metal catalyzed reactions to generate highly reactive 
alkyl peroxy, alkoxy and hydroxyl radicals (Combs et al., 
1975; Reddy and Massaro, 1983); 2) Alterations in the
metabolic fate of chemical carcinogens. It has been reported 
that Se inhibits aryl hydrocarbon hydroxylase activity of 
human lymphocytes in culture (Griffin, 1979). It also 
appears that Se treatment protects against 2- 
acetylaminofluorene carcinogenesis by increasing the ring
hydroxylation along with a decrease in the N-hydroxylation 
(Marshal et al., 1979); 3) There have been reports that Se
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inhibits events occurring during the promotion stage of 
carcinogenesis, as in the case of N-methyl-N-nitrosurea 
(Thompson and Becci, 1980), but little is known about these 
events or the possible mechanism(s) of Se effects. The 
increasing number of animal tumour model systems responsive 
to Se-mediated inhibition should allow the elucidation of the 
particular significance of these modes of action to be 
identified.
CHAPTER FIVE 
SOME EFFECTS OF ARSENIC ON TESTICULAR 
AND RENAL HEME METABOLISM
191
5.1 INTRODUCTION.
All tissues are susceptible to the toxic effects of 
chemicals, but the majority of compounds that cause systemic 
toxicity do not affect all organs equally, rather they 
exhibit toxicity in specific organs (Cohen, 1983). The kidney 
plays a major role in As excretion and it is one of the
primary organs in which As accumulates and exerts its
toxicity (Brown et al., 1976). There is little information 
regarding the effects of As in testis, but it has been 
reported that As also accumulates in this organ (Gunn et al.,
1967) and that it produces marked degeneration in the
germinal epithelium (Bencko et al., 1968).
This Chapter describes the effects of arsenic on some 
enzymes of the heme metabolism pathway in kidney and testis, 
and studies the differences in organ susceptibility to the 
administration of As in two different oxidation states, AsIII 
and AsV. A comparison is also made between the response 
patterns of liver and testis to the acute administration of 
arsenic and cadmium.
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5.2 T E S T I C U L A R  E F F E C T S .
5.2.1 Effects of sodium arsenite (AsIII).
The effects of 5 different dose levels at 16 hours, 
ranging from 12.5 to 100 umol/kg are shown in table 5.1. 
AsIII was administered by subcutaneous injection.
a) ALA synthetase.
A 677. increase in activity above control levels was 
observed at the highest dose (75 umol/kg). Lower doses 
produced no significant effects (Table 5.1).
b) Biliverdin reductase.
No change of activity was observed at any dose level 
(Table 5.1).
c) Heme oxygenase.
An increase of about 60 - 70 7 over control values was 
observed after treatment with 75 or 100 umol/kg of AsIII, 
lower doses produced no significant effects (Table 5.1).
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d) Cytochrome P-450.
There was a progressive decrease in P-450 
concentration at all doselevels above 25 umol/kg. At the 
highest dose (100 umol/kg) the concentration was reduced to 
27X of the control level (Table 5.1).
5.2.2 Effects of sodium arsenate (AsV).
The effects of AsV injected subcutaneously in doses 
ranging from 25 to 200 umol/kg were studied at 16 hours after 
treatment.
a) ALA synthetase.
A small but significant increase (13%) in the activity 
of this enzyme was observed at the highest dose (200 
umol/kg). No significant effects were observed at the lower 
dose (Table 5.2).
b) Biliverdin reductase.
No changes in the activity of this enzyme were 
observed at any dose level (Table 5.2).
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c) Heme oxygenase.
No significant effects of AsV on this enzyme activity 
were observed (Table 5.2).
d) Cytochrome P-450.
At the highest dose (200 umol/kg) the content of P-450 
was reduced to 7 1'/. of the control level. No significant 
changes were observed at lower doses (Table 5.2).
5.2.3 Effects of sodium selenite (SeIV) .
The effects at 16 hours of 3 different dose levels,
ranging from 5 to 20 umol/kg and administered by subcutaneous
injection are shown in table 5.3.
a) ALA Synthetase.
A small increase (18/) in the activity of this enzyme
was observed at the highest dose (20 umol/kg). No
significant effects were observed at lower doses (Table 5.3). 
SelV was administered by subcutaneous injection.
b) Biliverdin reductase.
No changes in the activity of this enzyme were 
observed at any dose level (table 5.3).
c) Heme oxygenase.
No significant effects of SelV on this enzyme activity 
were observed (Table 5.3).
d) Cytochrome P-450.
There were no detectable effects on P-450
concentration at any dose level (Table 5.3).
5.2.4 Effects of cadmium chloride.
The effects at 16 hours of 7 and 20 umol/kg
administered by subcutaneous injection are shown in table
5.4.
a) Biliverdin reductase.
No change of activity was noted at any dose level
(Table 5.4).
b) Heme oxygenase.
At the highest dose (20 umol/kg) the activity of HO 
was decreased to 47/ of control values by Cd. No significant 
change was observed at lower doses (Table 5.4).
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c) Cytochrome P-4 50.
At the highest dose, 
747. of the control level, 
observed at the lowest dose
the P-450 content was reduced to 
No significant reductions were 
(Table 5.4).
200
Table 5.4 Effects of cadmium chloride on testicular 
biliverdin reductase, heme oxygenase and cytochrome P-450.
CdCl 2 
(umol/kg)
Biliverdin
Reductase1
H erne
2Oxygenase
Cy toe hrome 
P-4503
Con trol 2.70 ± 0 .18 6.48 ± 0.79 34.0 ± 6.0
7 3.06 ± 1.20 6.08 ± 0.71
x
31.0 ± 5.0
20 2.22 ± 0.60 3.05 ± 0.14 25.0 ± 2.0
1 nmol bilirubin/mg cytosolic protein/h.
2 nmol bilirubin/mg microsomal protein.
3 pmol/mg microsomal protein.
All above given as X" ± S.D. (n = 14 for controls, n = at
least 3 for other data). These data were studied at 16 hours 
after subcutaneous administration of CdC^*
* Differs from control data, p < 0.05 •
5.3 DISCUSSION ON TESTICULAR EFFECTS.
There have been suggestions that the regulation of
heme metabolism in the testes differs from that of liver.
Tofilon and Piper (1980), reported that ALAS activity in rat
testes is refractory to treatment with the known hepatic ALAS
inducers allylisopropylacetamide (AIA) and 3 , 5 -
dicarbethoxy 1, 4 - dihydrocollidine (DDC). Maines et al.
(1982), reported that CdCl is a very effective inhibitor of
2
testicular HO, and suggested that the regulatory mechanisms 
for HO activity and the relationships of the enzyme with 
microsomal heme content are distinctly different from that of 
liver. The results of the present study do not support the 
above suggestions; testicular ALAS and HO activities, and P- 
450 content responded to AsIII administration in a similar 
way to that of liver. However, only the highest doses (75 
and 100 umol/kg) were able to elicit a response. The highest 
dose of AsV (200 umol/kg) resulted in increased ALAS activity 
and reduced P-450 concentration without significant effects 
in HO. SelV (20 umol/kg) increased ALAS activity without 
apparent effects on the rest of enzymes.
There are two possibilities that may help to explain 
the difference between the effects of As or Se on testicular 
ALAS and those observed after AIA or DDC treatment: 1) it is
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known that administration of As or Se produce high 
concentrations in most rat and mice organs a short time after 
exposure. The clearence from those organs is relatively 
fast, except in the testis-epididymis complex where As and 
Se accumulate and are retained (Gunn et al. , 1 967; Vahter et
al., 1982; Lindgreen et al., 1982). It is possible that AIA
and DDC, inducers of hepatic ALAS, failed to alter 
testicular ALAS activity because they were unable to reach 
the testicular cells in sufficient concentrations. This is 
known to occur for a number of substances, like salicylic 
acid or sulfoguanidine, which are prevented from passing the 
testicular capillary barrier (Gunn and Gould, 1970) 2) it
is known that AIA or DDC effects are mediated by their
active metabolites, therefore, it is possible that these 
active metabolites cannot be formed in sufficient 
concentrations in the testis (Tofilon and Piper, 1980).
An interesting observation regarding testicular HO is 
that under physiological conditions, the control rate of heme 
degradation is particularly high. In the present study, HO 
activity in testis of control animals was found to be 3.5 
times higher than that of liver (Tables 3.3 and 5.1), and 7- 
fold that of kidney (table 5.5). Spleen is the only organ 
which has been reported (Maines and Kappas, 1974) to have a 
higher HO activity than the testicular level reported in the 
present study . HO is most active in organs normally 
engaged in the sequestration and breakdown of senescent red 
cells; in view of this, the biological significance of high
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Liver
©
Testis
kidney
A
□
O
1»
0 25 50 75 100 150 200
Dose (umol/kg body wt.)
Fig. 5.1 Effects of arsenic on heme oxygenase activity in liver, 
kidney and testis. The effects were studied 16 hours after 
subcutaneous- administration.
Effects of AsIII on : liver (e), kidney (■) and testis (a ). 
Effects of AsV on : liver (o), kidney (□) and testis (a).
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HO activity in testis remains to be elucidated. The 
activities of ALAS, ALAD, uroporphyrinogen I synthetase and 
heme synthetase in testis seem to be lower than those 
reported for liver (Tait, 1978; Maines and Kutty, 1983), as 
it would be expected for an organ apparently much less 
involved in xenobiotic metabolism.
AsIII has a pronounced effect on testicular P-450 
concentration: a significant reduction was observed at doses
which were ineffective in altering ALAS and HO activities, 
and the highest dose (100 umol/kg) reduced P-450 
concentration to 26 I of control levels. This suggests that 
the degenerative changes in germinal epithelium reported to 
occur after As treatment (Bencko et al., 1968) are caused by 
reductions in steroidogenic activity subsequent to effects on 
P-450 content. Little is known about the content of
hemoproteins other than cytochromes P-450 and b .
5
In marked contrast to the effects of AsIII on ALAS and
HO activities, and to its own effects in liver (Table 3.14),
CdCl (20 umol/kg) decreased HO activity to 507. of control 
2
values. A reduction of 257. in P-450 concentration was also 
observed (Table 5.4), confirming results reported earlier 
(Maines et al., 1982). Cadmium, like As and Se, reaches the 
testis shortly after administration, but in contrast to these 
two metalloids, less is retained there than in any other 
organ (Gunn and Gould, 1970). Surprisingly therefore, in
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rodents, the testis is the organ most susceptible to Cd 
toxicity; an accumulation in the testis, of only 0.13'/. of an 
administered dose (20 umol/kg) produces hemorrhagic necrosis 
followed by atrophy and permanent sterility. Liver and 
kidneys, which may attain Cd concentrations 20 to 60-fold 
greater (Gunn and Gould, 1970), showed in this experiment no 
macroscopic evidence of damage. In contrast, As and Se do not 
seem to cause testicular necrosis or other macroscopic 
alterations despite their ability to accumulate in this 
organs, even after administration of doses which are in the 
lethal range. The question thus arises: is there a genuine
difference between the biochemical effects of As and Cd on 
rodent testis, or are the specific effects on heme catabolism 
of Cd masked by the massive injury it. produces ? Further 
experiments are required to answer this question. In 
addition, other metal ions such as Cu, Sn, Pb and Hg, known 
for their ability to increase HO activity in liver and other 
organs, have been shown to be ineffective in altering the 
enzyme activity in the testis (Maines and Kutty, 1983); there 
is no information about their effects on ALAS activity. The 
difference in tissue responsiveness to metal induction of HO 
may reflect one or more of a number of factors including: 
bioavailability to the testis, differences in binding 
affinities in the testis, cellular contents of functional 
groups which complex and block metal actions. In order to 
adequately interpret these data, it is important to obtain 
more information on intratissue and/or intracellular 
distribution of these elements.
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5.4 RENAL EFFECTS.
5.4.1 Effects of sodium arsenite (AsIII).
The effects of 5 different dose levels at 16 hours, 
ranging from 12.5 to 100 umol/kg are shown in table 5.5. 
AsIII was administered by subcutaneous injection.
a) ALA synthetase.
The enzyme activity showed a dose-dependent increase, 
being significant at doses above 25 umol/kg (Table 5.5). At 
the highest dose, the enzyme activity was about 3.5 times 
that of the control level.
b) Heme oxygenase.
The increase in this enzyme produced by AsIII was 
progressive and pronounced at all dose levels above 12.5 
umol/kg (Table 5.5). The increase in activity was directly 
related to the increase in dosage. At the highest dose (100 
umol/kg) an 11-fold increase over control values was 
observed.
c) Biliverdin reductase.
No change of activity was observed at any dose-level
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(Table 5.5).
d) Cytochromes P-450 and b .
5
There was a progressive decrease in P-450 
concentration at dose levels above 12.5 umol/kg (Table 5.5). 
At the highest dose (100 umol/kg) the concentration was 
reduced to 427. of the control level. No effect on cytochrome 
b5 concentration at any dose level was observed (Table 5.5).
5.4.2 Effects of sodium arsenate (AsV) .
The effects of AsV injected subcutaneously in doses 
ranging from 25 to 200 umol/kg and studied at 16 hours after 
treatment are shown in table 5.6.
a) ALA synthetase.
There was a dose-related increase in enzyme activity, 
being significant at doses above 100 umol/kg (Table 5.6). At 
the highest dose (200 umol/kg), the enzyme activity was about
3.5 times that of control level.
b) Heme oxygenase.
The enzyme activity showed a dose-dependent increase, 
being significant at all doses given (Table 5.6). At the
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highest dose (200 umol/kg) a 6-fold increase over control 
values was observed.
c) Biliverdin reductase.
No change of activity was observed at any dose level 
(Table 5.6).
d) Cytochromes P-450 and b .
5
There was a progressive decrease in P-450
concentration at dose levels above 25 umol/kg of AsV (Table
5.6). At the highest dose (200 umol/kg) the concentration
was reduced to 40'/. of the control level. No effect on
cytochrome b at any dose level was observed (Table 5.6).
5
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5.5 DISCUSSION ON RENAL EFFECTS.
The results of this study indicate that As 
administration produces alterations in renal heme metabolism 
similar to those observed in liver, i.e. it increases ALAS
and HO activities and decreases P-450 concentration (Tables
5.5 and 5.6). As in liver, the effects of AsIII on kidney 
were more pronounced than those of AsV: on a molar basis,
AsIII increased HO activity 5.5 times as much as AsV,
confirming results reported earlier by Sardana et al (1981); 
this difference in potency was less apparent for the effects 
on ALAS and P-450, where AsIII was twice as potent as AsV 
(Tables 5.5 and 5.6). Although AsIII was more potent than 
AsV in both liver and kidney, AsV affected the above 
mentioned enzymes in kidney at doses which were ineffective
in liver and testis (Tables 3.7, 5.2 and 5.6; Fig. 5.1).
There is some indirect evidence which may explain this
difference in the relative potency of AsIII and AsV between 
liver and kidney: 1) AsIII administration produced higher
concentrations than equimolar doses of AsV in most tissues 
due to a more pronounced binding to cellular organelles 
(Brown et al., 1976), the exceptions being kidney and
skeleton (Vahter, 1981; Vahter and Marafante, 1983); 2)
hepatocytes have a relatively low AsV uptake, as compared to 
that of AsIII (Lerman et al., 1983) and 3) in dogs, the fast 
initial clearance of unmetabolized AsV from other tissues 
gives rise to high concentrations in kidney, where part of it
before being eliminated undergoes tubular reabsorption 
(Ginsburg and Lotspeich, 1963) followed by intracellular 
reduction to AsIII, producing net secretion of AsIII 
(Ginsburg, 1965). It has been suggested that a similar 
mechanism operates in rabbits and mice (Vahter and Marafante, 
1983). From above, it is clear that AsV selectively 
accumulates in kidney, but there is still an open question: 
are the renal effects of AsV produced by the high 
concentrations reached, or are they due to the effectiveness 
of its transformation to AsIII ? It would be interesting to 
administer probenecid to AsV treated animals in order to 
investigate if it could block the tubular reabsorption of 
AsV, thus decreasing the amount available for intracellular 
reduction.
Although the regulation of heme metabolism in kidney 
is less well studied than that in liver, and the attempts in 
the present study to assess changes in renal "free heme" pool 
(measuring TP activity) were unsuccessful, it seems 
reasonable to assume that renal ALAS induction is a response 
to heme depletion. It appears that the degree of ALAS 
induction (relative to control values) in kidney is higher 
than in liver; the highest doses of AsIII and AsV were able 
to increase renal ALAS 3-fold, while in liver the maximum 
increase produced by AsIII was about 2 fold. This effect 
suggests that kidney could be an important contributor to the 
porphyria produced by As, however, the relative difference in
heme turnover between liver and kidney needs to be 
considered. There are few reports dealing with renal
porphyria: Woods and Fowler (1977a) have reported that
methylmercury produces renal porphyria (without hepatic 
involvement) in rats. It would be interesting to investigate 
the effects of As on uroroporphyrinogen synthetase, 
uroporphyrinogen decarboxylase and heme synthetase and on the 
renal content of porphyrins to elucidate this point.
As observed in liver, no effects of AsIII or AsV on 
biliverdin reductase activity were found in kidney. This
absence of effects is not surprising, since the only metal 
that has been reported to alter this enzyme activity in vivo 
is mercury, which at high doses (30 umol/kg) decreased the 
activity by 50/. (Kutty and Maines, 1983 ); interestingly, Hg 
does not affect the enzyme activity in liver. As discussed 
previously (Section 3.3.5), it is highly unlikely that
biliverdin reductase plays an important role in the 
regulation of heme catabolism.
Under physiological conditions, renal HO activity is 
very low, but Pimstone et al. (1971a) have reported that 
following a single intravenous injection of hemoglobin a 36- 
fold increase in activity was observed, while in liver only a 
2-fold increase was seen. Although there is little 
information published on the regulation of heme catabolism to 
interpret these findings, they suggest the possibility that 
renal HO induction could be related not only to the cellular
level of heme, but also be extended to the degradation of 
hemoglobin heme reabsorbed by the tubular cells. Arsenic 
shares the ability to induce renal HO with several ions like 
Sn (Maines and Kappas, 1 976d ), Hg, Pb, Cu, Cd (Maines and 
Kappas, 1976c), Sb (Drummond and Kappas, 1981b) and Ni 
(Sunderman et al., 1983); it appears that AsIII is one of the 
more potent of these elements. At the moment, no clear 
evidence is available as to whether HO induction in kidney is 
mediated entirely by a heme-dependent mechanism, or by one 
that is partly or totally independent of "free heme" levels. 
Further experiments are needed to clarify this point.
The kidney appears to be less concerned than liver 
with P-450-dependent oxidative metabolism of xenobiotics and 
more with the metabolism of endogenous compounds (Connelly 
and Bridges, 1980). The marked decrease in P-450 content 
produced by both AsIII and AsV (Tables 5.5 and 5.6), suggests 
that renal functions mediated by the P-450 system could be 
primary targets of acute As toxicity. The w-hydroxylation of 
fatty acids seems to be one of the most important functions 
of P-450 in kidney, if it is impaired (by a reduction in P- 
450 content, for example), the consequent excess of saturated 
fatty acids is known to produce mitochondrial swelling and 
respiratory uncoupling, while the excess of w-hydroxylated 
products caused neither swelling nor respiratory uncoupling 
(Ellin and Orrenius, 1975). It is possible that the
mitochondrial swelling and respiratory uncoupling observed in
215
kidney after As administration (Brown et al., 1976), could be 
produced by damage to this form of P-450. This possibility 
could be followed by investigating whether As produces a 
selective effect on this P-450 species and also by comparing 
As effects with the effects of other metals.
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CHAPTER SIX 
SUMMARY AND FINAL DISCUSSION
6.1 EFFECTS OF ARSENIC.
In liver, arsenic produced a dose-related decrease in 
the percentage of TP saturated with heme. Dose-relsrted 
increases in ALAS and HO activities accompanied by dose- 
related decreases in P-450 content were also observed. The
cytosolic heme status is a major target by virtue of the
inhibitory effects of As on uroporphyrinogen synthetase and
heme synthetase, and its inducing effect on HO. The
magnitude of these effects was related to the oxidation state
of the As salts used. AsIII was more potent than AsV.
However, the differences in relative potency varied between 
enzymes. Nonetheless, the results are in agreement with the 
general concept that AsIII is more toxic than AsV, and that
AsV may require to be converted to AsIII to exert its toxic
action.
So far, most experimental work devoted to studying the 
relationships between TP activity and heme metabolism 
alterations has been focused on the heme saturation value, 
and has attached much less importance to the effects on the 
apoenzyme. However, the study of both effects is necessary in 
order to understand the effects on ALAS and HO. The time- 
course study of AsIII effects showed a drastic reduction in 
TP "total enzyme" activity during the first 4 hours after 
treatment. This reduction may have occurred as a result of 
AsIII interfering with the conjugation of apo-Tp with heme or
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by inhibiting apoprotein synthesis. These effects suggested 
that the heme utilization by TP, as opposed to the heme 
saturation, could serve as an alternative explanation for the
effects on ALAS and HO: The net effect of the reduction in
"total enzyme" values would be a reduction in the number of 
apo-TP molecules saturated with heme, thus allowing the 
unused heme to increase the "free heme" pool size. This could 
result initially in inhibition of ALAS activity and an
increase in HO activity. Further experiments are needed to
explore in detail this possibility. The results from this 
study are in agreement with Badawy's suggestion that the heme 
saturation of the TP-apoenzyme is sensitive to treatments 
that modify liver heme concentration. The chemically mediated 
increase in ALAS activity is thougt to be caused by a 
reduction in the "free heme" pool (Meyer, 1982), the latter 
effect is produced by As inhibiting the synthesis of heme and 
increasing its degradation. However, it remains to be shown 
which parameter, heme saturation of TP or ALAS, reflect more 
accurately changes in the "free heme" pool size.
The increase in HO produced by As in liver 16 hours 
after treatment, appears to be mediated by a mechanism 
largely or entirely independent of heme, since the observed 
changes could not be explained by the classical regulatory 
free heme" pool model i.e. there were no indications of 
increases in the "free heme" pool, as measured by the heme 
saturation of TP, that could trigger a positive feedback on 
HO. On the contrary, it seems that one of the reasons for the
"free heme" pool depletion was the increased HO activity. The 
disparity between the effects of AsIII on ALAS (2-fold) and 
HO (8-fold) plus the fact that 8 molecules of ALA are needed 
to form one molecule of heme, suggests that the relationship 
between heme synthesis and degradation is out of balance as a 
result of As exposure. The extrapolation of these effects to
the in. vivo situation is difficult because substrate
s . . . .accesibility could limit the increase in HO activity. Further 
A
studies are required to identify the role of alterations in 
heme catabolism in the genesis of more overt toxic effects of 
As and other metals.
It is possible that the dose-dependent reduction in 
hepatic P-450 concentration produced by AsIII and AsV could 
have been produced by peroxidative damage to microsomal 
membranes, supporting this possibility is the suggestion that 
As reduces catalase activity (Squibb and Fowler (1983). The 
reduction in P-450 was accompanied by dose-related decreases 
in the activity of ethoxycoumarin and ethoxyresorufin 0- 
deethylases. There were indications that the inhibitory 
effect of As was substrate dependent, the effect on ERD being
more pronounced than that on ECD. This might imply a
*
selective effect of As on certain P-450 isoforms. Further
experiments are needed to determine if these observations
represent a direct specific effect on a particular isoform
e.g. p-448, or are due to more general effect of As on
hemoprotein synthesis/degradation. Not enough is known about
the relative susceptibility of cytochrome P-450 to chemicals 
which alter heme metabolism and the relative turnover rate of 
specific forms of the cytochrome to answer this question. 
These effects on P-450 isoforms may be reflected in a 
diminished ability of cells to carry out oxidations of drug 
and other chemicals that depend on P-450 and P-448. If so, 
this would in some causes lead to the toxicity of a compound 
being increased and in others to a decrease in toxicity.
Although only the higher doses of AsIII (75 and 100 
umol/kg) were able to elicit a testicular response, the 
general effect was similar to that of liver i.e. increases in 
ALAS and HO activities accompanied by reductions in P-450 
content. Maines et al. (1982) based on their finding that 
cadmium is a potent inhibitor of testicular HO have suggested 
that the HO regulatory mechanism(s) and the relationship 
between this enzyme's activity and microsomal heme content 
are distinctly different from that of liver. The results of 
the present study do not support this suggestion. The massive 
testicular injury produced by Cd is considered as an 
alternative explanation for the inhibitory effect of Cd on HO 
activity. Under physiological conditions testicular heme 
oxygenase activity is higher than in most organs. Although 
the physiological significance of this observation has not 
yet been elucidated, it is more likely to be associated with 
the high P-450 dependent steroid biosynthesis than to the 
process of spermatogenesis per se, because HO activity is 10- 
fold higher in microsomes derived from Leydig cells than in
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those from Sertoli cells (Maines, 1984b). If HO does indeed 
regulate steroidogenic activity, then perhaps the resultant 
changes in steroid levels produced by As treatment play a 
role in the degenerative effects it causes in the ' germinal 
epithelium (Bencko et al., 1968). Judging from the similar 
increases in HO and ALAS activities, it appears that the 
deficit in the heme synthesis/ degradation produced by As in 
testis, is not as marked as in liver.
AsV and SelV acute treatment produced a small increase 
in ALAS activity without significant effects on HO activity, 
suggesting that testicular ALAS is more sensitive than HO to 
the effects of these salts.
Although AsIII was more potent than AsV in both liver 
and kidney, AsV affected renal ALAS, HO and P-450 at doses 
which were ineffective in liver and testis. It also appears 
that the kidney is able to respond with increases in ALAS 
activity greater than those observed in liver (as compared to 
control values), if the effectiveness of uroporphyrinogen 
decarboxylase inhibition is similar between liver and kidney 
then the kidney could be an important contributor to the 
porphyria produced by As. However, there is an open question 
: is the particular response of kidney to AsV produced by the 
high concentrations of AsV reached in this organ (Vahter and 
Marafante, 1983), or more likely, is it due to the processes 
of tubular re-absorption arid subsequent intracellular
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reduction to AsIII ? Experiments administering inhibitors of 
renal tubular transport may contribute to answer this
question. Further experiments are also required to study the 
regulation of heme metabolism and its alterations in
extrahepatic organs and the possible relationship between 
these effects and the subsequent genesis of overt toxic
effects in target organs.
The main effects of continuous exposure to AsIII were 
: 1) a progressive increase in TP "total enzyme activity"; 2)
an initial decrease in the degree of heme saturation of TP, 
which remained more or less constant during the period of
treatment; 3) an initial increase in ALAS activity (60*/)
which after 10 days of exposure was reduced to a 307. 
increase. In marked contrast to the dose-related increases in 
HO activity and cytochrome P-450 reductions observed after 
the acute administration of AsIII, no significant effects on 
these parameters were observed after continuous exposure. 
These observations were interpreted as indicative that a new 
equilibrium, at a lower level, between synthesis and 
degradation of heme had been reached during the continuous
treatment. It was also considered that an adaptive response 
to the toxic effects of AsIII on heme metabolism was taking 
place. Further studies in experimental animals and humans are 
needed to investigate this process. AsIII produces porphyria 
in rats, but there are no reports of this effect occurring in 
human populations exposed to As, and there is a need to 
investigate if the skin lesions observed in individuals
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chronically exposed to As are related to alterations in 
porphyrin metabolism.
Arsenic is an important environmental contaminant in 
several countries, including Mexico, with a proven risk to 
the human population. The explanation of As effects in man 
depend, in large part, on relating the results of 
experimental work, both in vitro and in. vivo. with the 
clinical findings in exposed populations. The overall aims 
for future studies in this field are : 1) identify the
earliest detectable biochemical and clinical effects of As in 
man, using the knowledge of As effects on body tissues of the 
rat, to develop test(s) that could reflect tissue changes 
resulting from As exposure; 2) identify possible ways of 
reducing chronic As toxicity once it has been established.
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6.2 EFFECTS OF SELENIUM.
Se produced effects on TP, ALAS and HO similar to 
those produced by AsIII; however, Se was more potent in this 
regard than either AsIII or AsV. It was also more toxic, 
doses of 40 umol/kg and higher producing death in all animals 
in less than 12 hours. The differences between the induction 
of ALAS and HO were not as marked as those observed with 
AsIII, indicating that the balance between hepatic heme 
synthesis and degradation resulting from Se and As exposure 
are distinctly different.
All the elements whose effects on these enzymes have 
been reported, induce HO and concomitantly reduce P-450 
concentration together with the activity of P-450 dependent 
monooxygenases, Se is a notable exception to this. The effect 
of Se to increase HO activity, without significantly 
affecting P-450 concentration, supporting the idea that P- 
450 destruction is not a prerequisite for HO induction. It 
also suggests that Se could be a useful tool for further 
studying^ the role of P-450 in the regulation of heme 
metabolism. It should provide a useful adjunction to methods 
such as pretreatment with classical P-450 inhibitors e.g. SKF 
525A, which are thought to bind to the active sites of P-450 
and thereby stabilise it.
225
Se appears to be the first element reported to 
increase epoxide hydrolase activity. However, in comparison 
with 2-acetamidofluorene or aflatoxin which respectively 
produced 10 and 5-fold induction (Sharma et al., 1981), its 
potency is relatively low, being 2-fold at the maximum dose. 
This effect might contribute to the explanation of the 
protective effect of Se against such compounds as aflatoxins 
or DMBA, which have to be transformed to epoxides in order to 
exert their carcinogenic effects (Grant et al., 1977; Welsch 
et al., 1977). As yet we have no evidence to explain how or 
why Se induces EH, but it is possible that EH is coinduced 
with other enzymes affected during a toxic process or that it 
is a particular response to certain forms of toxic or 
carcinogenic damage.
It appears that selenium has a dual effect on As- 
induced hepatotoxicity. On the one hand, it has additive 
effects in reducing the heme saturation of TP, and on the 
other, it seems to protect against the decrease in P-450 
levels produced by AsIII. The additive effects of AsIII and 
SelV on HO activity, plus the ability of As to inhibit heme 
synthesis at other steps not affected by Se, might explain 
the additive effects of these metalloids. Possible 
explanations for the P-450 protective effect include: the
role of Se, as a component of glutathione peroxidase, in 
maintaining the integrity of cellular and subcellular 
membranes from the oxidative damage caused by metals, or less
226
likely, that Se complexes with P-450 heme preventing the 
degradatory effects of AsIII.
Further studies are needed to determine if Se protects 
against other manifestations of As toxicity and/or against 
similar manifestations produced by other toxic agents. While 
it is important to delineate the protective effects, it is 
equally important to study the mechanisms underlying such 
effects. Regarding studies on human populations, it would be 
interesting to investigate the possibility of interactions 
between these metalloids, for example, the effects of high As 
intake on the Se status of the exposed individuals, and vice- 
versa, since Se levels might modify As toxicity.
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